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Dendritic cells (DCs) are a group of immune cells that include both classical dendritic 
cells (cDCs) and plasmacytoid dendritic cells (pDCs). cDCs are further comprised of two distinct 
subsets, cDC1s and cDC2s, which play critical roles in the initiation of innate and adaptive 
immune responses. Understanding how these lineages develop and function is therefore 
paramount. All DCs require the receptor tyrosine kinase Flt3 and its ligand Flt3L for their 
development, but the loss of Flt3L in mice leads to a more severe DC deficiency than does the 
loss of Flt3. This has led to speculation that Flt3L can bind to an alternate receptor that also 
supports DC development. However, we found that Flt3L administration to Flt3-/- mice does not 
generate DCs, arguing against a second receptor. Instead, Flt3-/- DC progenitors matured in 
response to macrophage colony-stimulating factor (M-CSF) or stem cell factor, and deletion of 
Csf1r in Flt3-/- mice further reduced DC development, indicating that these cytokines could 
compensate for Flt3. Surprisingly, Flt3-/- DC progenitors displayed enhanced M-CSF signaling, 
suggesting that loss of Flt3 increased responsiveness to other cytokines. In agreement, deletion 
of Flt3 in Flt3l-/- mice paradoxically rescued their severe DC deficiency. We therefore conclude 
x 
 
that cytokines play a supportive role in DC development, and that the discrepancy between Flt3-/- 
and Flt3l-/- mice results from the increased sensitivity of Flt3-/- progenitors to these supportive 
cytokines. 
The specification of immune lineages such as DCs during hematopoiesis is dependent 
upon the precise induction of lineage-determining transcription factors in multipotent 
progenitors, such as the induction of Irf8 in the common dendritic cell progenitor (CDP) that 
drives cDC1 development. To uncover the mechanisms regulating this induction, we identified 
Irf8 enhancers via chromatin profiling of DCs and used CRISPR/Cas9 genome editing to test 
their functions in vivo. A +32 kb Irf8 enhancer active in mature cDC1s was required for the 
development and anti-tumor functions of this lineage, but was not required for its specification. 
To identify enhancers controlling cDC1 specification, we performed ATAC-seq on DC 
progenitors. Unexpectedly, a +41 kb Irf8 enhancer, which binds E2A and is active in pDCs, was 
transiently accessible in cDC1 progenitors but not in mature cDC1s. Deleting this enhancer 
reduced Irf8 expression in pDCs, as expected, but also surprisingly prevented Irf8 induction in 
CDPs and completely abolished cDC1 specification. We thus found that cryptic activation of the 
+41 kb Irf8 enhancer was responsible for specifying cDC1 fate. Collectively, our studies have 
provided insight into the transcriptional mechanisms regulating the development of DCs. 
Manipulation of these mechanisms in humans may prove useful in enhancing cytotoxic immune 
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1.1  Abstract 
Dendritic cells (DCs) play critical roles in mediating innate and adaptive immune 
responses. The functions of DCs were originally obscured by their overlap with other 
mononuclear phagocytes, but new mouse models have allowed for the selective ablation of 
subsets of DCs and have helped to identify their non-redundant roles in the immune system. 
These tools have elucidated the functions of DCs in host defense against pathogens, 
autoimmunity, and cancer. They have also provided insight into how DCs develop from their 
multipotent hematopoietic precursors. In this dissertation, we first approached the problem of 
promiscuity between cytokines and their receptors in regulating DC development. We found that 
the less severe DC deficiency found in Flt3–/– mice as compared to Flt3l–/– mice was due to the 
enhanced responsiveness of Flt3–/– progenitors to compensatory cytokines that could also support 
DC development. Second, we studied the roles of enhancers in the Irf8 locus in the induction of 
this critical lineage-determining transcription factor in multipotent progenitors in order to specify 
classical type I dendritic cell (cDC1) fate. A +32 kb Irf8 enhancer was required for the 
maturation of cDC1s, but not for their specification. Instead, a +41 kb Irf8 enhancer that was 
only active in mature pDCs and was also cryptically activated in cDC1 progenitors was required 
for the specification of this lineage. Analysis of this enhancer found that it bound to E proteins, 
and consistently E2A-deficient progenitors failed to generate cDC1s. Our analysis of cryptic 
enhancer activity therefore revealed previously unrecognized transcriptional networks involved 
in specifying cDC1 fate. Collectively, these advances have provided insight into how DCs 





1.2 Dendritic cells and the immune response	
The vertebrate immune system has evolved the remarkable capacity to robustly and 
precisely eliminate the wide variety of potential threats it encounters, from single cell bacteria to 
multicellular parasites to even transformed oncogenic versions of its own cellular components. 
To achieve this goal, many diverse lineages of effector cells must act together in different 
capacities throughout the course of the immune response. As with any system possessing such 
complexity, the careful control and coordination of the numerous components of the immune 
system is critical for its proper functioning. As our understanding of each cell type acting within 
this system has grown, it has become increasingly apparent that dendritic cells (DCs) act as the 
central regulators of the entire immune response, responsible both for sensing the nature of the 
threats faced and for activating the precise combination of effectors required to eradicate them. 
First isolated by Ralph Steinman and Zanvil Cohn, DCs were identified by their stellate 
morphology and capacity to stimulate naïve T cells 1-3. DCs comprise two major branches, the 
classical DCs (cDCs) identified by Steinman and the lymphocyte-like plasmacytoid DCs (pDCs) 
that produce Type 1 interferon in response to pathogens 4-7. cDCs can be further divided into two 
major subsets recently renamed cDC1s and cDC2s 8. All DCs originate from bone marrow (BM) 
progenitors arising from hematopoietic stem cells, starting with the macrophage/dendritic cell 
progenitor (MDP) 9,10, which gives rise to the common dendritic cell progenitor (CDP) 11,12, 
which finally gives rise to committed progenitors for each branch of DC such as the pre-cDC1 
and the pre-cDC2 13,14. 
cDCs express the integrin CD11c and MHC class II 15,16, and each subset can be 
distinguished by additional markers. Resident cDC1s in the spleen and lymph nodes (LNs) 
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express CD8α, CD24, and XCR1, while cDC2s express CD4 and Sirpα 17,18. In nonlymphoid 
tissues, all cDCs express CD24, which distinguishes them from macrophages that instead express 
CD64 19-21.  Nonlymphoid tissue cDC1s also express XCR1 and CD103, while cDC2s express 
CD11b and Sirpα. Migratory cDCs that traffic from nonlymphoid tissues to LNs express these 
same markers they expressed in the periphery. There are several exceptions to these rules, 
however, such as CD11b+ cDC2s in the small intestine that comprise both CD103+ and CD103- 
fractions 22,23. While these varied markers have historically been used to identify cDC subsets, a 
recent analysis suggests that a more simple and consistent identification of these cells across 
most tissues is possible by gating cDCs as CD11c+MHCII+CD26+CD64-F4/80-, and within this 
population cDC1s as XCR1+ and cDC2s as Sirpα+ 24. pDCs also express CD11c and MHCII, but 
can be segregated by their additional expression of B220, Siglec-H, and Bst2 25,26. 
While cDCs were discovered for their ability to serve as potent antigen-presenting cells 
(APCs), it is now clear that they also have non-redundant roles in innate immune responses 23,27. 
Their early recognition of pathogens and rapid cytokine production activates innate immune cells 
such as innate lymphoid cells (ILCs) and natural killer (NK) cells to limit pathogen spread until 
adaptive immunity can be initiated. Indeed, the heterogeneity of cDCs can itself be viewed as an 
evolutionary adaptation for the coordinated activation of the specific innate and adaptive effector 
responses best suited to control various forms of pathogens 28. cDC1s, for example, recognize 
intracellular pathogens and initiate type 1 immune responses that require the early activation of 
ILC1s and NK cells as well as eventual Th1 polarization 27. Some cDC2s, on the other hand, 
govern type 2 immune responses against parasites in which they activate ILC2s and Th2 cells 29. 
Other cDC2s sense extracellular bacteria and initiate type 3 immune responses by activating 
ILC3s and Th17 cells 23,30. In this way, each cDC subset acts as the gatekeeper for a specific 
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module of the immune response, recognizing a particular type of threat and activating both the 
innate and adaptive defenses best suited for overcoming it. 
Since the time of their discovery, there has been considerable debate over whether DCs 
possess unique functions or whether they are redundant with macrophages and other mononuclear 
cells 31. Fortunately, increasingly sophisticated mouse models for the specific ablation of DCs or 
for the conditional deletion of genes in these cells have helped resolve some of these controversies, 
revealing how immune responses are compromised in the absence of DCs and thus the roles these 
cells play in the normal response. These mouse models have been critical for elucidating the unique 
functions of DCs and resolving previously ambiguous conclusions. This dissertation will first 
provide an overview of the mouse models that have been developed to interrogate DC function 
and how these models have progressively clarified the role of DCs in various types of immune 
responses. As recent reviews have discussed DC development 17,18, this overview will focus 
primarily on how DCs function in immune responses to pathogens, autoimmunity, and cancer. 
 
1.3  Mouse models for studying dendritic cells 
Numerous models of constitutive and inducible DC depletion have been generated and 
used to identify the specific functions of DC subsets. In this section, we will first describe the 
different strains developed, their specificity, and their limitations. We will organize this by 
categories of DTR/DTA based models, Cre strains, and transcription factor knockout mice. In the 
next section we will discuss the discoveries made with these models regarding the functions of 




Depletion of dendritic cells by DTR/DTA systems 
The first models of genetic ablation of cell lineages were transgenic mice in which cell 
type-specific promoters drove expression of the diphtheria toxin (DT) A-chain 32,33. This toxin 
disrupts protein translation by catalyzing the ADP-ribosylation of polypeptide chain elongation 
factor 2 and eventually leads to cell death 34-36. While DT efficiently ablates the cells in which it 
is expressed, it can be problematic as even low levels of off-target expression can lead to death 
of unintended cells or even to effects on embryogenesis or morphogenesis 37. Later mouse 
models overcame this problem by expressing the human or simian DT receptor (DTR) under the 
control of a cell type-specific promoter, with subsequent administration of DT to these mice 38. 
As the mouse ortholog of the DTR is orders of magnitude less sensitive to DT 39,40, this allows 
for the efficient depletion of only DTR-expressing cells and has the added benefit of allowing for 
inducible depletion of these target cells rather than constitutive ablation. 
The first DTR based model used for DCs was the Itgax-DTR strain, a transgenic line 
expressing a DTR-GFP fusion protein under the control of the murine promoter for the gene 
Itgax, which codes for the integrin CD11c 41. DT administration completely depleted CD11c+ 
DCs within 24 hours, with no observable depletion of splenic B cells or F4/80+ macrophages. 
DCs began to reappear 3 days after DT treatment. While this strain was vital for early work 
confirming the functions of DCs in T cell priming and pathogen responses, several limitations 
have emerged. First, repeated administration of DT led to death in these mice, restricting the 
duration through which depletion could be studied 41. This lethality was likely due to off-target 
expression of the Itgax-DTR transgene in radioresistant or non-hematopoietic tissues, since BM 
chimeras of WT BM into Itgax-DTR recipients also died after repeated DT treatment. This 
limitation can be overcome by generating chimeras of Itgax-DTR BM into WT recipients, which 
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tolerate repeated DT treatment 42. Another caveat derives from CD11c expression by non-DCs 
and the depletion by DT of such cells, which include splenic metallophilic and marginal zone 
macrophages, LN sinusoidal macrophages 43, alveolar macrophages 44, activated CD8 T cells 41, 
and plasma cells 45. Ablation of these cells complicates analysis with this strain, since 
phenotypes observed may result from their depletion rather than that of DCs. Some CD11c+ 
cells, notably pDCs, are not depleted in this model, indicating that the level of CD11c expressed 
by cells influences whether they are depleted 46. 
A similar DTR strain, Itgax-DOG 47, is a BAC transgenic line in which the Itgax 
promoter drives expression of a fusion protein composed of DTR, a portion of ovalbumin, and 
GFP (DOG). Continuous DT treatment in these mice does not cause lethality, perhaps due to 
more faithful expression of the BAC compared with the promoter-based transgene. Depletion of 
splenic macrophages was also observed after DT treatment in these mice, but whether CD8 T 
cells and plasma cells were similarly affected has not been evaluated. 
The recently developed Zbtb46-DTR mouse allows for more specific depletion of cDCs 
48. This strain has sequences for an internal ribosome entry site (IRES) and a DTR-mCherry 
fusion protein inserted into the 3’ untranslated region (UTR) of the endogenous Zbtb46 gene, 
which codes for the zinc finger transcription factor Zbtb46 (also known as zDC) whose 
expression in hematopoietic lineages is restricted to cDCs. However, a single administration of 
DT into Zbtb46-DTR mice or into chimeras of WT BM into Zbtb46-DTR recipients proved 
lethal, indicating zDC expression in vital radioresistant or non-hematopoietic cells. Further work 
indicated these vital cells may be endothelial cells 49. DT treatment of Zbtb46-DTR BM into WT 
recipient chimeras depleted cDCs alone without ablation of B cells, T cells, neutrophils, natural 
killer cells, pDCs, or monocytes. This strain therefore allows for the specific and complete 
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deletion of cDCs, with the caveat that BM chimeras must be used. To circumvent this need, the 
Zbtb46-LSL-DTR mouse was generated 50, in which the IRES-mCherry-DTR is preceded by a 
loxP flanked transcriptional Stop cassette (LSL) that terminates transcription of the locus before 
the DTR. Transcription of the DTR proceeds only after Cre-mediated excision of the Stop 
cassette. After crossing the Zbtb46-LSL-DTR strain to a Csf1r-cre strain 50, DT administration 
specifically depleted cDCs and did not lead to lethality. This model allows for the continuous 
depletion of cDCs for at least 4 weeks without the need for BM chimeras. 
Several DTR strains allow for depletion of specific DC subsets. The first were two strains 
that expressed DTR from the endogenous Cd207 gene that codes for langerin, a C-type lectin 
expressed on epidermal Langerhans cells and dermal cDC1s. One strain was generated by 
inserting an IRES DTR-egfp into the 3’ UTR of the Cd207 gene 51, while in the second strain the 
first Cd207 coding exon was replaced with a DTR-egfp cassette 52. In both strains, DT treatment 
depletes Langerhans cells as well as cDC1s in skin-draining LNs. Additionally, a BAC 
transgenic CD207-DTA mouse strain was generated using a BAC in which an IRES DTA was 
inserted into the 3’ UTR of the human CD207 gene that codes for langerin 53. This strain has 
constitutive ablation of Langerhans cells but not of cDC1s in skin-draining LNs, suggesting that 
the human CD207 promoter is controlled differently from its murine equivalent. It was later 
demonstrated that these mice also lack CD103+CD11b+ cDC2s in the intestinal lamina propria 54. 
The Ly75-DTR strain was generated by inserting an IRES DTR-eGFP into the 3’ UTR of 
the Ly75 gene that codes for CD205, an endocytic type I C-type lectin-like receptor also known 
as DEC-205 55. DT administration to this mouse also resulted in lethality, necessitating the use of 
Ly75-DTR into WT recipient BM chimeras. DT treatment of such chimeras depleted CD205+ 
cDCs, the majority of which were CD8α+ cDC1s. CD205 is also expressed on B cells at 10-50 
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fold lower levels than on BM derived DCs 56 and accordingly a minor decrease in splenic B cells 
was observed upon DT treatment to Ly75-DTR mice. However, CD205 is also expressed at 
much higher levels in germinal center (GC) B cells 57 as well as all migratory cDCs and 
Langerhans cells 58, but it was not determined whether DT treatment also depleted these cells. 
The Clec9a-DTR BAC transgenic mouse, in which the first Clec9a coding exon in the 
BAC was replaced with DTR, also allows for depletion of cDC1s 59. DT treatment completely 
ablates cDC1s, but also causes a ~50% decrease in pDCs, which may be due to the lower 
expression of Clec9a in mature pDCs 60,61. Clec9a is expressed in the common dendritic cell 
progenitor (CDP) 62, so continuous DT treatment may deplete this progenitor and therefore all 
DCs over prolonged periods. Though this issue was not examined in the original study, at least 
one report indicated that cDC2s were unaffected after 15 days of DT treatment 63. 
Two more recent DTR strains specifically deplete cDC1s. In the Xcr1-DTRvenus strain, 
the first Xcr1 coding exon was replaced by a cassette encoding a DTR-venus fusion protein 64. 
XCR1 is a chemokine receptor uniquely expressed by cDC1s in humans, mice, and sheep 65,66. 
DT treatment to this strain completely depleted cDC1s with no decrease in T cells, B cells, NK 
cells, granulocytes, monocytes, cDC2s, or pDCs. Expression of the Venus fluorescent protein 
was likewise restricted to cDC1s. This subset was depleted by 24 hours after DT treatment and 
began to recover on day 4 after treatment. A similar mouse strain, referred to as Karma, has an 
IRES tdTomato-2A-DTR inserted into the 3’ UTR of the endogenous a530099j19rik gene 67, 
which like XCR1 is highly specific for cDC1s. Both tdTomato expression and cell ablation after 
DT treatment were specific to cDC1s. 
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The Clec4a4-DTR strain, a BAC transgenic line in which an IRES DTR was inserted into 
the 3' UTR of the Clec4a4 gene on the BAC, allows for ablation of cDC2s 63. Clec4a4 (also 
known as DCIR2) is a C-type lectin expressed by cDC2s and recognized by the 33D1 antibody 
first used to define this subset 68,69. DT treatment in this strain severely reduces CD103+CD11b+ 
cDC2s in the colonic lamina propria and CD11b+ cDC2s in the mesenteric LNs, and partially 
depletes CD103-CD11b+ cDC2s and CD64+CX3CR1+ macrophages in the colonic lamina 
propria. Whether depletion of other cells occurs and whether cDC2s in other organs are similarly 
depleted remains to be determined. A second strain thought to deplete a subset of cDC2s is the 
Mgl2-DTR strain, in which the first coding exon of the endogenous Mgl2 gene was replaced by a 
DTR-gfp cassette 70. DT treatment in this strain depletes the Mgl2+ population of dermal cDC2s, 
but whether DCs in other tissues are also depleted remains to be analyzed. 
Several DTR strains have been generated for pDC depletion. The first was the CLEC4C-
DTR BAC transgenic strain, which replaced the exons of the human gene CLEC4C in the BAC 
with the sequence for DTR 71. CLEC4C codes for BDCA-2, a C-type lectin uniquely expressed 
by human pDCs with no equivalent in mouse pDCs, but its human promoter remains active in 
mouse pDCs as DT treatment in CLEC4C-DTR mice specifically and completely depleted pDCs. 
No reduction was observed in B cells, cDCs, T cells, NK cells, macrophages, monocytes, or 
neutrophils. Second, a Siglech-DTR strain was generated by knocking an IRES DTR-egfp 
sequence into the 3' UTR of the endogenous murine Siglech gene 72. Homozygous Siglech-DTR 
mice lacked expression of Siglec-H on pDCs, implying that the IRES DTR cassette somehow 
altered native Siglec-H expression. In this strain, DT administration completely depletes pDCs in 
the spleen, mesenteric LNs, and BM, with no apparent effect on cDCs. However, Siglec-H 
deficiency has been associated with altered cytokine responses 73 and perhaps abnormal kidney 
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and testes function 74, which may influence the phenotypes of this strain. Third, a Siglech-DTR 
BAC transgenic strain was generated on the Balb/c background by replacing the coding exons of 
Siglech in a BAC with the sequence for DTR 59. DT treatment in these mice completely depleted 
pDCs with no effect on cDCs. A separate BAC transgenic Siglech-DTR line on the C57BL/6 
background was later generated, and analysis of both Siglech-DTR lines found that Siglec-H was 
also expressed by marginal zone macrophages and DT treatment ablated these cells as well as 
pDCs 73. This indicates that cell ablation in Siglech-DTR strains may not be limited to pDCs, 
complicating analysis with these lines. 
Finally, several DTR based systems for the depletion of monocytes and macrophages 
(reviewed in 75), have been generated that are driven by genes such as CCR2 and CX3CR1. 
These have helped segregate the independent functions of monocytes and cDCs. One useful 
model for this purpose is the Cx3cr1-LSL-DTR strain 76, in which an LSL-DTR was inserted into 
the endogenous Cx3cr1 locus. This strain was crossed to Itgax-cre so that DT treatment 
specifically depletes CD11c+CX3CR1+ cells, which include CD103-CD11b+ cDC2s and 
monocyte-derived CD11b+ macrophages in the intestinal lamina propria 22. Another useful model 
is the MM-DTR strain, which was a cross between the Csf1r-LSL-DTR and LysM-cre strains, 
and in which DTR expression is limited to monocytes and monocyte-derived macrophages 77. 
Table 1.1 provides a summary of DTR strains useful for the study of DC function. 
An important caveat for some DTR strains is the reduced LN cellularity seen even without 
DT treatment 78. In a cross between the Clec9a-cre strain and a Rosa26-LSL-DTR strain 79, 
reduced cellularity was observed in skin-draining and mesenteric LNs even without DT treatment. 
There was also reduced cellularity in skin-draining LNs of Itgax-DTR mice, Cd207-DTR mice, 
and a cross between Itgax-cre and Rosa26-LSL-DTR mice. There was no decrease observed in 
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Itgax-DOG mice, so this phenomenon must be evaluated in each individual strain. The basis for 
this effect is unclear. 
 
Cre strains for conditional deletion of genes in dendritic cells 
The Cre-loxP system allows for conditional deletion of genes in specific cell lineages 80. 
In this system, two 34-bp loxP sites are inserted on either side of a gene or exon, which is then 
said to be “floxed”. Cell type-specific promoters are then used to express the bacteriophage P1 
cre gene, which encodes an integrase that mediates recombination between two adjacent loxP 
sites, leading to deletion of the intervening DNA and inactivation of the floxed gene in Cre+ 
cells. 
 The earliest Cre strains developed for cDCs were based on CD11c expression. First was 
an Itgax-cre BAC transgenic line in which the first coding exon of Itgax was replaced with cre 
81. When crossed to the Rosa26-LSL-yfp strain 82, in which Cre-mediated excision of a STOP 
cassette allows YFP expression, splenic DCs were >95% labeled and pDCs were ~86% labeled. 
However, background deletion of 5-12% was seen in splenic T, B, and NK cells. A later study 
also found deletion in 20-40% of blood monocytes, nearly ~100% of alveolar macrophages, 70% 
of splenic red pulp macrophages, 35% of marginal zone macrophages, and 20% of peritoneal 
macrophages 83. Therefore, as with Itgax-DTR strains, Itgax-cre is active in non-DC populations. 
The second Itgax-cre strain is a transgenic line expressing cre-IRES-gfp under the control of the 
Itgax promoter 84. GFP expression in this line was found to be uniformly high in cDC1s and 
cDC2s as well as in pDCs, but no expression was seen in T cells or B cells. Whether deletion of 
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genes occurred in cell types other than DCs, especially other CD11c+ populations such as 
macrophages, was not evaluated and remains to be resolved. 
 The Clec9a-cre strain was generated by replacing the first two exons of the endogenous 
Clec9a gene with cre 62. Clec9a is first expressed at the CDP stage and is maintained in cDC1s 
and pDCs, but not in cDC2s 60-62. The Clec9a-cre strain achieved deletion in ~100% of cDC1s, 
~50% of cDC2s, and ~20% of pDCs, suggesting that the transient expression of Cre at the CDP 
stage is insufficient for full deletion in cDC2 precursors and that pDCs do not express high 
enough levels of Cre for complete deletion. Deletion was not observed in any other cell types. 
 Recently a Zbtb46-cre line was produced by inserting an IRES-cre cassette into the 3’ 
UTR of the endogenous Zbtb46 gene, allowing for more specific deletion of genes in cDCs 85. 
When crossed to Rosa26-LSL-yfp mice, the Zbtb46-cre achieved deletion in ~65% of cDCs, 
which was lower than the ~100% deletion with Itgax-cre, but also demonstrated <10% deletion 
in T cells, B cells, and monocytes, which was also consistently lower than the deletion seen with 
Itgax-cre. Also <10% deletion was seen in red pulp macrophages, pDCs, and small intestinal 
macrophages, in contrast to the Itgax-cre strain where ~70% of red pulp macrophages and pDCs 
and ~100% of small intestinal lamina propria macrophages showed deletion. Zbtb46-cre also 
induced ~95% deletion of a floxed MHCII allele in cDCs, indicating that deletion of some alleles 
may be more complete than others. It was not evaluated whether Zbtb46-cre is as active in 
endothelial cells as the Zbtb46-DTR strain is. 
The first Cre strain for targeting specific DC subsets was the Cd207-cre, in which a cre 
cassette was inserted into the second exon of the endogenous Cd207 gene 86. This strain achieved 
nearly complete deletion in Langerhans cells and langerin+ cDC1s in the dermis, skin-draining 
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LNs, and lung. A second Cre line useful for targeting particular DC subsets is the Xcr1-cre strain, 
in which the first exon of the endogenous Xcr1 gene was replaced by cre 87. This was crossed to 
Rosa26-lacZbpAfloxDTA mice 88, in which Cre excises a loxP flanked lacZ-polyadenylation (bpA) 
sequence and allows for DTA expression and cell ablation. This cross resulted in nearly complete 
ablation of cDC1s in the spleen, MLN, and intestinal lamina propria, but no reduction in cDC2s in 
these organs. There was no reduction in CD4 or CD8 T cells in the spleen or MLN, but T cells and 
intraepithelial lymphocytes in the intestinal lamina propria were reduced, which was attributed to 
the absence of cDC1s. Finally, in the BAC transgenic Siglech-cre strain, the first exon of Siglech 
was replaced with a cre IRES mCherry cassette 89. However, this strain only achieved deletion in 
~30% of pDCs and ~2% of all lymphoid cells, and so is better suited for lineage tracing than 
functional analysis. 
 
Transcription factor based depletion of dendritic cells 
Several transcription factors have been identified whose deletion selectively depletes 
specific subsets of DCs, and these knockout mice provide useful models for studying DC 
function. One of the earliest identified was the Irf8-/- strain, which lacks cDC1s 90,91, but also has 
impairments in B cells 92, monocytes 93, eosinophils 94, and basophils 95. Irf8-/- mice were also 
thought to lack pDCs 90, but more recently it was determined that pDCs do not require IRF8 for 
their development but instead that loss of this factor affects their expression of cell-surface 
markers and their ability to produce interferon 96. Irf8-/- mice therefore do not serve as a model of 
specific cDC1 depletion, but this can be overcome by crossing a floxed Irf8 allele to the Itgax-
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cre strain 97, which depletes cDC1s and CD64+CD11b+ macrophages in the intestinal lamina 
propria, or to the Zbtb46-cre strain 98, which specifically depletes cDC1s. 
 Id2-/- mice lack cDC1s 99, but also have defects in NK cells 100 and ILCs 101. Nfil3-/- mice 
similarly lack cDC1s 102, NK cells 103, and ILCs 104,105. The similarity of Id2-/- and Nfil3-/- mice 
may result from an epistatic action of Nfil3 on the expression of Id2 during DC development, as 
has been suggested for NK cell development 106. 
Batf3-/- mice are selectively deficient in cDC1s 107. Batf3 and the AP-1 transcription 
factor Jun form a heterodimer that interacts with IRF8 to bind AP-1/IRF consensus elements 
(AICEs) 108,109. Batf3 acts to maintain the expression of IRF8 by autoactivation during 
development of cDC1s, without which cDC1s divert to cDC2 fate 13. Batf3-/- mice on the 
129SvEv and Balb/C backgrounds have an almost complete lack of cDC1s in lymphoid and 
nonlymphoid tissues 110, but interestingly in the C57BL/6 background they retain cells 
resembling cDC1s in skin-draining LNs 108. 
Few known transcription factors selectively control cDC2 development. Relb-/- mice have 
DCs with reduced immunogenicity 111, and reportedly a partial cell-intrinsic defect in cDC2 
development 112. RelB acts in the noncanonical NFκB signaling pathway activated by 
lymphotoxin-β receptor (LTβR) signaling, and Ltbr-/- mice also have a cell-intrinsic but partial 
reduction in CD4+ cDC2s 113. It has not been tested whether the impact of RelB deficiency on 
DCs is secondary to deficient LTβR signaling. As Relb-/- mice develop severe multiorgan 
inflammation and hematopoietic abnormalities 114, and Ltbr-/- mice lack lymph nodes 115, neither 
strain is a convenient model for testing DC function. Conditional deletion of Ltbr with Itgax-cre 
has been used to overcome this limitation 116. 
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Other factors that influence cDC2 development include Notch2 and Klf4. Conditional 
deletion of the Notch cofactor Rbpj 81 or Notch2 23,30 using Itgax-cre demonstrated a specific 
depletion of CD11b+ESAM+ cDC2s in the spleen and CD103+CD11b+ cDC2s in the intestinal 
lamina propria and MLNs, without apparent loss of other cell types. Notch2f/f Itgax-cre mice did 
exhibit gene expression changes in remaining cDC1s and cDC2s, however, indicating possible 
effects of Notch2 in these lineages 23. Conditional deletion of the transcription factor Klf4 with 
Itgax-cre also led to the depletion of subsets of cDC2s 29 similar to migratory CD24- CD11b- 
cDC2s in skin-draining LNs 117. 
Irf4-/- mice do not lack cDC2s, but instead have partial impairments in the number or 
functioning of these cells. CD11b+ cDC2s are present in the skin of Irf4-/- mice, but fail to 
migrate to LNs 118,119. Similarly, conditional deletion of Irf4 with Itgax-cre resulted in a partial 
reduction in CD11b+ cDC2s in the lung but an almost complete absence of CD11b+ cDC2s in the 
lung draining LNs 19, as well as a partial reduction in CD103+CD11b+ cDC2s in the intestinal 
lamina propria and a more complete reduction in mesenteric LNs 19,120. Finally, conditional 
deletion of Irf4 with Itgax-cre depletes a PDL2+Mgl2+ population of cDC2s in skin-draining LNs 
but not the dermis 121. But although Irf4f/f Itgax-cre mice can serve as a useful model for cDC2 
deficiency, IRF4 also plays a role in other CD11c+ cells such as M2 macrophages 122 and GM-
CSF activated monocytes 123, and these may also be affected in this strain. 
Several transcription factors have been identified that regulate pDC development. The first 
model of specific pDC deficiency was conditional deletion of Tcf4, which encodes the factor E2-
2, with Itgax-cre 124. Recently, conditional deletion of the transcription factor Zeb2 using Itgax-
cre also demonstrated selective pDC deficiency 125. Table 1.3 provides a summary of the 




1.4  Functions of dendritic cells. 
Since their discovery, cDCs were recognized as possessing a remarkable capacity to 
stimulate naïve T cells and to initiate adaptive immune responses 2,3. Subsequent work, based in 
large part on the models described above, has shown that DCs are also critical for - not just 
participants in - early innate immune responses, activating innate lymphoid cells (ILCs) and other 
cells involved in the immediate response to pathogens. Additionally, subsets of cDCs play varied 
roles in autoimmunity and responses to tumors. Below we discuss the studies that identified these 
functional aspects of DCs, what tools were used to arrive at these conclusions, and confounding 
factors that may require further resolution. 
 
General adaptive immune responses 
The first study to use Itgax-DTR mice showed that the absence of CD11c+ cells led to the 
loss of CD8 T cell priming to cell-associated antigens and to the intracellular pathogens Listeria 
monocytogenes and malaria 41. This provided the first direct in vivo evidence for the role of 
CD11c+ cells in T cell priming. Subsequent use of the Itgax-DTR strain showed a requirement 
for CD11c+ cells in priming CD8 T cells against lymphocytic choriomeningitis virus (LCMV) 
126, herpes simplex virus (HSV) 127, vesicular stomatitis virus (VSV) 128, and influenza 129,130, as 
well as in CD4 T cell priming against HSV 127, Mycobacterium tuberculosis (Mtb) 131, and 
immune complexes 132. Depletion of CD11c+ cells in Itgax-DTR mice also impaired the 
expansion of antigen-specific memory CD8 T cells during rechallenge with Listeria, VSV, or 
influenza 133 or with LCMV 134. 
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 Later studies used additional models to validate the specific role of cDCs and not other 
CD11c+ cells in T cell priming. Specific ablation of cDCs with the Zbtb46-DTR strain resulted in 
a complete inability to prime CD8 or CD4 T cells against soluble antigen 48, and also a failure to 
prime CD4 T cells against Mtb 135. Finally, cDC specific deletion of MHCII using Zbtb46-cre 
led to a complete reduction in CD4 T cell priming to soluble antigen 85. 
Targeting antigen to specific DC subsets has indicated that there may be a specialization 
of roles between subsets, with cDC1s preferentially priming CD8 T cells and cDC2s priming 
CD4 T cells 69. cDC1s have also been recognized as the cells most efficient in cross-presentation 
of exogenous antigens on MHC class I 136. Studies using mouse models with selective depletion 
of one subset have provided evidence to support this dichotomy. Batf3-/- mice failed to prime 
CD8 T cells against cell-associated antigen or West Nile virus (WNV), but still had intact 
priming of CD4 T cells 107. Batf3-/- mice also mounted reduced CD8 T cell responses to 
cytomegalovirus (CMV) 137, influenza 138,139, cowpox virus 140, HSV 141,142, and malaria 143. 
Depleting cDC1s using the Xcr1-DTRvenus strain also abrogated CD8 T cell priming against 
soluble and cell-associated antigen as well as against Listeria infection 64. CD4 T cells could still 
be primed against soluble antigen in these mice. A study using Karma mice similarly showed 
that depletion of cDC1s led to deficient CD8 T cell priming to soluble protein as well as failure 
to reactivate memory CD8 T cells in response to Listeria, vaccinia virus, and VSV 67. Taken 
together these studies suggest that cDCs alone are responsible for priming T cells, with a specific 
role for cDC1s in priming naïve CD8 T cells and activating memory CD8 T cells during recall 
responses. Future work with specific depletion of cDC2s is needed to confirm their unique role 
in priming CD4 T cells. 
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Recent work has also indicated that CD4 T cell help in CD8 T cell responses might be 
mediated through “licensing” of cDC1s. Analysis of immune responses suggests that CD4 T 
cells are primed by DCs earlier than CD8 T cells, and that later in the response clusters of these 
three cell types form during which CD4 T cells may "license" cDC1s in order to enhance 
priming of CD8 T cells 144,145. In agreement with this model, one study found that mixed bone 
marrow chimeric mice made of Xcr1-DTR:H2-Ab1-/- BM, in which following DT treatment all 
remaining cDC1s lack MHCII expression, generated fewer antigen-specific CD8 T cells upon 
vaccinia virus infection 145. MHCII expression in cDC1s may therefore serve as a mechanism by 
which they receive CD4 T cell help rather than for their direct priming of naïve CD4 T cells. 
Several studies have implicated DCs in the induction of Tfh cells and the initiation of the 
germinal center (GC) response. Depletion of all CD11c+ cells by Itgax-DTR was found to diminish 
the number of Tfh cells induced in response to Toxoplasma infection 146. Specific cDC depletion 
with Zbtb46-DTR mice also abolished GC responses and antibody production against allogeneic 
red blood cells (RBCs) 147. This was attributed to the function of cDC2s, as Batf3-/- mice had intact 
antibody responses but Irf4f/f Itgax-cre mice did not 147. Another study found that CD25 expression 
by cDCs was crucial for Tfh induction 148. In this study, mixed BM chimera mice reconstituted 
with Zbtb46-DTR:Il2ra-/- BM, in which after DT treatment all remaining cDCs lack the IL-2 
receptor alpha chain (CD25), failed to generate antibodies or GC B cells upon sheep RBC 
immunization. cDC2s in the spleen can induce expression of CD25, suggesting these may be the 
specific cells involved in this process 148. Finally, IgA class switching in Peyer’s patches was also 
found to be regulated by DCs 149. This study utilized mixed BM chimeras made from Itgax-
DTR:Ltbr-/- BM, in which following DT treatment all remaining DCs lack the LTb receptor and 
thus certain cDC2s fail to develop. After DT treatment, these chimeras had fewer IgA class-
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switched GC B cells in Peyer’s patches. This appears to involve the activation of latent TGF-β by 
the integrin chains Itgβ8 and Itgαv on DCs and presentation of the active cytokine by DCs to B 
cells, as Itgax-cre mediated deletion of Itgb8 also resulted in reduced IgA+ GC B cells 149. 
 
Type 1 immune responses 
Type 1 immune responses are mounted against intracellular pathogens that require IFN-g 
activated macrophages and cytotoxic CD8 T cells for their clearance. Early nonspecific sources of 
IFN-g are NK cells and ILC1s, while antigen-specific Th1 and CD8 T cells are responsible for 
producing this cytokine later in the immune response. IL-12 is critical for the activation of type 1 
responses, as it induces NK cells and ILC1s to secrete IFN-g 150, and is also responsible for the 
polarization of naïve T cells to Th1 cells 151. Several studies have established that cDC1s are vital 
for mounting type 1 responses because of their non-redundant production of IL-12 and their ability 
to prime CD8 T cells. 
 The first indication that cDC1s are important in these responses was a study 
demonstrating that Irf8-/- mice had increased susceptibility to Toxoplamsa gondii infection and 
reduced serum IL-12 levels 152, though given the myriad defects in this mouse this could not be 
attributed specifically to cDC1s. Later, Itgax-DTR mice were used to show that CD11c+ cells 
were required for IL-12 and IFN-γ production and protection against Toxoplasma infection 153. 
Finally, Batf3-/- mice that specifically lack cDC1s were found to be susceptible to Toxoplasma, 
demonstrating that these cells were indeed critical for resistance 27. Mixed chimeras made from 
Batf3-/-:Il12a-/- BM, in which all cDC1s that develop are deficient in IL-12 production, were 
susceptible to Toxoplasma infection, indicating that cDC1s are the non-redundant source of IL-
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12 necessary for resistance to infection 27. Additionally, depletion of cDC1s using the Karma 
strain abolished IL-12 production in response to soluble Toxoplasma antigen 67. Batf3-/- mice also 
have reduced IFN-γ production from NK cells during Toxoplasma infection, suggesting that IL-
12 from cDC1s is critical for NK cell activation in this response 154. 
The role of cDCs in type 1 responses to several other intracellular pathogens has also 
been documented. During infection by Listeria, Itgax-DTR 155, Batf3-/- 156, Ly75-DTR 55, and 
Xcr1-DTRvenus 64 mice all had reduced CD8 T cell responses. However, many of these strains 
also exhibited a reduced splenic Listeria burden and Batf3-/- mice actually demonstrated 
increased resistance to infection. This is because Listeria must infect cDC1s in the splenic 
marginal zone in order to spread to and proliferate in the lymphoid areas of the spleen 155, so 
Batf3-/- mice lacking these cells show reduced susceptibility to infection. Finally, constitutive 
deletion of CD11c+ cells, achieved by crossing Itgax-cre mice to Rosa26-LSL-DTA mice 157, 
diminished IFN-γ production from NK cells, NKT cells, and T cells during Listeria infection 158. 
Leishmania major, another intracellular pathogen, similarly requires cDC1s for its 
clearance, as Batf3-/- mice exhibit greater disease burden from infection 159 and generate fewer 
Th1 cells 160. Another study used Batf3-/- and Cd207-DTR mice to demonstrate that cDC1s are 
required for the priming of CD8 T cells and Th1 cells against skin infection by the fungus 
Candida albicans 161. 
Several studies have implicated DCs in NK cell homeostasis. Depletion of CD11c+ cells in 
Itgax-DTR mice diminished steady-state numbers of NK cells 162 and reduced their cytotoxicity 
and IFN- γ production in several infection models 127,163,164. NK cell survival and activation 
requires trans-presentation of IL-15, whereby a non-NK cell that expresses the non-signaling 
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receptor chain IL-15Rα binds IL-15 and presents to the full IL-15αβγ receptor on NK cells 165. 
One study implicated a CD11c+ cell as the trans-presenting cell by using mixed BM chimera mice 
made from Itgax-DTR:Il15-/- BM or from Itgax-DTR:Il15rα-/- BM 166. In these chimeras, DT 
treatment causes all remaining CD11c+ cells to lack IL-15 or IL-15Rα, respectively, and after DT 
treatment these chimeras show severely reduced NK cell activation in vivo. Future studies are 
needed to clarify whether cDCs are involved in this activity, and if so which subsets.  
 
Type 2 immune responses   
Type 2 responses are carried out against multicellular parasites at barrier surfaces in order 
to aid in their expulsion. Many cytokines play key roles in this response. These include IL-25 
and IL-33, which activate ILC2s to produce effector cytokines such as IL-4, IL-5, and IL-13 150, 
and IL-4, which polarizes naïve T cells to Th2 cells 167. Much remains unknown about the 
initiation of type 2 immune responses, and it has been controversial whether DCs are even 
involved directly. 
An early study found that depletion of CD11c+ cells in Itgax-DTR mice did not impair 
Th2 cell polarization in response to immunization with papain 168, although another study using 
the same strain found that it did 169. A later study also found that depletion of CD11c+ cells in 
Itgax-DTR mice abrogated type 2 responses, this time to inhaled house dust mite (HDM) 
allergen 170. This study implicated an FcεRI expressing CD11c+MHCII+ cell population as being 
the principal APC responsible. Subsequent studies also found that CD11c+ cell depletion by 
Itgax-DTR reduced numbers of Th2 cells after infections with the helminthes Schistosoma 
mansoni 171, Heligmosomoides polygyrus 172, and Nippostrongylus brasiliensis 173. 
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Other models have suggested putative Th2 inducing DC subsets. Two groups 
demonstrated that depletion of an Mgl2+ subset of cDC2s, either with the Mgl2-DTR strain 70 or 
by conditional deletion of Irf4 with Itgax-cre 121, diminished Th2 priming in response to papain 
and Nippostrongylus infection. Irf4f/f Itgax-cre mice also had reduced Th2 responses after HDM 
allergen challenge 174. Another study found that depletion of a subset of cDC2s in the Klf4f/f 
Itgax-cre strain increased susceptibility to Schistosoma mansoni infection and diminished 
allergic inflammation after intransal HDM challenge 29. Also, a subset of CXCR5+ DCs, which 
was depleted by using Itgax-DTR:Cxcr5-/- BM chimeras, appeared to be required for Th2 
responses to Heligmosomoides infection 175. Finally, Batf3-/- mice develop somewhat stronger 
Th2 responses to helminth infection, suggesting that the IL-12 produced by cDC1s regulates Th2 
polarization carried out by other DCs 176. 
Cytokine production by DCs has not been established in any of these models, so whether 
they control type 2 responses by this mechanism or some other remains to be determined. Recent 
studies have suggested that ILC2s may be the critical source of cytokines acting to induce type 2 
responses 177,178. Conceivably, ILC2s and DCs may cooperate in Th2 priming, but this area awaits 
further studies.      
 
Type 3 immune responses 
Type 3 immune responses at barrier surfaces such as the lungs and intestines control 
infections by extracellular bacteria and fungi and require several cytokines, including IL-23 and 
IL-6. IL-6 and TGF-β initiate Th17 cell polarization 179, and IL-23 increases the survival and 
expansion of committed Th17 cells 180. IL-23 is also crucial in innate responses for activating 
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ILC3s to produce IL-22, which in turn promotes production of bactericidal lectins such as 
RegIIIγ from small intestinal epithelial cells 150,181. 
Citrobacter rodentium, a mouse pathogen used to study type 3 immune responses, 
requires IL-23 and IL-22 for its clearance 182-184. An early study that implicated cDCs in response 
to oral Citrobacter infection found that conditional deletion of Ltbr by Itgax-cre, which depleted 
a subset of cDC2s, reduced colonic IL-22 production and increased pathogen burden 116. Later 
studies demonstrated that depletion of all cDCs in Zbtb46-DTR mice 23,77 led to severe 
susceptibility to Citrobacter infection, as did depletion of cDC2s with Notch2f/f Itgax-cre mice 23. 
Mixed BM chimeras reconstituted with Notch2f/f Itgax-cre:Il23a-/- BM were also severely 
susceptible to Citrobacter infection, indicating that Notch2-dependent cDC2s are the critical 
source of IL-23 in defense against this pathogen 23. NFκB signaling in CD11c+ cells is also 
critical, as mice with conditional deletion of Myd88 with Itgax-cre also showed susceptibility to 
Citrobacter 185. Importantly, mice depleted of all cDCs or Notch2-dependent cDC2s die at ~day 
10 after Citrobacter infection, while Rag2-/- mice lacking B and T cells die at ~day 30 after 
infection 182. This suggests that cDC2s are critical for activating innate defenses during 
Citrobacter infection and not just for initiating adaptive immunity. 
Several recent studies have suggested contributions from multiple cDC2 subsets in 
defense against Citrobacter. First, CD207-DTA mice, which lack intestinal CD103+CD11b+ 
cDC2s, were not found to be susceptible to Citrobacter infection 54. Thus, the lethality seen with 
Notch2 deficiency may be due to an impact on the function of CD103-CD11b+ cDC2s, rather 
than the depletion of CD103+CD11b+ cDC2s. In accordance with this possibility, Cx3cr1-LSL-
DTR mice crossed to Itgax-cre, in which DT treatment depletes CD103-CD11b+CX3CR1+ 
cDC2s and CD11b+ macrophages, also showed susceptibility to Citrobacter and reduced IL-22 
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production 185. Finally, MM-DTR mice, which lack monocytes and monocyte-derived 
macrophages, did not display susceptibility to Citrobacter, suggesting that CD103-CD11b+ 
cDC2s and not CD11b+ macrophages are the critical cells for defense against this pathogen 77. 
However, direct comparison of these different models may be required to eliminate confounding 
effects such as variable microbiota in the strains used in each study. 
Studies have also implicated cDC2s in various other type 3 responses, but the reported 
mechanisms by which they act have varied. Several groups found that depletion of intestinal 
CD103+CD11b+ cDC2s, using Notch2f/f Itgax-cre, Irf4f/f Itgax-cre, or CD207-DTA mice, resulted 
in fewer small intestinal Th17 cells at steady state 19,30,54. Another study using the Irf4f/f Itgax-cre 
strain similarly found reduced numbers of Th17 cells at steady state in the small intestine lamina 
propria and mesenteric lymph nodes, and also reduced Th17 polarization after immunization 
with antigen plus αCD40 and LPS 120. This study observed reduced levels of IL-6 in Irf4-/- DCs, 
which might explain the reduced Th17 priming. A second group found deficient Th17 priming in 
Irf4f/f Itgax-cre mice after lung infection by the fungal pathogen Aspergillus fumigatus, which 
was attributed to the loss of CD11b+ cDC2s that normally express high levels of IL-23, IL-6, and 
TGF-β 19. 
In agreement, another study used BM chimeras to show that CD11c+ cells must produce 
IL-6 and TGF-β to induce Th17 responses to Streptococcus pyogenes 186. They found that BM 
chimeras of Itgax-DTR:Il6-/- or Itgax-DTR:Tgfb1f/f BM, in which DT treatment causes all 
remaining DCs to be deficient in either IL-6 or TGF-β respectively, had reduced Th17 responses 
to this pathogen. This was confirmed in Tgfb1f/f Itgax-cre mice and specifically found to involve 
Mgl2+ cDC2s, as DT treated Mgl2-DTR:Il6-/- mixed BM chimeric mice also had reduced Th17 
induction upon Streptococcus pyogenes infection 186. A separate study used Mgl2-DTR:Il23a-/- 
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mixed BM chimeras to determine that Mgl2+ cDC2s must produce IL-23 in order to activate IL-
17 secretion from dermal γδ T cells during cutaneous Candida albicans infection 187. Finally, a 
study using the Il23af/f Itgax-cre strain concluded that IL-23 from CD11c+ cells was important 
for Th17 and Th1 induction in response to Helicobacter hepaticus infection 188, although the 
relative contributions of cDCs and macrophages in this infection remains to be defined with 
more specific methods. While depletion of cDC2s has revealed defects in type 3 responses to 
several pathogens, responses to many of these infections, specifically Citrobacter 23, 
Streptococcus 186, and Candida 187,189, are intact in mice lacking cDC1s. This again underscores 
the functional specialization of different cDC subsets and the non-redundant roles they play in 
host defense. 
Control of type 3 responses against segmented filamentous bacteria (SFB) may differ from 
those described above. SFB are a commensal organism present in some mice microbiota that 
induce an antigen-specific Th17 response in colonized mice 190. Conditional deletion of MHCII 
with Itgax-cre reduced Th17 induction after inoculation with SFB, which was interpreted to mean 
cDCs were responsible for priming against this organism. But Batf3-/-CD207-DTA mice, which 
lack cDC1s and CD103+CD11b+ cDC2s, and Flt3l-/- mice, which have substantially reduced 
numbers of all cDCs 191, had no impairment in Th17 priming 192,193. Instead, depletion of 
monocytes with the Ccr2-DTR strain abrogated Th17 induction against SFB, and this could be 
restored by transfer of wildtype monocytes, suggesting that monocyte-derived intestinal 
macrophages prime this response 194. This example illustrates how some conclusions regarding 
cDC function drawn from CD11c-based systems may need re-interpretation with follow-up studies 




Dendritic cells in autoimmunity 
DCs are important for the induction of tolerance to self-antigens and for the pathogenicity 
of several autoimmune syndromes. Early studies found a relationship between DC and Treg 
numbers, and that depletion of Tregs with a Foxp3-DTR strain greatly expanded cDCs 195. This 
expansion was due to increased numbers of cDC progenitors and was dependent on Flt3L, a 
crucial growth factor for cDCs 196. Conversely, depletion of DCs in Itgax-DTR mice or in Flt3l-/- 
mice reduced splenic Treg numbers, while expansion of DCs by exogenous Flt3L increased Treg 
numbers 197. This phenomenon held for certain antigen-specific Treg clones as well 198. 
DCs primarily control Treg numbers by regulating their proliferation rather than their 
induction, as Tregs transferred into Itgax-DTR mice treated with DT divided less than when 
transferred into WT mice 197. This control of proliferation required MHCII expression by DCs, as 
both Itgax-DTR:H2-Ab1-/- mixed BM chimeric mice treated with DT and H2-Ab1 f/- Itgax-cre 
mice also showed a decrease in Treg numbers and proliferation 197. Later work also concluded 
that DCs do not play a primary role in Treg induction in the thymus, as neither constitutive 
depletion of DCs in mice with Itgax-cre crossed to Rosa26-LSL-DTA nor H2-Ab1 f/f Itgax-cre 
mice had differences in the absolute number of Foxp3+ cells that develop in the thymus 199,200. 
However, several recent studies have demonstrated that at least some Treg clones are 
induced in the thymus by DCs, especially clones that recognize self-antigens expressed by the 
transcription factor AIRE. One group identified certain T cell clones that convert to Tregs in the 
thymus in response to AIRE-dependent antigens in wildtype mice, but not in mice that were 
depleted of CD11c+ cells by crossing the Itgax-cre to the Rosa26-LSL-DTA strain 201. These 
same T cells also did not convert in Batf3-/- mice, suggesting that cDC1s controlled their 
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induction. A subsequent study reported that both polyclonal Tregs and a specific AIRE-
dependent Treg were reduced in number in mice with conditional deletion of MHCII by Itgax-
cre, but in contrast to the previous study found that this AIRE-dependent Treg still developed in 
Batf3-/- mice 198. This suggests that the specific Treg clone or the nature of the antigen it 
recognizes may determine which cDC subset is responsible for its induction. 
 DCs also play a role in several models of autoimmunity. Studies using Itgax-DTR mice 
show that CD11c+ cells are required for pathogenesis in ovalbumin-driven asthma 44 and in Th2-
mediated peanut food allergy 202. Conditional deletion of Myd88 with Itgax-cre also diminished 
colitis in Il10-/- mice 203 and decreased lupus-like symptoms in Lyn-/- mice 204, suggesting that 
NFκB signaling in CD11c+ cells contributes to autoimmunity. Constitutively depleting CD11c+ 
cells in a model of lupus, achieved by crossing the Rosa26-LSL-DTA and Itgax-cre alleles onto 
the lupus-prone MRL.Faslpr background, reduced disease severity, in part by decreasing T and B 
cell activation 205. Disease incidence partly involved MyD88 signaling in CD11c+ cells, since 
Myd88f/f Itgax-cre mice on this background also had reduced dermatitis and T cell activation, but 
not reduced nephritis 206. In the nonobese diabetic (NOD) model of murine diabetes, cDC1s are 
required for disease initiation, as Batf3-/- NOD mice are completely free of lymphocyte 
infiltration into and destruction of pancreatic islets 207. Conversely, increased activity of DCs can 
lead to autoimmunity, often from aberrant cytokine production or inappropriate activation of 
autoreactive T cells. This was seen when Itgax-cre was used to delete inhibitory signaling 
molecules such as Fas 84 β-catenin 208, FADD 209, A20 210, TRAF6 211, Lyn 212, and Caspase-8 213. 
Recent work has also implicated cDCs in establishing oral tolerance to ingested antigens. 
Using Zbtb46-DTR mice, one study demonstrated a loss of oral tolerance in mice lacking all cDCs 
98. These mice failed to induce Tregs against orally fed antigen and generated an immune response 
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to subsequent peripheral antigen challenge. Oral tolerance was intact in Irf8f/f Zbtb46-cre mice that 
lack cDC1s, although antigen-specific Treg conversion was partially impaired. This suggests 
cDC1s are important in establishing oral tolerance but that other cDCs can compensate for their 
loss. A separate study found that for orally fed antigen to be tolerized it is phagocytosed by 
CX3CR1+ macrophages in the intestinal lamina propria and subsequently transferred to 
CD103+CD11b+ cDC2s through gap junctions made up of connexin-43 214. Conditional deletion 
of Gja1, which encodes connexin-43, with Itgax-cre reduced the number of Tregs induced to orally 
fed antigen and also diminished oral tolerance established to this same antigen. Also, conditional 
deletion of Itgb8, which encodes the integrin Itgβ8 that activates latent TGF-β, with Itgax-cre 
resulted in autoimmune inflammatory bowel disease and reduced numbers of colonic Tregs, 
suggesting that CD11c+ cells are critical sources of active TGF-β for the induction of Tregs in 
response to gut antigens 215. 
 
Dendritic cells in tumor immunity 
Recent work has expanded our understanding of the roles of DCs in antitumor immune 
responses. Studies using Itgax-DTR mice demonstrated that depletion of CD11c+ cells reduced 
CD8 T cell responses against transferred tumor cells 216,217 and reduced survival in oncogene-
driven tumor models 218. cDC1s in particular were critical for antitumor responses, as Batf3-/- 
mice failed to reject transplanted immunogenic fibrosarcomas  107 and failed to induce T cell 
infiltration into autochthonous oncogene-driven melanoma 219. cDC1s are also required for the 
antitumor effects of many cancer therapies, as Batf3-/- mice have reduced responses to 
therapeutic PD-L1 blockade, Flt3L injection, or polyI:C injection 220 as well as to anti-CD137 or 
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anti-PD1 therapy 221. cDC1s must migrate to LNs to activate tumor-specific CD8 T cells, as 
mixed BM chimeras made with Xcr1-DTR:Ccr7-/- BM, in which DT treatment causes all 
remaining cDC1s to lack CCR7, are not able to reject tumors 222. Finally, cDCs play a role in 
opposing the establishment of metastatic foci, as Zbtb46-DTR mice depleted of cDCs mice had 
increased numbers of melanoma metastases to the lung 223. 
 Two studies have demonstrated that interferon signaling in DCs is necessary for the 
initiation of antitumor immune responses. In the first, conditional deletion of the type 1 
interferon receptor Ifnar1 with Itgax-cre prevented rejection of transplanted fibrosarcomas 224. 
IFNAR deficient cDC1s also displayed deficient cross-presentation of antigens to CD8 T cells, 
suggesting that an inability to cross-present tumor antigens and activate CD8 T cells underlies 
the inability to reject tumors in this strain 224. In the second, Ifnar1-/-:Batf3-/- mixed BM chimeras 
failed to prime CD8 T cells to tumor antigens, suggesting that interferon signaling is specifically 
necessary in cDC1s 225. 
Comparison of Zbtb46-DTR and Itgax-DTR mice reveals a partial redundancy between 
cDCs and other CD11c+ cells in some aspects of the antitumor response. When immunized with 
tumor antigens and challenged with melanoma, DT treatment in either strain led to a failure to 
reject tumors 48. But mice depleted of CD11c+ cells succumbed to tumors faster than mice depleted 
of cDCs, suggesting that CD11c+ non-cDCs can compensate in driving antitumor responses.  
Others studies have distinguished various macrophage and DC populations present within the 
tumor microenvironment 226,227, and future studies may provide a better understanding of the roles 






The increasing precision by which cDC subsets can be ablated in mouse models has greatly 
expanded our understanding of their functions. It is now clear that cDCs are a unique lineage 
comprised of distinct functional subsets critical for both innate and adaptive immunity. Further 
work is needed to resolve the apparent heterogeneity in cDC2s 228, and to test for their potential 
activities.  In particular, how cDC2s control type 2 immune responses is unclear, including whether 
they provide instructive signals themselves, whether they are the primary APCs, and whether they, 
or other cells such as epithelial tuft cells, directly sense the pathogen. While these and other 
questions remain, it is now clear that DCs are the critical regulators of the entire immune response 
and that to understand the immune system we must fully analyze these remarkable cells. 
In this dissertation, we address key questions regarding dendritic cell development and 
functions. First, in Chapter 2, we resolved a long-standing paradox regarding the tyrosine kinase 
receptor Flt3 and its ligand Flt3L. We determined that the less severe DC deficiency in Flt3–/– mice 
as compared to Flt3l–/– mice was due to the enhanced responsiveness of Flt3–/– progenitors to 
compensatory cytokines that could also support DC development. This established that Flt3L does 
not have instructive roles in DC development, and instead that committed DC precursors can 
mature in response to multiple cytokines. In Chapter 3, we analyzed enhancer usage within the 
Irf8 locus to determine how this critical transcription factor was induced in order to specify cDC1 
fate. Irf8 is the lineage-determining transcription factor for cDC1s, but it remains unclear how this 
factor is induced in the multipotent CDP in order to specify cDC1 fate. We therefore identified 
active enhancers in this locus by chromatin profiling of DCs and used CRISPR/Cas9 to delete 
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these enhancers and identify the effects in vivo. We found that a +32 kb Irf8 enhancer is responsible 
for the maturation of cDC1s, but not for their specification. Deletion of a previously identified -50 
kb Irf8 enhancer thought to be active in early DC precursors also did not affect DC development, 
but did reduce Irf8 expression in monocytes and macrophages and lead to increased susceptibility 
to Salmonella typhimurium infection. To identify enhancers involved in specification, we 
performed ATAC-seq on all DC precursors. This surprisingly revealed that a +41 kb Irf8 enhancer, 
which we had previously found to be active in mature pDCs, was transiently active in cDC1 
progenitors but not in mature cDC1s. Deletion of this +41 kb Irf8 enhancer eliminated Irf8 
induction in the CDP and subsequent cDC1 specification. This enhancer was bound by E proteins, 
and consistently E2A-deficient DC progenitors failed to generate cDC1s. We therefore conclude 
that transient activation of the +41 kb Irf8 enhancer by E proteins is responsible for cDC1 fate 
specification. 
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Table 1.1. Comparison of DTA/DTR based mouse models for dendritic cell depletion 




marginal zone, sinusoidal, 
and alveolar 
macrophages, activated 
CD8 T cells, plasma cells 
Repeated DT treatment 
leads to death, requires 
CD11c-DTR into WT BM 
chimeras 
 









cDCs DT treatment leads to death, 




cDCs Requires crossing to Cre 
strain active in cDC lineage 
Cd207-DTR (Knockin) 
 














cDC1s, ~15% splenic B 
cells 
DT treatment leads to death, 
requires CD205-DTR into 




Depletion of germinal 
center B cells, migratory 
cDCs, and Langerhans cells 















macrophages in intestinal 
lamina propria and MLNs 
DC depletion in other 
organs not analyzed 
Mgl2-DTR 
 






pDCs Loss of SiglecH expression 
in homozygous knockin 
mice 
 
Depletion of marginal zone 















Requires crossing to Cre 












Table 1.2. Comparison of Cre strains for conditional deletion of genes in dendritic cells 
Strain Cells Affected Caveats 
Itgax-cre (BAC) 
 
~100% of cDCs, pDCs, 
alveolar macrophages, 
~70% red pulp 
macrophages, 20-40% 
monocytes, marginal zone 
macrophages, peritoneal 
macrophages, ~5-12% T, B, 
NK cells 
Germline deletion possible 
Itgax-cre (Transgene) 
 
cDCs, pDCs Deletion in other cell types 
was not analyzed, most 
likely similar to other Itgax-
cre strain 
 
Clec9a-cre   ~100% of cDC1s, ~50% of 
cDC2s, ~20% of pDCs 
Begins deletion at CDP 
stage, low or transient 
expression may affect 
deletion efficiency in 




65-95% cDCs, <10% in all 
other cell types 
Deletion efficiency variable 
depending on floxed allele 
Cd207-cre  Langerhans cells, 
Langerin+ cDC1s in dermis, 






Siglech-cre  ~30% of pDCs, ~2% of 
other lymphoid cells 





Deletion in marginal zone 








Table 1.3. Comparison of transcription factor knockout mice that affect dendritic cell 
development 
Strain Cells Depleted Caveats 
Irf8-/- 
 
cDC1s, B cells, monocytes, 
eosinophils, basophils  
Myeloid neoplasia 
eventually results with age 
 
Conditional deletion with 
Itgax-cre or Zbtb46-cre can 
prevent depletion of other 




cDC1s, NK cells, ILCs  
Nfil3-/- 
 
cDC1s, NK cells, ILCs  
Batf3-/- 
 
cDC1s In certain genetic 
backgrounds residual 










CD11b+ESAM+ cDC2s in 
spleen 
Loss of lymph nodes, can 
overcome with conditional 
deletion with Itgax-cre 
Notch2f/f Itgax-cre 
 
CD11b+ESAM+ cDC2s in 
spleen, CD103+CD11b+ 
cDC2s in small intestine 
lamina propria 
Transcriptional changes 
also evident in cDC1s and 
CD11b+ cDC2s 
Klf4f/f Itgax-cre  
 
Subset of cDC2s similar to 







~50% CD11b+ cDC2s in 
lung, ~50% 
CD103+CD11b+ cDC2s in 
small intestine lamina 
propria, complete absence 
of cDC2s in lymph nodes 
cDC2s cannot migrate, 
failure to migrate may 
explain many observed 
phenotypes 
 
May also affect M2 













Figure 1.1. Functions of dendritic cell subsets in the immune response. Classical dendritic cells 
(cDCs) play critical roles in both innate and adaptive immunity. Furthermore, each subset of cDC 
appears to possess unique functions and to control the immune response against specific forms of 
pathogens. cDC1s control type 1 immune responses against viruses and intracellular pathogens 
(left panel). In these responses they prime naïve CD8 T cells, reactivate memory CD8 T cells, 
activate ILC1s, and induce Th1 cells. Their production of the cytokine IL-12 is vital for many of 
these functions. cDC1s also play a role in inducing Tregs against orally fed antigens and AIRE-
dependent self-antigens expressed in the thymus, though it appears that in some cases cDC2s can 
also mediate Treg conversion to these antigens. Some cDC2s, on the other hand, regulate type 2 
immune responses against parasites in which they induce Th2 cells (right panel). The exact 
mechanism by which they do this is unclear. Other cDC2s control type 3 immune responses against 
extracellular bacteria and fungi (right panel). In these responses, cDC2s produce IL-23 in order to 
activate ILC3s and to induce Th17 cells. Their production of IL-6 and TGF-β also contributes to 
the polarization of Th17 cells. Finally, cDC2s are also responsible for the induction of T follicular 
helper (Tfh) cells that regulate the germinal center response. DTR, diphtheria toxin receptor; VSV, 
vesicular stomatitis virus; LCMV, lymphocytic choriomeningitis virus; WNV, west nile virus; 
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The receptor Flt3 and its ligand Flt3L are both critical for dendritic cell (DC) 
development, but DC deficiency is more severe in Flt3l–/– mice than in Flt3–/– mice. This has led 
to speculation that Flt3L binds to another receptor that also supports DC development. However, 
we found that Flt3L administration does not generate DCs in Flt3–/– mice, arguing against a 
second receptor. Instead, Flt3–/– DC progenitors matured in response to M-CSF or SCF, and 
deletion of Csf1r in Flt3–/– mice further reduced DC development, indicating that these cytokines 
could compensate for Flt3. Surprisingly, Flt3–/– DC progenitors displayed enhanced M-CSF 
signaling, suggesting that loss of Flt3 increased responsiveness to other cytokines. In agreement, 
deletion of Flt3 in Flt3l–/– mice paradoxically rescued their severe DC deficiency. Thus, multiple 
cytokines can support DC development and the discrepancy between Flt3–/– and Flt3l–/– mice 
results from the increased sensitivity of Flt3–/– progenitors to these cytokines.  
 
2.2 Introduction 
Dendritic cells (DCs) are immune cells with critical functions in both the innate and 
adaptive immune response that develop from hematopoietic progenitor cells 1,2. The earliest 
committed progenitor with DC fate potential is the macrophage/DC progenitor (MDP) 3,4, which 
develops into a common DC progenitor (CDP) that can give rise to plasmacytoid DCs (pDCs) as 
well as the classical DC (cDC) subsets, cDC1s and cDC2s 5,6. Committed cDC progenitors 




 The development of DCs is dependent upon the class III receptor tyrosine kinase (RTK) 
Fms-like tyrosine kinase 3 (Flt3) and its ligand Flt3L 12,13. Flt3 was first identified as a gene 
enriched in hematopoietic stem cells that encoded a protein homologous to the receptor c-Kit 14. 
It was later recognized to be expressed on mature DCs and their progenitors as well 15. Flt3 
shares structural properties and downstream signaling pathways with c-Kit and CSF1R, other 
members of the class III RTK family that are also expressed by committed DC progenitors 5,7,16. 
The ligand for Flt3, Flt3L, was subsequently cloned and found to induce proliferation in early 
bone marrow (BM) progenitors 17. Later, a role for Flt3L in DC homeostasis was uncovered from 
the expansion of DCs in mice and humans who were administered this cytokine 18,19. Further, 
treatment of BM progenitors in vitro with Flt3L also supports the development of mature DCs 
20,21, and Flt3+ progenitors preferentially gave rise to DCs in vivo 22. Finally, genetic inactivation 
of the Flt3 23 or Flt3l 12 genes in mice was observed to decrease the numbers of DCs 12,13, 
confirming their importance in DC homeostasis. 
 These original studies of Flt3–/– and Flt3l–/– mice surprisingly appeared to find DC 
deficiencies of varying severity in these two strains. Flt3l–/– mice analyzed between 5 and 14 
weeks of age have a 4 to 10-fold reduction in splenic CD8α– DCs and a 6 to 14-fold reduction in 
splenic CD8α+ DCs 12. Meanwhile, an analysis of Flt3–/– mice found that while all DCs are 
reduced by 85% at two weeks of age, they are reduced by only 43% (cDCs) or 65% (pDCs) at 9 
weeks of age 13. Another study that examined both strains between 8 and 12 weeks of age 
similarly found more severe reductions in CD8α+ DCs and CD11b+ DCs in Flt3l–/– mice 
compared to Flt3–/– mice 24. This discrepancy has also been noted in the development of pre-pro 
B cells, with Flt3l–/– mice demonstrating a severe reduction in this population while Flt3–/– mice 
have only a two-fold reduction 23,25-27. However, no study has directly compared Flt3–/– mice 
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with Flt3l–/– mice over time, so it is unknown if the defects caused by Flt3L deficiency improve 
with age, as with Flt3 deficiency, or whether Flt3–/– mice and Flt3l–/– mice simply have distinct 
phenotypes. Nevertheless, these apparent discrepancies in phenotypes have led to suggestions 
that Flt3L could act on a second receptor other than Flt3 to support DC or B cell development, 
explaining the more severe defects in Flt3l–/– mice 27-31. 
Cytokines such as Flt3L can play supportive and instructive roles in the development of 
hematopoietic lineages 32,33, and the actions of a given cytokine may depend upon the progenitor 
stage and cell type it acts upon 34,35. For DCs, an instructive role for Flt3 was suggested by the 
redirection of megakaryocyte-erythrocyte progenitors (MEPs) toward DC fate upon forced Flt3 
overexpression 36 and by transgenic mice in which Flt3L overexpression leads to a robust 
expansion of DCs, lymphocytes, and myeloid cells at the expense of erythrocytes and platelets 37. 
Nonetheless, Flt3L administration does not increase in vivo DC output from early Flt3+ 
progenitors such as CLPs, CMPs, or GMPs 38, and the continued presence of DCs in Flt3–/– and 
Flt3l–/– mice, albeit at reduced numbers, suggests that DC development can occur through some 
unidentified mechanism in the absence of this cytokine pathway. Thus, it remains unclear what 
specific role is played by Flt3L in DC progenitor specification and development, as well as 
whether any other cytokines can contribute to this process. 
To address the apparent discrepancy in phenotypes between Flt3–/– and Flt3l–/– mice, we 
directly compared DC development in these strains over time. We confirmed that Flt3l–/– mice 
show a severe and persistent DC defect while Flt3–/– mice have a less severe defect at all ages 
analyzed. However, we were unable to demonstrate activity for Flt3L on a second receptor as has 
been proposed. Instead, we found that DC progenitors developed normally without instructional 
cues from Flt3 signaling, and surprisingly that these progenitors could mature in Flt3–/– mice in 
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response to M-CSF and SCF, ligands for other class III RTKs expressed by these cells. Deletion 
of Csf1r in Flt3–/– mice also led to a further reduction in DC development in a cell-intrinsic manner, 
indicating that this cytokine pathway was partially compensating for the loss of Flt3 in vivo. 
Although the expression of CSF1R and c-Kit was not altered in Flt3–/– progenitors, we found that 
these progenitors were more responsive to stimulation by M-CSF, suggesting that the absence of 
Flt3 potentiates signaling by other class III RTKs. To test whether this effect was responsible for 
the discrepancy between Flt3–/– and Flt3l–/– mice, we generated Flt3–/–Flt3l–/– mice and found that 
the additional deletion of Flt3 paradoxically restored DC numbers in Flt3l–/– mice. We conclude 
that multiple cytokine pathways can support the development of DCs, and that the discrepancy 
between Flt3–/– and Flt3l–/– mice is due to the enhanced sensitivity of Flt3–/– BM progenitors to 
signaling by these alternative cytokines.    
 
2.3 Results 
Flt3l–/– mice have a more severe DC deficiency than Flt3–/– mice 
The original studies that analyzed Flt3–/– and Flt3l–/– mice did not directly compare these 
strains at similar ages, so the previously noted phenotypic discrepancy may simply have been 
due to mismatched comparisons 12,13. We therefore examined matched sets of Flt3–/– and Flt3l–/– 
mice at both 2 and 8 weeks of age (Figs. 2.1 and 2.3). We confirmed the previous report of 
severe reductions in the percent (Fig. 2.1, C and E) and numbers (Fig. 2.1, D and F) of splenic 
cDCs and pDCs at 2 weeks in both Flt3–/– and Flt3l–/– mice. We also found severe reductions in 
both populations in the skin draining lymph nodes (SLNs) (Fig. 2.2, B and C), and lungs (Fig. 
2.2G) of these strains. Even at this age, however, the defect in cDCs and pDCs was more severe 
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in Flt3l–/– mice than in Flt3–/– mice in all organs analyzed.  We also observed previously 
unrecognized heterozygous phenotypes in both Flt3+/– and Flt3l+/– mice compared with wild type 
(WT) mice. Flt3l+/– mice showed a 2-fold reduction in DC numbers relative to WT mice, while 
surprisingly, Flt3+/– mice had significantly more DCs than WT mice (Fig. 2.1, C-F). 
By contrast, at 8 weeks, Flt3–/– mice showed only a mild deficiency in the percent and 
number of splenic DCs, while Flt3l–/– mice continued having severely reduced DC populations 
compared to both WT and Flt3–/– mice (Fig. 2.3, A-F). Findings were similar for cDCs and pDCs 
in the SLNs (Fig. 2.3, D and E) and for cDCs in the lungs (Fig. 3H). Heterozygous phenotypes 
were again observed at 8 weeks, with Flt3l+/– mice showing a 2-fold reduction in DCs compared 
with WT mice and Flt3+/– mice having consistently greater numbers of DCs compared with WT 
mice (Fig. 2.3, A-F). In summary, the more severe DC defect in Flt3l–/– mice compared to Flt3–/– 
mice appears to be an inherent difference between these strains. 
 
Flt3L does not support DC development from Flt3–/– BM or in Flt3–/– mice  
 To explain the discrepancy between Flt3–/– and Flt3l–/– mice, some have suggested that 
Flt3L could support DC development in Flt3–/– mice by acting on a second receptor, thus 
explaining the less severe phenotype of Flt3–/– mice 27-31. To test for evidence of a second Flt3L 
receptor, we cultured WT and Flt3–/– BM in vitro with Flt3L and assessed DC development, 
hypothesizing that Flt3L could bind to its second receptor in Flt3–/– BM and generate DCs. 
However, while Flt3L supported robust DC development from WT BM, it did not generate DCs 
from Flt3–/– BM (Fig. 2.4, A-E). Thus, in vitro, we were unable to provide evidence for a second 
receptor responding to Flt3L. We next administered Flt3L in vivo (Fig. 2.4, F-J). Flt3L 
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administration to WT mice caused a significant increase in the percent and numbers of splenic 
DCs, as expected 18, but failed to increase DCs in Flt3–/– mice (Fig. 2.4, F-J). In summary, we 
find no evidence for actions of Flt3L on a second receptor. 
 Since DCs in Flt3–/– mice appeared to arise independently of Flt3L, we wondered 
whether they were developmentally or functionally impaired. We therefore examined the 
transcriptional profile of splenic cDC1s and cDC2s from WT and Flt3–/– mice using gene 
expression microarrays. We found no substantial changes in gene expression in either cDC 
subset, with the only annotated transcript showing a greater than 4-fold change being Flt3 itself 
(Fig. 2.5, A and B). In addition, we found that Flt3–/– cDC1s were able to cross-present cell-
associated and soluble antigen to CD8 T cells as efficiently as WT cDC1s (Fig. 2.5, C-E), 
suggesting they were functionally similar. We next examined the transcriptional profile of 
splenic pDCs from WT and Flt3–/– mice (Fig. 2.5F). We again found only minor differences 
between these populations, with Flt3 being the only annotated transcript showing a greater than 
4-fold increase in expression in WT pDCs and with several genes encoding Igκ segments being 
more highly expressed in Flt3–/– pDCs. pDCs have been found to develop from both myeloid and 
lymphoid progenitors 39, with pDCs derived from lymphoid progenitors showcasing 
rearrangements of D-J segments in the immunoglobulin genes. The increased expression of these 
genes encoding Igκ segments in Flt3–/– pDCs could therefore indicate that the pDCs in Flt3–/– 
mice preferentially arise from lymphoid rather than myeloid progenitors. Other than these genes, 
we found that the expression of the vast majority of transcripts was similar between WT and 
Flt3–/– pDCs (Fig. 2.5F). Finally, we stimulated WT and Flt3–/– pDCs with CpG 
oligodeoxynucleotides and found that both populations produced a comparable amount of IFN-α 
(Fig. 2.5G). Together, these results suggest that the DCs in Flt3–/– mice are transcriptionally and 
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functionally similar to WT DCs, implying that Flt3 signaling is not essential for generating 
functional DCs. 
 
Committed DC progenitors develop in Flt3–/– BM and can mature in response to M-CSF 
and SCF 
We next considered whether Flt3–/– DCs could be maturing in response to alternative 
cytokines. The receptors for M-CSF (CD115/CSF1R) and for SCF (CD117/c-Kit) are both 
expressed by the MDP and CDP 40, suggesting that these cytokines could act on these 
progenitors, and M-CSF has also been reported to support the development of some DC subsets 
in vitro 41. To help identify cDCs in the Flt3–/– background, we crossed Flt3–/– mice to 
Zbtb46GFP/+ mice to generate Flt3–/–Zbtb46GFP/+ mice, in which we could use Zbtb46GFP 
expression to distinguish cDCs from other lineages 42-44. We then cultured bulk BM from WT 
(Flt3+/+Zbtb46GFP/+), Flt3+/–Zbtb46GFP/+, and Flt3–/–Zbtb46GFP/+ mice with Flt3L, M-CSF, or 
SCF and assessed DC development. Surprisingly, we found that all three cytokines supported the 
development of cDC1s and cDC2s from WT and Flt3+/– BM, while M-CSF and SCF also 
supported cDC development from Flt3–/– BM (Fig. 2.6, A and B). Notably, M-CSF and SCF 
generated a greater percent (Fig. 2.6B) and number (Fig. 2.7A) of cDCs from Flt3–/– BM than 
from WT BM, suggesting that Flt3–/– BM may be more responsive to these cytokines than WT 
BM. Importantly, the cDCs generated in all cultures were uniformly positive for Zbtb46GFP 
expression (Fig. 2.6A), confirming their identity as bona fide cDCs 42-44. 
To further characterize these cells and to identify any heterogeneity in the populations, 
we examined the expression of a variety of functional markers in cDCs from each culture 
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condition. We found that the cDCs generated in response to each cytokine generally expressed 
similar levels of costimulatory molecules such as CD86, PD-L2, CD40, and CD205, surface 
markers such as CD24, CD172a, and CD11b, DC specific markers such as Flt3/CD135 (the 
cDCs from Flt3L cultures expressed low levels of this receptor, potentially due to 
downregulation after exposure to Flt3L), CCR7, and CD117, and that they all expressed 
similarly low levels of macrophage markers such as CD115 and CD64 (Fig. 2.7B). Thus, we 
concluded that the cDCs that mature in response to M-CSF and SCF are generally similar in 
phenotype to those that are generated by Flt3L. Finally, we found that Flt3L, M-CSF, and SCF 
could all support pDC development from WT BM and that M-CSF and SCF could also support 
pDC development from Flt3–/– BM (Fig. 2.8A). 
Since mature DCs could be generated from the BM of Flt3–/– mice, we wondered if DC 
progenitor specification was occurring normally in these mice. Identifying the CDP relies on Flt3 
expression 5 and is therefore not possible in Flt3–/– mice. However, two restricted cDC 
progenitors downstream of the CDP, the pre-cDC1 and pre-cDC2, can be identified with 
Zbtb46GFP expression and additional markers without the need for Flt3 7. We therefore analyzed 
BM from Flt3–/–Zbtb46GFP/+ mice to identify these progenitors, and found normal frequencies of 
pre-cDC1s and pre-cDC2s compared with Flt3+/+Zbtb46GFP/+ mice (Fig. 2.6C). As a control, BM 
from Irf8–/–Zbtb46GFP/+ mice lacked pre-cDC1s and had reduced pre-cDC2s, as expected 7. Thus, 
cDC progenitor specification appears to be independent of Flt3 signaling. 
 We next asked whether M-CSF and SCF could act directly on committed DC progenitors 
to support their maturation. To address this question, we sort purified WT CDPs, which express 
Flt3, CSF1R, and c-Kit, and cultured them with Flt3L, M-CSF or SCF. These cytokines each 
supported development of the CDP into mature Zbtb46GFP-positive cDC1s and cDC2s (Fig. 
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2.9A) as well as pDCs (Fig. 8B). In addition, pre-cDC2s, which normally express CSF1R and 
Flt3, were isolated from Flt3+/+ mice and Flt3–/– mice and cultured with Flt3L and M-CSF. As 
expected, Flt3L supported development of the pre-cDC2 into mature Zbtb46GFP-positive cDC2s 
from Flt3+/+ progenitors but not from Flt3–/– progenitors (Fig. 2.9B). In contrast, M-CSF 
supported development of the pre-cDC2 into Zbtb46GFP-positive cDC2s from both WT and Flt3–
/– progenitors (Fig. 2.9B). When we analyzed cell divisions using cell proliferation dye tracing, 
we found that in response to M-CSF Flt3–/– pre-cDC2s proliferated more than WT pre-cDC2s 
(Fig. 2.9C), again suggesting that Flt3–/– progenitors were more responsive to M-CSF than WT 
progenitors. Thus, our data suggests that specified DC progenitors that develop in the presence or 
absence of Flt3 signaling can mature in response to cytokines other than Flt3L. 
 
DC development in Flt3–/– mice is substantially dependent upon CSF1R 
To determine whether M-CSF supported the in vivo DC development observed in Flt3–/– 
mice, we deleted Csf1r 45 in WT and Flt3–/– mice using a tamoxifen-inducible Cre recombinase 
46. Deletion of Csf1r in WT mice caused a small decrease in splenic cDC percentage and 
numbers, consistent with a previous report describing a minor role for CSF1R in cDC 
homeostasis (Fig. 2.10, A, C, and D) 24. In contrast, deletion of Csf1r in Flt3–/– mice led to a 
substantial reduction in cDCs (Fig. 2.10, B-D), confirming that cDCs developing in Flt3–/– mice 
arise in part through the actions of CSF1R. pDC development, on the other hand, was unaffected 
by the additional deletion of Csf1r (Fig. 2.10, E and F), consistent with prior studies showing that 
pDC progenitors are enriched in the CSF1R– fraction of BM progenitors 47 and that almost all 
pDCs are derived from an IL-7R+ progenitor 48. Our gene expression data had also indicated that 
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the pDCs in Flt3–/– mice may be preferentially developing from lymphoid progenitors (Fig. 
2.5F), which, combined with the lack of a role for CSF1R, suggests that the pDCs in Flt3–/– mice 
may be developing in response to compensatory signaling from a receptor expressed on 
lymphoid progenitors such as IL-7R. In summary, a substantial portion of cDC but not pDC 
development in Flt3–/– mice is dependent upon CSF1R. 
To test whether this action of CSF1R was cell-intrinsic to DC progenitors, we generated 
mixed bone marrow chimeras with a 50:50 mix of Flt3–/– BM and either Flt3–/–Csf1rf/fR26+/+ BM 
(CreERT2–) or Flt3–/–Csf1rf/fR26CreERT2/+ BM (CreERT2+). While all BM progenitors in these 
chimeras were deficient in Flt3, tamoxifen treatment led to the additional deletion of CSF1R in 
half of the BM cells in CreERT2+ chimeras but not in CreERT2– chimeras (Fig. 2.10G). Thus, 
we could directly compare the DC potential of progenitors lacking both Flt3 and CSF1R with 
progenitors lacking only Flt3. In CreERT2+ chimeras, cDCs preferentially developed from Flt3–
/– BM cells, rather than from Flt3–/–Csf1r–/– BM, while in CreERT2– chimeras there was no skew 
in DC development between Flt3–/– and Flt3–/–Csf1rf/fR26+/+ BM (Fig. 2.10, G and H). This 
result suggests that the contribution of CSF1R to DC development in Flt3–/– progenitors is cell-
intrinsic. 
 
Flt3–/– progenitors express normal levels of CSF1R and c-Kit but display enhanced 
signaling from these receptors 
 Since M-CSF and SCF could support DC development independently of Flt3, we 
wondered if the discrepancy between Flt3–/– and Flt3l–/– mice might be due to differences in the 
expression or signaling of CSF1R or c-Kit in these different strains. First, we found no 
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differences in surface expression of CSF1R or c-Kit in total BM isolated from WT, Flt3–/–, and 
Flt3l–/– mice (Fig. 2.11A). We next sought to quantify the expression of these receptors in early 
DC progenitors, but as Flt3 is required to identify the MDP and CDP 5, we could not analyze 
these progenitors in Flt3–/– mice. We therefore generated Flt3l–/–Zbtb46GFP/+ mice to identify the 
pre-cDC1 and pre-cDC2 in Flt3l–/– mice, which would allow us to compare these progenitors in 
WT, Flt3–/–, and Flt3l–/– mice. We found that both progenitors still developed in Flt3l–/– mice, but 
were substantially fewer in number relative to WT and Flt3–/– mice (Fig. 2.12A). This was 
similar to the reported deficiency in MDPs and CDPs in Flt3l–/– mice 49, suggesting that all DC 
progenitors are affected by the loss of Flt3L. We found, however, that the expression of CSF1R 
and c-Kit was not different in pre-cDC1s or pre-cDC2s from Flt3–/– or Flt3l–/– mice relative to 
WT mice (Fig. 2.11B), again suggesting that changes in receptor expression did not explain the 
differences between these strains. Finally, we sought to determine the expression of these 
receptors in mature splenic cDCs from these strains, but as collagenase digestion of the spleen 
impairs detection of these receptors by FACS 50, we instead used gene expression microarrays. 
We found no differences in Csf1r or Kit gene expression in splenic cDC1 or cDC2s from WT, 
Flt3–/–, and Flt3l–/– mice (Fig. 2.11C). Thus, we excluded differences in receptor expression as a 
cause of the discrepancy between Flt3–/– and Flt3l–/– mice. 
 The in vitro DC development supported by M-CSF and SCF was greater in Flt3–/– BM 
relative to WT BM (Fig. 2.6B) and Flt3–/– pre-cDC2s proliferated more than WT pre-cDC2s in 
response to M-CSF (Fig. 2.9C), suggesting there was some alteration in receptor sensitivity 
between WT and Flt3–/– mice. Flt3, CSF1R, and c-Kit are all class III RTKs that share signaling 
adaptor molecules, such as the Src-homology and collagen (SHC) proteins and Grb2 16,31,51,52. 
We wondered whether the loss of Flt3 might increase the availability of these adaptors and 
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thereby enhance signaling from CSF1R or c-Kit. To test this, we quantified the sensitivity of 
CSF1R signaling in BM progenitors.  We treated serum-starved BM cells from Flt3+/+, Flt3+/–, 
or Flt3–/– mice with varying concentrations of M-CSF and quantified phosphorylation of the 
MAPK pathway protein Erk1/2 in pre-cDC2s (Fig. 2.13A). We examined this progenitor because 
it expresses CSF1R and can be identified independently of Flt3 by using Zbtb46-GFP expression 
7. Over a range of concentrations, both the percentage of pre-cDC2s responding to M-CSF and 
the intensity of signaling in each progenitor was greater in Flt3–/– pre-cDC2s compared to Flt3+/+ 
pre-cDC2 cells, with Flt3+/– pre-cDC2s displaying an intermediate phenotype (Fig. 2.13, A and 
B). Thus, the loss of Flt3 directly enhances the sensitivity and strength of CSF1R signaling in 
response to M-CSF. Importantly, no differences were observed in M-CSF signaling sensitivity in 
Flt3l–/– pre-cDC2s relative to WT for most concentrations of M-CSF (Fig. 2.12B), indicating that 
the increased sensitivity to M-CSF was specific to Flt3–/– mice and could possibly explain the 
difference between these mice and Flt3l–/– mice. 
 
Deletion of Flt3 in Flt3l–/– mice paradoxically restores DC development 
The increased sensitivity of CSF1R signaling in Flt3–/– DC progenitors could explain the 
discrepancy in DC numbers between Flt3–/– and Flt3l–/– mice. Flt3–/– DC progenitors could respond 
more robustly to alternative cytokines such as M-CSF or SCF and thus develop greater numbers 
of DCs. This hypothesis predicts that the increased CSF1R sensitivity in Flt3–/– mice should occur 
regardless of the presence of Flt3L, and thus that loss of Flt3 in the Flt3l–/– background should 
enhance CSF1R signaling and potentially increase DC numbers. To test this hypothesis, we 
crossed Flt3–/– and Flt3l–/– mice to generate Flt3–/–Flt3l–/– mice and characterized DC development 
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in the resulting littermates. We first found that, unlike Flt3+/– mice, Flt3+/–Flt3l+/– mice had mildly 
reduced DC numbers (Fig. 2.14, A-E). This suggests that the decrease in DCs we found in Flt3l+/– 
mice (Fig. 2.1 and 2.3) was more impactful than the increase in DCs observed in Flt3+/– mice (Fig. 
2.1 and 2.2), and that together these alleles resulted in a net decrease in DC numbers in Flt3+/–
Flt3l+/– mice. But most surprisingly, we found that Flt3–/–Flt3l–/– mice had an increase in splenic 
cDC and pDC percentage and numbers relative to Flt3l–/– mice and were indistinguishable from 
Flt3–/– mice (Fig. 2.14, A-E). This increase was also observed in cDCs and pDCs in the SLNs (Fig. 
2.15, A and B), as well as in cDCs in the lung (Fig. 2.15C). Thus, paradoxically, the severe DC 
deficiency observed in Flt3l–/– mice was rescued by the additional loss of Flt3. These results 
suggest that the discrepancy observed between Flt3–/– and Flt3l–/– mice is, at least in part, due to 
an inherent alteration in the response of DC progenitors to alternative cytokines secondary to the 
loss of Flt3.   
 
2.4 Discussion 
In this study, we have identified the previously unknown cytokine pathways that support 
the residual DC development seen in Flt3–/– and Flt3l–/– mice, and we provide an explanation for 
the puzzling discrepancy in phenotypes between these two strains. While both Flt3 and Flt3L 
have long been recognized to play major roles in DC homeostasis 12,13, it had remained unclear 
through what mechanism DCs continue to arise in mice deficient in either of these factors. We 
have demonstrated here that M-CSF and SCF, two cytokines whose receptors are expressed in 
DC progenitors, are capable of generating DCs from both WT and Flt3–/– bone marrow 
progenitors in vitro. We also found that a substantial fraction of the DCs that arise in vivo in 
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Flt3–/– mice are dependent upon CSF1R for their development, with c-Kit possibly responsible 
for generating the remainder of the DCs. 
Loss of a receptor and its unique ligand would generally be expected to produce the same 
phenotype. However, our direct comparison of Flt3–/– and Flt3l–/– mice clearly document that 
loss of the ligand causes a more severe and durable DC deficiency than loss of the receptor. We 
were unable to find evidence to support previous suggestions that Flt3L might be acting at a 
second receptor besides Flt3 27-31. Instead, we found that Flt3–/– DC progenitors exhibit an 
intrinsic alteration in the sensitivity of other cytokine receptors compared with WT progenitors. 
This may allow compensatory cytokines such as M-CSF and SCF to generate a greater number 
of DCs in Flt3–/– mice relative to WT or Flt3l–/– mice. We therefore predicted, and then 
validated, the paradoxical result that the severe DC defect in Flt3l–/– mice is actually restored 
upon deletion of Flt3. Thus, it appears that the discrepancy in DC development between Flt3–/– 
and Flt3l–/– mice arises secondary to a phenotype of increased sensitivity of Flt3–/– DC 
progenitors to alternative cytokines. It is possible that a similar increase in sensitivity to IL-7 in 
early B cell progenitors could explain the previously identified discrepancy in B cell 
development between these strains 27. 
The increased sensitivity of Flt3+/– progenitors to M-CSF (Fig. 9) might also explain the 
increased DC numbers we observed in Flt3+/– mice (Figs. 1 and 2). Flt3+/– BM produced DCs in 
response to Flt3L as well as to M-CSF (Fig. 5B), so the increased DC numbers seen in Flt3+/– 
mice conceivably results from the combination of both normal Flt3L signaling and enhanced M-
CSF signaling contributing to DC development in these mice. By contrast, in Flt3–/– mice only 
enhanced M-CSF signaling but not Flt3L signaling contributes to DC development, and these 
mice therefore have fewer DCs despite their even greater sensitivity to M-CSF. 
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We have not explored the biochemical basis for the altered sensitivity observed in Flt3–/– 
DC progenitors. Conceivably, loss of Flt3 increases the availability of shared signaling adaptor 
molecules such as SHC and Grb2 used by other class III RTKs 16,31,51,52. The increased availability 
of these adaptors could then allow other receptors acting through them to activate downstream 
pathways more quickly and potently. While the exact mechanism remains to be uncovered, our 
results highlight the potential for unintended consequences that may result when manipulating the 
levels of signaling molecules in complex biological systems. The deletion of Flt3 appears to have 
ramifications beyond simply the loss of signaling by this receptor, and the study of other receptor 
knockout mice may have similar caveats that should be considered.  
 
2.5 Materials and Methods 
Mice. 
All mice were bred and maintained on the C57BL/6 background in a specific pathogen-
free animal facility following institutional guidelines and with protocols approved by the Animal 
Studies Committee at Washington University in St. Louis. Unless otherwise specified, 
experiments were performed with mice 6–10 weeks of age. No differences were observed 
between male and female mice in any assays and so mice of both genders were used throughout 
this study. Within individual experiments mice used were age- and sex-matched littermates 
whenever possible. 
Flt3–/– mice 23 were a gift from Dr. E. Camilla Forsberg. Zbtb46GFP/+ mice have been 
previously described 7,42. The following mice were purchased from The Jackson Laboratory: 
Flt3l–/– (C57BL/6-Flt3ltm1Imx/TacMmjax), CD45.1+ (B6.SJL-Ptprca Pepcb/BoyJ), OT-I 
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(C57BL/6-Tg(TcraTcrb)1100Mjb/J), Csf1rf/f (B6.Cg-Csf1rtm1.2Jwp/J), and R26CreERT2/+ (B6.129-
Gt(ROSA)26Sortm1(cre/ERT2)Tyj/J). 
 
Dendritic cell preparation. 
Lymphoid and nonlymphoid organ DCs were harvested and prepared as described 
previously 42. Briefly, spleens and SLNs (inguinal, axillary, and brachial) were minced and 
digested in 5 mL of Iscove’s modified Dulbecco’s media (IMDM) + 10% FCS (cIMDM) with 
250 μg/mL collagenase B (Roche) and 30 U/mL DNaseI (Sigma-Aldrich) for 45 min at 37°C 
with stirring. Lungs were minced and digested in 5 mL of cIMDM with 4 mg/mL collagenase D 
(Roche) and 30 U/mL DNaseI (Sigma-Aldrich) for 1.5 hours at 37°C with stirring. After 
digestion, cell suspensions from all organs were passed through 70-μm strainers and red blood 
cells were then lysed with ammonium chloride-potassium bicarbonate (ACK) lysis buffer. Cells 
were counted with a Vi-CELL analyzer (Beckman Coulter) and 3-5x106 cells were used per 
antibody staining reaction. 
For experiments requiring sorting of splenic cDC subsets, cDCs were first enriched from 
total spleen cells with CD11c microbeads (Miltenyi Biotec). cDCs were then sorted on a 
FACSAria Fusion. cDC1s were sorted as CD11c+MHC-II+CD24+CD172a–F4/80– and cDC2s 
were sorted as CD11c+MHCII+CD24–CD172a+F4/80–. Sort purity of >95% was confirmed by 
post-sort analysis before cells were used for further experiments. 
For experiments requiring sorting of splenic pDC subsets, spleen cells were first depleted 
of CD3-, B220-, and Ly6G-expressing cells by staining with the corresponding biotinylated 
antibodies followed by depletion with MagniSort Streptavidin Negative Selection Beads 
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(Thermo Fisher). pDCs were then sorted on a FACSAria Fusion as B220+CD317+. Sort purity of 
>95% was confirmed by post-sort analysis before cells were used for further experiments. 
 
Antibodies and flow cytometry. 
Samples were stained at 4°C in MACS buffer (DPBS + 0.5% BSA + 2 mM EDTA) in the 
presence of Fc block (2.4G2; BD Biosciences). The following antibodies were purchased from 
BD Biosciences: CD8α V450 (53-6.7); CD11b PE (M1/70); CD19 Biotin (1D3); CD44 APC-
Cy7 (IM7); CD45R AlexaFluor 488, V450 (RA3-6B2); CD45.2 PerCP-Cy5.5 (104); CD64 
Alexa Fluor 647 (X54-5/7.1); CD103 BV421 (M290), CD117 BUV395 (2B8); CD127 BV421 
(SB/199); CD135 PE-CF594 (A2F10.1); Ly-6C Alexa Fluor 700 (AL-21); I-A/I-E V500 
(M5/114.15.2). From eBioscience: CD11c PE (N418); CD44 APC (IM7); CD105 Biotin 
(MJ7/18); CD117 PE/Cy7 (2B8); CD172a PerCP-eFluor710 (P84); CD317 APC (eBio927); 
F4/80 APC-eFluor 780 (BM8). From Invitrogen: TCR Vα2 PE (B20.1); CD172a PerCP-
eFluor710 (P84). From Tonbo Biosciences: CD3e Biotin (145-2C11); CD11c APC-Cy7 (N418); 
CD45.1 PE-Cy7 (A20); I-A/I-E V450 (M5/114.15.2). From BioLegend: CD4 APC (RM4-5); 
CD24 PE/Cy7 (M1/69); CD45.1 BV605 (A20); CD45.2 Alexa Fluor700 (104); CD115 BV711 
(ASF98); Ly-6G Biotin (1A8); GFP Alexa Fluor488 (FM264G); Siglec H PE (551); Ter-119 
Biotin (TER-119); TCR Vα2 PE, PerCP-Cy5.5 (B20.1). From Cell Signaling: P-p44/42 MAPK 
(Erk1/2) (T202/Y204) PE (197G2). In general, all antibodies were used at a dilution of 1:200 
unless specified otherwise by the manufacturer. Cells were analyzed on a FACSCanto II or 




Bone marrow isolation and cell culture. 
Bone marrow (BM) was harvested from the femur, tibia, and pelvis. Bones were 
fragmented by mortar and pestle in MACS buffer, and debris was removed by passing cells 
through a 70-μm strainer. Red blood cells were subsequently lysed with ACK lysis buffer. Cells 
were counted on a Vi-CELL analyzer (Beckman Coulter), and 3-5x106 cells were stained for 
analysis. For Flt3L culture experiments, whole BM (8x106 cells in 4 mL of cIMDM) was 
cultured at 37°C with 100 ng/mL of Flt3L (Peprotech) or equivalent volume of PBS (vehicle) for 
9 days. For comparative cytokine culture experiments, whole BM (6x106 cells in 4 mL of 
cIMDM) was cultured at 37°C with 100 ng/mL of Flt3L (Peprotech), 20 ng/mL M-CSF 
(Peprotech), 50 ng/mL of SCF (Peprotech), or equivalent volume of PBS (vehicle) for 7 days. 
For all culture experiments, loosely adherent and suspension cells were harvested by gentle 
pipetting at the indicated time point and stained with fluorescent antibodies for analysis by flow 
cytometry. 
 
In vivo Flt3L administration. 
Flt3+/+ or Flt3–/– mice were injected subcutaneously with sterile saline (vehicle) or 10 ug 
of purified Flt3L-Fc fusion protein (generated in-house) daily for 8 days and analyzed on the 
following day. 
 
Expression microarray analysis. 
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 Total RNA was extracted from sorted splenic DCs with an RNAqueous-Micro kit 
(Ambion), amplified with an Ovation Pico WTA System (NuGEN), and hybridized to Mouse 
Gene 1.0 ST arrays (Affymetrix). Expression values were analyzed after robust multiarray 
average (RMA) summarization and quantile normalization using ArrayStar 4 software 
(DNASTAR). All gene expression microarray data has been deposited in the NCBI Gene 
Expression Omnibus database with accession numbers GSE110789 and GSE110790. 
 
Antigen presentation assays. 
In vitro cell-associated cross-presentation assays have been described previously 57. 
Briefly, Listeria monocytogenes (LM)-OVA (a gift from H. Shen) was grown in Brain-Heart 
Infusion broth at 37°C for 6 hours and then frozen overnight after dilution plating for titer 
enumeration. Bacteria was subsequently thawed and washed three times with PBS before heat 
killing at 80°C for 1 hour and then freezing at -80°C. OT-I T cells were meanwhile sorted from 
spleens of OT-I mice as B220–CD4–CD11c–CD45.1+CD8+Vα2+ and labeled with CFSE 
(eBioscience). Sort purity of >95% was confirmed by post-sort analysis before cells were used 
for assays. 10,000 sorted splenic cDCs of the indicated subset from Flt3+/+ or Flt3–/– mice and 
25,000 sorted CFSE-labeled OT-I T cells were incubated with various doses of heat-killed LM-
OVA for 3 days at 37°C. After incubation was complete, OT-I cells were assayed for CFSE 
dilution and CD44 expression. 
For soluble OVA presentation assays, 10,000 sorted splenic cDCs of the indicated subset 
from Flt3+/+ or Flt3–/– mice and 25,000 sorted CFSE-labeled OT-I T cells were incubated with 
the indicated concentration of OVA (Worthington Biochemical Corporation) for 3 days at 37°C. 
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After incubation was complete, OT-I T cells were assayed for CFSE dilution and CD44 
expression. 
Alternatively, sorted splenic cDCs of the indicated subset from Flt3+/+ or Flt3–/– mice 
were incubated with 0.1 mg/mL of soluble OVA (Worthington Biochemical Corporation) for 45 
minutes at 37°C, washed three times with PBS, and then different numbers of cDCs were 
incubated with 25,000 sorted CFSE-labeled OT-I T cells for 3 days at 37°C. After incubation 
was complete, OT-I T cells were assayed for CFSE dilution and CD44 expression. 
 
Type I interferon production from pDCs. 
25,000 sorted pDCs from Flt3+/+ or Flt3–/– mice were incubated overnight at 37°C in 
cIMDM with 100 ng/mL of Flt3L plus either 6 ug/mL of CpG-A oligodeoxynucleotides or the 
equivalent volume of PBS (vehicle). The next day cells were spun down and the supernatant was 
collected. IFN-α in the supernatant was measured using the PBL Verikine Mouse IFN Alpha All 
Subtype ELISA Kit, High Sensitivity (PBL Assay Science). 
 
Progenitor sorting and culture. 
For sorting experiments, BM was isolated as described above and depleted of CD3-, 
CD19-, CD105-, Ter119-, and Ly6G-expressing cells by staining with the corresponding 
biotinylated antibodies followed by depletion with MagniSort Streptavidin Negative Selection 
Beads (Thermo Fisher). The entirety of the remaining BM was then stained with fluorescent 
antibodies prior to sorting. Gates used to define CDPs, pre-cDC1s, and pre-cDC2s were based on 
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previous studies 5,7. CDPs were identified as Lin–CD117intCD135+CD115+CD11c–MHCII–; pre-
cDC1s as Lin–CD117intCD11c+MHCIIintZbtb46-GFP+; and pre-cDC2s as Lin–
CD117loCD115+CD11c+MHCII–Zbtb46-GFP+. Lineage markers included CD3, CD19, CD105, 
Ter119, and Ly6G. A FACSAria Fusion was used for sorting, and cells were sorted into cIMDM. 
Sort purity of >95% was confirmed by post-sort analysis before cells were used for further 
experiments. Sorted cells were cultured at 37°C in 200 μL total volume of cIMDM with 100 
ng/mL Flt3L (Peprotech), 20 ng/mL M-CSF (Peprotech), 50 ng/mL SCF (Peprotech), or 
equivalent volume of PBS (vehicle) for 5 days. 
For cell proliferation studies, sorted pre-cDC2s were washed three times with PBS to remove 
serum and then incubated with 10 μM of eBioscience Cell Proliferation Dye eFluor 450 (Thermo 
Fisher Scientific) at 37°C for 10 minutes. Reaction was quenched by the direct addition of FCS 
and cells were washed three times with cIMDM. Cells were subsequently cultured at 37°C in 
200 μL total volume of cIMDM with 20 ng/mL M-CSF (Peprotech) for 5 days. 
 
Tamoxifen administration. 
Mice were orally gavaged with 4 mg of tamoxifen (Sigma Aldrich) dissolved in corn oil 
(Sigma Aldrich) for an initial loading dose and then placed on tamoxifen citrate chow (Envigo) 
for 4-5 weeks. Mice were given up to two days of regular chow per week if significant weight 
loss was observed. After treatment, mice were rested on regular chow for one week before 




Bone marrow chimeras. 
Bone marrow cells from donor mice were collected as described above. To generate 
mixed bone marrow chimeras, bone marrow cells were isolated from mice of the appropriate 
genotypes, counted with a Vi-CELL analyzer (Beckman Coulter), and mixed at a ratio of 1:1 
before transplantation. Recipient mice received a single dose of 1050 rads of whole-body 
irradiation and then received a transplant of 10x106 total BM cells the following day. Mice were 
allowed to reconstitute for 8-10 weeks before further experiments or analyses were conducted. 
 
Bone marrow progenitor cytokine stimulation. 
BM was isolated and lineage-depleted as described above. Lin– BM cells were then 
aliquoted at 1x106 cells per condition and serum-starved in plain IMDM for 4 hours at 37°C. 
Following starvation, M-CSF was added at the indicated concentrations and cells were incubated 
at 37°C for 5 minutes for stimulation. Cells were then fixed for 15 minutes at room temperature 
by adding paraformaldehyde (Electron Microscopy Sciences) directly to cells to a final 
concentration of 2%. Cells were washed twice with MACS buffer and then permeabilized by 
adding ice-cold methanol directly to cells with gentle vortexing followed by incubation at 4°C 
for 30 minutes. Cells were again washed twice with MACS buffer and then stained with 
fluorescent antibodies against cell-surface and intracellular antigens for 30 minutes at room 
temperature. Antibodies were previously tested individually to ensure their functionality in fixed 
and permeabilized cells. Flow cytometric analyses were then performed on stained cells. For 
analysis, we used integrated MFI, which combines frequency and MFI into a single measure of 





 All statistical analyses were performed using Prism 7 (GraphPad Software). Statistical 
significance was evaluated using unpaired two-tailed Student's t-test unless otherwise noted. 
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Figure 2.1.  Flt3l–/– mice have a more severe DC deficiency than Flt3–/– mice at two weeks of 
age. (A and B) Splenocytes from mice of the indicated genotypes at two weeks of age were 
analyzed by flow cytometry for DC populations. Shown are representative two-color histograms 
of live cells. Numbers specify the percent of cells within the indicated gates. (C-E) Summary 
data for the percent (C) and number (D) of splenic cDCs and the percent (E) and number (F) of 
splenic pDCs in mice of the indicated genotypes. Dots represent biological replicates; small 
horizontal lines indicate the mean. Data are pooled from seven independent experiments (n = 5 






Figure 2.2.  DC deficiency in skin-draining lymph nodes and lungs is more severe in Flt3l–/– 
mice than in Flt3–/– mice. (A) Gating strategy used for identifying resident cDCs 
(CD11c+MHCIIint) and pDCs (B220+CD317+) in the skin-draining lymph nodes by flow 
cytometry. Numbers specify the percent of cells within the indicated gates. (B-E) Summary data 
for the percent of cDCs (B and D) and pDCs (C and E) in SLNs of mice of the indicated 
genotypes at 2 weeks (B and C) or 8 weeks (D and E) of age. Dots represent biological 
replicates; small horizontal lines indicate the mean. Data are pooled from sixteen independent 
90 
 
experiments (n = 5-9 mice per genotype). (F) Gating strategy used for identifying cDCs 
(CD45.2+CD24+B220–CD11c+MHCII+) in the lung by flow cytometry. (G and H) Summary data 
for the percent of cDCs amongst CD45+ cells in lungs of mice of the indicated genotypes at 2 
weeks (G) or 8 weeks (H) of age. Dots represent biological replicates; small horizontal lines 
indicate the mean. Data are pooled from sixteen independent experiments (n = 5-9 mice per 






Figure 2.3.  Flt3l–/– mice continue to have a more severe DC deficiency than Flt3–/– mice at 
eight weeks of age. (A and B) Splenocytes from mice of the indicated genotypes at eight weeks 
of age were analyzed by flow cytometry for DC populations. Shown are representative two-color 
histograms of live cells. Numbers specify the percent of cells within the indicated gates. (C-E) 
Summary data for the percent (C) and number (D) of splenic cDCs and the percent (E) and 
number (F) of splenic pDCs in mice of the indicated genotypes. Dots represent biological 
replicates; small horizontal lines indicate the mean. Data are pooled from nine independent 
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experiments (n = 5-9 mice per genotype). *P<0.05; **P<0.01; ****P<0.0001 using unpaired, 





Figure 2.4.  Flt3L fails to generate DCs in Flt3–/– mice. (A-E) BM cells from WT (Flt3+/+) or 
Flt3–/– mice were treated with vehicle or Flt3L and cultured for 9 days. Live cells were 
subsequently analyzed by flow cytometry for DC populations. (A) Shown are representative two-
color histograms of live cells pre-gated as indicated above the plots. Numbers specify the 
percentage of cells within the indicated gates. (B-E) Summary data for the percent (B) and 
number (C) of cDCs in each culture, and for the percent (D) and number (E) of pDCs in each 
culture. Dots represent biological replicates; small horizontal lines indicate the mean. Data are 
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pooled from three independent experiments (n = 4 mice per genotype). (F-J) WT (Flt3+/+) and 
Flt3–/– mice were administered vehicle or Flt3L subcutaneously for 8 days and splenocytes were 
subsequently analyzed by flow cytometry on day 9 for DC populations. (F) Shown are 
representative two-color histograms of live cells. Numbers specify the percent of cells within the 
indicated gates. (G-J) Summary data for the percent (G) and number (H) of splenic cDCs and the 
percent (I) and number (J) of splenic pDCs. Dots represent biological replicates; small horizontal 
lines indicate the mean. Data are pooled from two independent experiments (n = 5 mice per 
group). ns, not significant (P>0.05); *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001 using 





Figure 2.5.  Flt3–/– DCs are transcriptionally and functionally similar to WT DCs. (A and B) 
Microarray analysis of gene expression in cDC1s (A) or cDC2s (B) from Flt3+/+ and Flt3–/– 
mice, presented as M-plots. Colors indicate higher (red) or lower (blue) expression in Flt3+/+ 
cells than in Flt3–/– cells. Annotated genes with a greater than four-fold change in expression are 
specified (n = 2 biological replicates per subset per genotype). (C) Sorted cDC subsets from 
Flt3+/+ or Flt3–/– mice were cultured for 3 days with CFSE-labeled OT-I cells and different doses 
of heat-killed Listeria monocytogenes-OVA (HKLM-OVA) and then assayed for OT-I 
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proliferation (CFSE–CD44+). Summary data for the percent of proliferated OT-I cells in cultures 
with cDC subsets from the indicated genotypes are shown. Dots represent the mean; error bars 
represent the s.e.m. Data are pooled from two independent experiments (n = 4 mice per 
genotype). (D) Sorted cDC subsets from Flt3+/+ or Flt3–/– mice were cultured for 3 days with 
CFSE-labeled OT-I cells and different doses of soluble OVA as antigen and then assayed for 
OT-I proliferation (CFSE–CD44+). Summary data for the percent of proliferated OT-I cells in 
cultures with cDC subsets from the indicated genotypes are shown. Dots represent the mean; 
error bars represent the s.e.m. Data are pooled from two independent experiments (n = 4 mice 
per genotype). (E) Sorted cDC subsets from Flt3+/+ or Flt3–/– mice were incubated with soluble 
OVA, washed, and then different numbers of cDCs were cultured with CFSE-labeled OT-I cells 
for 3 days after which OT-I proliferation was assayed. Summary data for the percent of 
proliferated OT-I cells in cultures with the cDC subsets from the indicated genotypes are shown. 
Dots represent the mean; error bars represent the s.e.m. Data are pooled from two independent 
experiments (n = 4 mice per genotype). (F) Microarray analysis of gene expression in pDCs from 
Flt3+/+ and Flt3–/– mice, presented as M-plots. Colors indicate higher (red) or lower (blue) 
expression in Flt3+/+ cells than in Flt3–/– cells. Annotated genes with a greater than four-fold 
change in expression are specified (n = 2 biological replicates per subset per genotype). (G) 
Sorted pDCs from Flt3+/+ or Flt3–/– mice were stimulated with vehicle or CpG-A 
oligodeoxynucleotides overnight and then the cell supernatant was analyzed for IFN-α 
production. Summary data for the quantity of IFN-α produced by pDCs of the indicated 
genotypes are shown. Dots represent biological replicates; small horizontal lines indicate the 






Figure 2.6.  Flt3–/– bone marrow generates mature DCs in response to M-CSF or SCF and 
contains committed DC progenitors. (A and B) BM cells from mice of the indicated genotypes 
were treated with vehicle, Flt3L, M-CSF, or SCF and cultured for 7 days. Live cells were 
subsequently analyzed by flow cytometry for development of DCs. (A) Shown are representative 
two-color histograms of live cells pre-gated as indicated above the plots and one-color 
histograms of Zbtb46GFP expression in cells of the indicated subtype. Numbers represent the 
percent of cells within the indicated gates. (B) Summary data for the percent of cDCs in each 
culture. Dots represent biological replicates; small horizontal lines indicate the mean. Data are 
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pooled from five independent experiments (n = 5-7 mice per genotype). (C) BM cells from mice 
of the indicated genotypes were analyzed by flow cytometry for DC progenitor populations; 
lineage markers include CD3, CD19, CD105, Ter119, and Ly-6G. Representative two-color 
histograms are shown of live cells pre-gated as indicated above the plots. Numbers specify the 
percent of cells within the indicated gates. Data are representative of four independent 
experiments (n = 7 mice per genotype). ns, not significant (P>0.05); **P<0.01; ***P<0.001; 






Figure 2.7.  cDCs from M-CSF and SCF cultures are phenotypically similar to cDCs from 
Flt3L cultures. (A and B) BM cells from mice of the indicated genotypes were treated with 
vehicle, Flt3L, MCSF, or SCF and cultured for 7 days. Live cells were subsequently analyzed by 
flow cytometry for the development of cDCs and for their surface marker expression. (A) 
Summary data for the number of cDCs in each culture. Dots represent biological replicates; 
small horizontal lines indicate the mean. Data are pooled from five independent experiments (n = 
5-7 mice per genotype). (B) cDCs (B220–F4/80–CD11c+MHCII+) in cultures were analyzed by 
flow cytometry for surface marker expression. Shown are representative one-color histograms of 
the indicated marker in cDCs from the indicated cytokine cultures. Data are representative of two 
independent experiments (n = 4 mice). ns, not significant (P>0.05); **P<0.01; ***P<0.001 using 






Figure 2.8.  M-CSF and SCF support pDC development from Flt3–/– bone marrow. (A) BM 
cells from mice of the indicated genotypes were treated with vehicle, Flt3L, MCSF, or SCF and 
cultured for 7 days. Live cells were subsequently analyzed by flow cytometry to quantify pDC 
development. Shown are representative two-color histograms of live cells pre-gated as indicated 
above the plots. Numbers specify the percent of cells within the indicated gates. Data are 
representative of three independent experiments (n = 5 mice per genotype). (B) CDPs (Lin–
cKitintCD135+CD115+CD11c–MHCII–) were sorted from Zbtb46GFP/+ mice and cultured with 
vehicle, Flt3L, MCSF, or SCF for 5 days. Live cells were subsequently analyzed by flow 
cytometry to quantify pDC development. Shown are representative two-color histograms of live 
cells pre-gated as indicated above the plots. Numbers specify the percent of cells within the 
indicated gates. Data are representative of three independent experiments (sorted cells from 3 to 





Figure 2.9.  Committed DC progenitors can mature in response to M-CSF and SCF. (A) 
CDPs (Lin–CD117intCD135+CD115+CD11c–MHCII–) were sorted from Zbtb46GFP/+ mice and 
cultured with vehicle, Flt3L, M-CSF, or SCF for 5 days. Cells were subsequently analyzed by 
flow cytometry for development of DCs. Shown are representative two-color histograms of live 
cells pre-gated as indicated above the plots and one-color histograms of Zbtb46GFP expression. 
Numbers specify the percent of cells within the indicated gates. Data are representative of three 
independent experiments (sorted cells from 3-5 mice were pooled in each individual 
experiment). (B) Pre-cDC2s (Lin–CD115+CD11c+MHCII–Zbtb46+) were sorted from 
Flt3+/+Zbtb46GFP/+ or Flt3–/–Zbtb46GFP/+ mice as indicated and cultured with vehicle, Flt3L, or 
M-CSF for 5 days. Cells were subsequently analyzed by flow cytometry for development of 
DCs. Shown are representative two-color histograms of live cells pre-gated as indicated above 
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the plots and one-color histograms of Zbtb46GFP expression in cells of the indicated subtype. 
Numbers specify the percent of cells within the indicated gates. Data are representative of three 
independent experiments (sorted cells from 3-5 mice per genotype were pooled in each 
individual experiment). (C) Pre-cDC2s were sorted from Flt3+/+Zbtb46GFP/+ or Flt3–/–
Zbtb46GFP/+ mice, labeled with Cell Proliferation Dye (CPD), and cultured with M-CSF for 5 
days. Cells were subsequently analyzed by flow cytometry for dilution of CPD to determine the 
number of divisions they underwent. Shown is a representative one-color histogram of CPD 
levels and the percent of cells at each division. Data are representative of two independent 








Figure 2.10.  cDC development in Flt3–/– mice is dependent upon CSF1R. (A-F) Mice of the 
indicated genotypes were treated with tamoxifen to delete Csf1r. After treatment, splenocytes 
were analyzed by flow cytometry for DC populations. (A and B) Shown are representative two-
color histograms of live cells. Numbers specify the percent of cells within the indicated gates. 
(C-E) Summary data of the percent (C) and number (D) of splenic cDCs and for the percent (E) 
and number (F) of splenic pDCs in mice of the indicated genotypes. Dots represent biological 
replicates; small horizontal lines indicate the mean. Data are pooled from seven independent 
experiments. (n = 3-6 mice per genotype). (G and H) WT CD45.1+ mice were lethally irradiated 
and reconstituted with Flt3–/– CD45.1+:Flt3–/–Csf1rf/fR26+/+CD45.2+ bone marrow at a 1:1 ratio 
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(CreERT2–) or Flt3–/–CD45.1+:Flt3–/–Csf1rf/fR26CreERT2/+CD45.2+ bone marrow at a 1:1 ratio 
(CreERT2+). After reconstitution and tamoxifen treatment to delete Csf1r, spleens and BM were 
analyzed by flow cytometry. (G) Shown are representative two-color histograms (pregating, 
above plots; splenic B cells, B220+CD24+; splenic cDCs, CD11c+MHCII+; BM CSF1R+ cells, 
CD115+). Numbers specify the percent of cells within the indicated gates. (H) Summary data of 
the chimerism ratio of splenic cDCs presented as the ratio of CD45.1+ to CD45.2+ cDCs 
normalized to the ratio of CD45.1+ to CD45.2+ B cells within the same mouse. Dots represent 
individual mice; small horizontal lines indicate the mean. Data are pooled from four independent 
experiments (n = 6-9 chimeras per genotype). ns, not significant (P>0.05); *P<0.05; **P<0.01; 






Figure 2.11.  Flt3–/– and Flt3l–/– BM progenitors and cDCs express normal levels of CSF1R 
and c-Kit. (A) BM cells from mice of the indicated genotypes were analyzed by flow cytometry 
for cytokine receptor expression. Representative two-color histograms of live cells are shown. 
Data are representative of at least three independent experiments (n = 4-7 mice per genotype). 
(B) Pre-cDC1s and pre-cDC2s from mice of the indicated genotypes were analyzed by flow 
cytometry for cytokine receptor expression levels. Representative one-color histograms of each 
receptor are shown. Data are representative of three independent experiments. (C) Expression of 
the indicated genes in splenic cDC1s and cDC2s from mice of the indicated genotypes was 
determined by gene expression microarray analysis. Dots represent biological replicates (n = 2 






Figure 2.12.  Committed DC progenitors arise in Flt3l–/– bone marrow and do not display 
increased sensitivity to M-CSF relative to WT progenitors. (A) BM cells from mice of the 
indicated genotypes were analyzed by flow cytometry for DC progenitor populations; lineage 
markers include CD3, CD19, CD105, Ter119, and Ly-6G. Representative two-color histograms 
are shown of live cells pre-gated as indicated above the plots. Numbers specify the percent of 
cells within the indicated gates. Data are representative of three independent experiments (n = 3 
mice per genotype). (B) BM from mice of the indicated genotypes was treated with M-CSF and 
assayed for phosphorylated Erk1/2 (pErk1/2) by intracellular flow cytometry. Shown are 
summary data presented as the Integrated MFI of pErk1/2 in pre-cDC2s from mice of the 
indicated genotypes stimulated with the indicated concentration of M-CSF. Dots indicate the 
mean from three independent experiments; error bars indicate the s.e.m (n = 3 mice per 





Figure 2.13.  Flt3–/– DC progenitors display increased sensitivity to M-CSF. (A and B) 
Serum-starved BM from mice of the indicated genotypes was treated with M-CSF and assayed 
for phosphorylated Erk1/2 (pErk1/2) by intracellular flow cytometry. (A) Shown are 
representative one-color histograms of pErk1/2 in pre-cDC2s stimulated with the indicated 
concentrations of M-CSF. Numbers in black indicate the percent of cells within the gate and 
numbers in red indicate the geometric mean fluorescence intensity (MFI) of pErk1/2 in the gated 
population. Data are representative of three independent experiments. (B) Summary data 
presented as the integrated MFI of pErk1/2 in pre-cDC2s from mice of the indicated genotypes 
stimulated with the indicated concentration of M-CSF. Dots indicate the mean from three 






Figure 2.14.  Deletion of Flt3 rescues the severe DC defect in Flt3l–/– mice. (A-E) Splenocytes 
from mice of the indicated genotypes at eight weeks of age were analyzed by flow cytometry for 
DC populations. (A) Shown are representative two-color histograms of live cells. Numbers 
specify the percent of cells within the indicated gates. (B-E) Summary data for the percent (B) 
and number (C) of splenic cDCs and the percent (D) and number (E) of splenic pDCs in mice of 
the indicated genotypes. Dots represent biological replicates; small horizontal lines indicate the 
mean. Data are pooled from six independent experiments (n = 4-5 mice per genotype). *P<0.05; 






Figure 2.15.  Deletion of Flt3 in Flt3l–/– mice reverses the severe DC defect in skin-draining 
lymph nodes and lungs. (A and B) Summary data for the percent of cDCs (A) and pDCs (B) 
determined as in Figure 2A in SLNs of mice of the indicated genotypes. Dots represent 
biological replicates; small horizontal lines indicate the mean. Data are pooled from at least three 
independent experiments (n = 2-5 mice per genotype). (C) Summary data for the percent of cDCs 
amongst CD45+ cells determined as in Figure 2F from mice of the indicated genotypes. Dots 
represent biological replicates pooled from groups of between 2 and 5 mice combined from at 
least 3 independent experiments; small horizontal lines indicate the mean. Data are pooled from 
six independent experiments (n = 4-5 mice per genotype). *P<0.05; ***P<0.001; ****P<0.0001 
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3.1 Abstract  
 Induction of the transcription factor Irf8 in the common dendritic cell progenitor (CDP) is 
required for classical type 1 dendritic cell (cDC1) fate specification, but the mechanisms 
controlling this induction are unclear. Here we identified Irf8 enhancers via chromatin profiling 
of DCs and used CRISPR/Cas9 genome editing to assess their roles in Irf8 regulation. An 
enhancer 32 kilobases downstream of the Irf8 transcriptional start site (+32 kb Irf8) that was 
active in mature cDC1s was required for the development of this lineage, but not for its 
specification. Instead, a +41 kb Irf8 enhancer previously thought to be active only in 
plasmacytoid DCs was found to also be transiently accessible in cDC1 progenitors, and deleting 
this enhancer prevented the induction of Irf8 in CDPs and abolished cDC1 specification. Thus, 













 The diversification of immune cells relies upon lineage-determining transcription factors 
that commit multipotent progenitors to a single fate 1,2. While early studies proposed that 
stochastic variations in the levels of these factors determined the eventual fate of progenitors 3, 
more recent work has instead suggested that the expression of individual factors is actively 
induced in order to specify a particular lineage 4. However, the precise mechanisms responsible 
for such induction remain unclear. 
Gene expression is primarily controlled by cis-acting enhancers bound by transcription 
factors 5. Certain genes are regulated entirely by a single enhancer 6,7, while others, including 
many genes important for development, contain multiple potentially redundant enhancers as a 
safeguard for continued expression 8,9. Further, enhancer usage in individual genes dynamically 
changes as progenitors mature, possibly indicating the actions of distinct transcriptional networks 
throughout the developmental progression of a cell type 10.  Analyzing the enhancers that 
regulate expression of lineage-determining transcription factors at developmental branch points 
could therefore identify the transcriptional mechanisms controlling fate choice. 
Denritic cells (DCs) are a group of immune cells critical for innate and adaptive immune 
responses that include ‘classical’ DCs (cDCs) 11 and plasmacytoid DCs (pDCs) 12.  cDCs are 
comprised of two functionally distinct lineages called cDC1 and cDC2 13.  cDC1s are critical for 
priming CD8 T cells during antiviral and antitumor immune responses 14, as well as for effective 
responses to checkpoint blockade therapy 15,16.  cDC1s are also the most promising substrates for 
cell-based cancer vaccines 17, so understanding their development is paramount. 
DCs are derived from hematopoietic precursors in the bone marrow (BM), the earliest of 
which is the monocyte/DC progenitor (MDP) 18. The MDP gives rise to a common DC 
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progenitor (CDP) 19,20, which produces distinct clonogenic progenitors, the pre-cDC1 and pre-
cDC2 21,22.  Several transcription factors regulate development of the cDC1 lineage, including 
Irf8, Batf3, Nfil3, and Id2 14,23-25. Although cDC1s can be generated in mice deficient in Nfil3, 
Batf3, or Id2 under inflammatory conditions 26,27, Irf8–/– mice have an absolute defect in both 
pre-cDC1 specification and cDC1 development that cannot be rescued by such conditions.  
Further, the Irf8 gene contains a super-enhancer in cDC1s, and Irf8 overexpression biases bone 
marrow progenitors towards cDC1 output21. These properties together suggest that Irf8 is the 
lineage-determining transcription factor for cDC1 fate. Understanding the enhancers that 
regulate Irf8 could therefore provide insight into how cDC1 fate specification from its 
multipotent progenitor, the CDP, is achieved. 
Our previous work identified two distinct enhancers within the Irf8 super-enhancer 
located at +32 kb and +41 kb relative to the Irf8 transcriptional start site (TSS) 21.  Using an 
integrating retroviral reporter, we demonstrated that the +32 kb Irf8 enhancer was selectively 
active in cDC1s, and that the +41 kb Irf8 enhancer was selectively active in pDCs.  The +32 kb 
Irf8 enhancer contained several AP1-IRF composite elements (AICEs) that bound IRF8 and 
BATF3 in cDC1s by ChIP-seq, suggesting this enhancer might support Irf8 expression through 
autoactivation.  The +41 kb Irf8 enhancer contained several E box motifs, suggesting that E 
proteins such as E2-2, the lineage-determining transcription factor of pDCs 28, might utilize this 
enhancer to drive Irf8 expression in pDCs. Finally, an Irf8 enhancer located at -50 kb was 
identified and analyzed using bacterial artificial chromosome (BAC) reporter transgenic mice, 
and was predicted to be required for Irf8 expression in MDPs 29.  However, until now the 




In this study, we used chromatin profiling of DCs and CRISPR/Cas9 genome editing to 
identify and delete enhancers regulating Irf8 in mice.  We found that the +32 kb Irf8 enhancer 
was required for normal and compensatory cDC1 development but not for pre-cDC1 
specification.  We also found that the -50 kb Irf8 enhancer was not required for Irf8 expression in 
MDPs, as was previously predicted, but rather regulated Irf8 levels selectively in 
monocyte/macrophage lineages. To find other enhancers regulating the cDC1 lineage, we 
performed ATAC-seq on DC progenitors. We surprisingly found that the +41 kb Irf8 enhancer 
became transiently accessible during the transition from the MDP to the pre-cDC1 before again 
closing in the mature cDC1. Deletion of the +41 kb Irf8 enhancer led to decreased Irf8 
expression in pDCs, as was predicted, but also surprisingly prevented Irf8 induction in CDPs and 
resulted in the loss of both pre-cDC1 and mature cDC1 development. Consistently, Tcf3–/– DC 
progenitors, which lack E2A, had reduced cDC1 potential. Thus cryptic activation of the Irf8 
+41 kb enhancer within CDPs is required for the induction of Irf8 and the subsequent 
specification of cDC1 fate.  
 
3.3 Results  
The +32 kb Irf8 enhancer is required for cDC1 development in vivo 
The +32 kb Irf8 enhancer was identified by ChIP-seq as a 547 bp region that bound the 
transcription factors BATF3, IRF8, and p300 in cDC1s and that contained four AICEs in the 5' 
portion of the region 21 (Figure 3.1A).  Reporter analysis indicated that the first three AICEs 
within this region were sufficient to confer cDC1 specific reporter activity, and that this activity 
could be abrogated by mutating these three AICEs (Figures 3.2A and 3.2B). The four AICES 
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contained in the 5' portion of the +32 kb Irf8 enhancer also accounted for the entire activity of 
the full length enhancer (Figure 3.2C).  Further, using Flt3L-treated BM cultures of R26Cas9/+ 
transgenic mice, we found that expression of an sgRNA directed to the central AICE in the 5’ 
half of the +32 kb Irf8 enhancer caused a reduction in cDC1 development that was as large as the 
reduction caused by an sgRNA directed at the Irf8 coding sequence itself (Figure 3.2D).  We 
therefore generated mice with deletions in this region by injecting zygotes with Cas9 mRNA and 
three sgRNAs, two flanking the first three AICEs in the 5’ half of the enhancer and a third 
downstream of the fourth AICE (Figures 3.1A and 3.2E).  This generated two lines of mice with 
deletions within the +32 kb Irf8 enhancer, one deleting 149 bp and eliminating 3 AICEs (Irf8 
+32 5’–/–- mice), and a second deleting 421 bp and eliminating all 4 AICEs (Irf8 +32–/– mice) 
(Figure 3.2F).  Both lines show severe reductions in cDC1 development in vivo (Figures 3.2G 
and 3.2H).  Deletion of 3 AICEs reduced cDC1 development by 10-fold compared with wildtype 
mice, and deletion of all 4 AICEs eliminated all residual cDC1s (Figure 3.2H).  All subsequent 
analyses used the more complete Irf8 +32–/– strain. 
 The defect in splenic cDC1 development in Irf8 +32–/– mice is more complete than in 
Batf3–/– mice and as severe as in Irf8–/– mice (Figures 3.1B and 3.1D).  Irf8 +32–/– mice showed 
no defects in other lineages, confirming the selective activity of this enhancer in cDC1s as 
predicted by our reporter assays.  pDCs were normal in frequency and intracellular IRF8 protein 
levels (Figures 3.1C and 3.1D), as were monocytes, neutrophils, red pulp macrophages, B cells, 
and T cells (Figures 3.3A-3.3C).  cDC1s in Irf8 +32–/– mice were absent in all tissues, such as in 
the lung (Figures 3.5A and 3.5B).  To test for a functional defect in Irf8 +32–/– mice, we 
analyzed a tumor rejection system that requires cDC1s (Figure 3.1E).  The regressor 
fibrosarcoma 1969, whose rejection relies on cross-presentation by cDC1s 31, was rejected by all 
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wildtype mice, but not by Irf8 +32–/– mice (Figure 3.1E).  These data indicated that the +32 kb 
Irf8 enhancer was absolutely required for cDC1 development and that its deletion generates a 
specific and functional defect restricted to this lineage. 
 
Compensatory cDC1 development requires the +32 kb Irf8 enhancer 
cDC1 development can occur in Batf3–/– mice due to compensation from BATF and 
BATF2, which can replace BATF3 for interactions with IRF8 30.  Compensatory cDC1 
development in Batf3–/– mice occurs in skin draining lymph nodes (SLNs) and under 
inflammatory settings such as after bone marrow transplantation or after administration of IL-12 
26,27.  We examined these settings to test if compensatory cDC1development can occur in Irf8 
+32–/– mice (Figure 3.4).  We found that cDC1s were clearly present in SLNs from wildtype and 
Batf3–/– mice, but were completely absent in Irf8 +32–/– mice (Figures 3.4A and 3.4B).  We 
further found that administration of IL-12 led to a complete restoration of splenic cDC1 in Batf3–
/– mice, but not in Irf8 +32–/– mice (Figures 3.4C and 3.4D).  Finally, we tested for cDC1 
compensation after BM transplantation 27.  We generated BM chimeras using wildtype, Irf8 +32–
/–, or Batf3–/– donor BM transplanted into irradiated wildtype mice (Figures 3.5C and 3.5D).  
cDC1s developed in chimeras produced from wildtype BM, as expected, and from Batf3–/– BM, 
as reported27.  However, cDC1s failed to develop in chimeras produced from Irf8 +32–/– BM.  In 
summary, all compensatory cDC1 development failed to occur in mice lacking the +32 kb Irf8 
enhancer. 
While IL-12 injection did not restore cDC1s in Irf8 +32–/– mice, it did increase the 
numbers of cDC2s (Figures 3.4C and 3.4D). This potentially resulted from specified pre-cDC1s 
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failing to maintain high Irf8 levels in response to IL-12 and their subsequent diversion to the 
cDC2 fate, as occurs with pre-cDC1s from Batf3–/– mice 21. We therefore sought to determine 
whether pre-cDC1 specification occurs in Irf8 +32–/– mice.  Previous identification of the pre-
cDC1 in BM relied upon Zbtb46-GFP expression.  However, we developed a method to identify 
the pre-cDC1 using CD226 expression in place of Zbtb46-GFP (Figure 3.6).  CD226 was not 
expressed in CDPs, but became expressed in pre-cDC1s (Figures 3.6A and 3.6B).  Like Zbtb46-
GFP expression, CD226 expression indicates pre-cDC1 specification, as Flt3L culture of Lin–
CD135+CD117intCD226+ BM cells, like Lin–CD135+CD117int Zbtb46-GFP+ BM cells, generated 
exclusively cDC1s (Figures 3.6C and 3.6D).  Also, Lin–CD135+CD117intCD226+ cells develop 
in wildtype mice, but not in Irf8–/– mice known to lack pre-cDC1s (Figure 3.4E)21.  Using CD226 
expression, we found that pre-cDC1s develop in Irf8 +32–/– mice in normal numbers but had 
reduced intracellular IRF8 protein levels (Figures 3.4E, 3.4F, and 3.5E), similar to the findings in 
Batf3–/– mice. And in contrast to wildtyppe pre-cDC1s, pre-cDC1s from Irf8 +32–/– mice 
cultured in Flt3L become cDC2s (Figure 3.4G). These cDC2s derived from Irf8 +32–/– pre-
cDC1s were transcriptionally similar to cDC2s arising from wildtype pre-cDC2s and 
transcriptionally distinct from cDC1s arising from wildtype pre-cDC1s, including in the 
expression of key cDC2 transcription factors such as Irf4 (Figure 3.6E-G). Though the cDC2s 
derived from Irf8 +32–/– pre-cDC1s retained CD24 expression, we found that there were no 
transcriptional differences between CD24+ cDC2s and CD24– cDC2s (Figure 3.6F), indicating 
that the diverted cDC2s that developed from Irf8 +32–/– pre-cDC1s were bona fide cDC2s. This 
result also recapitulated the diversion of Batf3–/– pre-cDC1s to the cDC2 fate (Fig. 3.6H). In 
summary, Irf8 +32–/– mice showed continued development of a specified pre-cDC1 progenitor in 




The -50 kb Irf8 enhancer regulates Irf8 expression in monocytes and macrophages  
 To identify enhancers regulating pre-cDC1 specification, we performed ChIP-seq of 
active histone marks in MDPs, CDPs, and pre-cDC1s. This analysis identified a region of active 
H3K27 acetylation at -50 kb relative to the Irf8 TSS that overlapped with a previously identified 
Irf8 enhancer 29 (Figure 3.7A).  Analysis of BAC transgenic Irf8 reporter mice had suggested 
that this -50 kb region contains two PU.1 binding sites and is required for Irf8 expression in the 
MDP29.  To test whether this enhancer regulated Irf8 induction and pre-cDC1 specification, we 
used CRISPR/Cas9 genome editing to generate mice with a 364 bp deletion that eliminates both 
of the PU.1 sites in this region (Irf8 -50–/– mice) (Figures 3.8A and 3.8B).  Irf8 -50–/– mice have 
normal frequencies of cDCs, pDCs, neutrophils, B cells, T cells, and red pulp macrophages 
(Figures 3.7B and 3.8C), all of which express normal levels of intracellular IRF8 protein 
(Figures 3.7C and 3.8D).  Frequencies and intracellular IRF8 protein levels of MDPs, CDPs, and 
pre-cDC1s were also normal in Irf8 -50–/– mice (Figures 3.7D and 3.7E), in contrast to the 
predictions based on the BAC transgenic Irf8 reporter mice29.    
 However, ATAC-seq analysis suggested that the -50 kb Irf8 enhancer was active in 
F4/80+ peritoneal macrophages and Ly6C+ monocytes (Figure 3.9A).  In Irf8 -50–/– mice, 
monocytes were present at normal numbers, but showed reduced intracellular IRF8 protein levels 
compared to wildtype mice (Figures 3.9B-3.9D).  Likewise, F4/80+ peritoneal macrophages in 
Irf8 -50–/– mice had greatly reduced intracellular IRF8 protein levels (Figures 3.9E and 3.9F). 
Irf8–/– mice have been reported to have decreased survival in Salmonella enterica Typhimurium 
infection, possibly due to IRF8 regulation of inflammasome activity in macrophages 32. 
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However, it was not determined whether the in vivo defect in germline Irf8–/– mice was cell-
intrinsic to macrophages.  We found that Irf8 -50–/– mice were more susceptible to Salmonella 
infection compared to wildtype mice (Figure 3.9G), consistent with a role for the -50 kb Irf8 
enhancer in controlling IRF8 protein levels in monocytes/macrophages during infections. In 
conclusion, the -50 kb Irf8 enhancer was not required for DC development but did regulate Irf8 
specifically in monocytes and macrophages. 
 
ATAC-seq reveals transient use of the +41 kb Irf8 enhancer during cDC1 development 
 To obtain base pair level resolution of accessible chromatin in progenitors, we next 
performed ATAC-seq on MDP, CDP, and pre-cDC1 populations 33,34 (Fig. 3.10). Pearson 
correlation analysis of all distal ATAC-seq peaks indicated that MDPs were most closely related 
to CDPs and least related to pre-cDC1s (Figure 3.10A).  During transition from MDPs to CDPs, 
687 unique peaks were gained, and 1,522 lost (Figure 3.10B).  By contrast, during transition 
from CDPs to pre-cDC1s, 14,630 peaks were gained, and 13,664 lost. Thus a large shift in 
chromatin accessibility occurs as CDPs transition to pre-cDC1s, which could potentially be 
related to the loss of alternative fate potentials in the pre-cDC1, to the differential proliferative 
capacities of these two cell types, or to a natural consequence of the differentiation process. 
 Five main k-means clusters of peaks were identified (Figure 3.10C).  Cluster 1 included 
peaks found only in MDPs.  Clusters 2 and 3 included peaks shared between MDPs and CDPs.  
Cluster 4 contained peaks found in both CDPs and pre-cDC1s, and cluster 5 included peaks 
present only in pre-cDC1s.  We identified the genes closest in linear distance to the peaks within 
each cluster, and inferred the transcription factor motifs enriched within these peaks (Figures 
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3.10C and 3.10D). Of note, the enrichment of transcription factors reflects the activity of any 
factor with a similar DNA binding motif rather than the activity of the specific factor that was 
enriched. For example, enrichment of Tcf3 could reflect the activity of other Tcf factors such as 
Tcf4 or Tcf12 within the clustered peaks. Peaks unique to MDPs (cluster 1) were in proximity to 
genes related to monocyte ontogeny, such as Mpo and Maf.  These peaks were enriched in motifs 
for transcription factors such as Cebpb and Atf that regulate the macrophage/monocyte lineages 
35,36 (Figures 3.10C and 3.10D). 
 The peaks identified in MDPs and CDPs (cluster 2 and 3) were enriched for motifs 
binding E proteins and Runx factors, both of which are required for DC development 28,37,38 
(Figures 3.10C and 3.10D). Runx1 was also among the genes most proximal to peaks within 
these clusters, and the Runx1 locus contained open chromatin peaks in the MDP and CDP that 
were lost in the pre-cDC1 (Figure 3.10E). 
The peaks found in CDPs and pre-cDC1s (cluster 4) were also enriched in motifs binding 
E proteins (Figure 3.10C).  Further, cluster 4 included the +41 kb Irf8 enhancer (Fig. 3.10C), 
which contains six predicted E box motifs and was previously found to be active in pDCs but not 
cDC1s21 (Figure 3.1A).  This unexpected ATAC-seq accessibility of the +41 kb Irf8 enhancer in 
the pre-cDC1 (Figure 3.10E) suggested that the activity of this enhancer could be important for 
cDC1 specification.  
 Finally, in the cluster of peaks found only in the pre-cDC1 (cluster 5) we found that Irf8 
and Batf3 were among the genes at closest proximity to open regions and that AP1-IRF motifs 
and PU.1 motifs were highly enriched within these regions (Figures 3.10C and 3.10D). 
Accessible chromatin peaks were also proximally located to genes known to be critically 
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involved in cDC1 function, such as Wdfy4 39 (Figure 3.10E). Finally, we found that the +32 kb 
Irf8 enhancer only became accessible at the pre-cDC1 stage (Figures 3.10C and 3.10E). 
Together, our data suggests that the +41 kb Irf8 enhancer was transiently active in cDC1 
progenitors before being replaced by activity at the +32 kb Irf8 enhancer in mature cDC1s. 
 
The +41 kb Irf8 enhancer is required for cDC1 specification 
 By ATAC-seq analysis, the +41 kb Irf8 enhancer was inactive in MDPs, became active in 
CDPs and pre-cDC1s, and was inactive again in mature cDC1s (Figure 3.11A).  This enhancer 
also bound p300 in pDCs, suggesting it regulated Irf8 expression in these cells21.  We targeted 
this enhancer using CRISPR/Cas9 genome editing with two flanking sgRNAs (Figure 3.11A), 
producing mice with a 361 bp deletion (Irf8 +41–/–) that eliminated all six predicted E boxes 
(Figures 3.12A and 3.12B).  As expected, Irf8 +41–/– mice had a pDC phenotype similar to the 
phenotype reported for Irf8–/– mice40. pDCs were present in Irf8 +41–/– mice, but had low protein 
levels of IRF8 and CD317 and increased protein levels of IRF4 (Figures 3.11B-3.11D).  By 
contrast, monocytes, neutrophils, red pulp macrophages, B cells, and T cells from these mice 
were normal in frequency and intracellular IRF8 protein levels (Figures 3.12C and 3.12D). 
However, Irf8 +41–/– mice completely lacked mature cDC1s (Figures 3.11B and 3.11D).  
We found normal frequencies of MDPs and CDPs in the bone marrow of Irf8 +41–/– mice, 
indicating that the +41 kb Irf8 enhancer was not required for the development of these 
progenitors (Figure 3.11E).  However, while the transition from the MDP to CDP is usually 
accompanied by a ~2-fold increase in intracellular IRF8 protein levels in wildtype CDPs, there 
was no increase in IRF8 levels in Irf8 +41–/– CDPs (Figure 3.11F).  Also, pre-cDC1s failed to 
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develop in Irf8 +41–/– mice, similarly to Irf8–/– mice (Figure 3.11G).  In summary, the +41 kb 
Irf8 enhancer was only transiently active during cDC1 progenitor development, but was 
absolutely required for Irf8 induction in the CDP and for cDC1 specification. 
 
E proteins are involved in cDC1 and pDC development 
 Since deletion of the +41 kb Irf8 enhancer abolished cDC1 specification, the factors that 
bound to this enhancer could be responsible for cDC1 fate commitment. The 454 bp region 
defining this enhancer contains predicted six E box motifs 21 (Figure 3.11A). ChIP-seq of LPS-
activated B cells, pre-plasmablasts, and plasmablasts, in which E proteins and IRF8 are active, 
showed E2A binding to the +41 kb Irf8 enhancer. ATAC-Seq of these populations also found 
that this site was accessible in wildtype B cells, but was not in B cells doubly deficient for the E 
proteins E2A (Tcf3) and E2-2 (Tcf4) (Figure 3.13A). 
 The E proteins E2A and E2-2 are known to regulate B cell development and pDC 
development respectively 28,41, but they have not been implicated in cDC development or function. 
Using the Tcf3fl/+VavCretg mice, which express an E2A-GFP fusion protein after Cre activity 41, 
we found that E2A was expressed in MDPs and CDPs, was reduced in pre-cDC1s, and was 
completely absent in mature cDC1s and pDCs (Figure 3.13B). This indicated that there was a 
transient period of E2A expression in DC progenitors.  E2A was also expressed in pre-B cells, as 
has been previously described41, and also in CMPs and CLPs (Fig. 3.14A). To test the relevance 
of this expression, we analyzed DC development from wildtype and Tcf3–/– BM using Flt3L-
treated cultures.  While wildtype BM showed normal cDC1 and pDC development in vitro, Tcf3–
/– BM showed severely impaired cDC1 and pDC development but normal cDC2 development 
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(Figures 3.13C and 3.13D).  However, cDC1s and pDCs continued to develop in Tcf3–/– mice in 
vivo, suggesting possible compensation for the actions of Tcf3 by another member of the Tcf family 
as has been previously described in B cells 42 (Figures 3.14B and 3.14C). To further characterize 
the role of Tcf3 in vivo, we generated bone marrow chimeras with mixed wildtype and Tcf3–/– bone 
marrow and assessed DC development after reconstitution (Figures 3.14D and 3.14E). We found 
that wildtype progenitors preferentially gave rise to cDC1s and exclusively gave rise to pDCs when 
in competition with Tcf3–/– progenitors. These results suggest a potential role for E proteins in 
cDC1 and pDC development. 
 
3.4 Discussion  
Our study analyzed the in vivo function of three different Irf8 enhancers, discovering 
unexpected and distinct roles in DC development and monocyte/macrophage function for each.  
Our initial aim was to understand the development of the cDC1 subset critical for antiviral and 
antitumor immunity. Irf8 is the lineage-determining transcription factor responsible for cDC1 
development23, but the molecular regulation of its transcription has not been well characterized.  
Previous studies have proposed that PU.1 regulated the induction of Irf8 in the MDP through a -
50 kb Irf8 enhancer 29, that BATF3 supports Irf8 autoactivation at the +32 kb Irf8 enhancer 21, 
and that there was a pDC-specific +41 kb Irf8 enhancer as well 21.  However, none had tested the 
roles of any Irf8 enhancer elements in vivo. 
In this study, we generated several targeted deletions of Irf8 enhancers using 
CRISPR/Cas9 genome editing in mice.  Our results have confirmed the +32 kb Irf8 enhancer's 
role in cDC1 development 21 and excluded a role for the -50 kb Irf8 enhancer in early Irf8 
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expression 29.  However, most importantly, our analysis has established a wholly unexpected 
requirement for the +41 kb Irf8 enhancer in Irf8 induction within the CDP and subsequent cDC1 
specification. This further suggested a previously unrecognized role for E proteins in this process 
as well. 
We have confirmed that the +32 kb Irf8 enhancer is required for normal and 
compensatory cDC1 development.  We had originally predicted this result because BATF3, 
which is required for cDC1 development, bound along with IRF8 to the +32 kb Irf8 enhancer.  
However, it was possible that BATF3 could also interact with other unidentified regions that 
serve as redundant enhancers to support cDC1 development. Our study found that not only was 
the +32 kb Irf8 enhancer required for normal cDC1 development, it was also required for the 
compensatory cDC1 development that can occur in Batf3–/– mice under various inflammatory 
settings.  Because of this compensatory cDC1 development in Batf3–/– mice, this strain has not 
been useful for examining the function of cDC1s in some settings. For example, during infection 
by Mycobacterium tuberculosis, cDC1s reappear in Batf3–/– mice, so that the role of these cells in 
protection cannot be evaluated 26.  Also, Batf3 has functions in other lineages, such as T cells and 
perhaps macrophages 43, so Batf3–/– mice might manifest phenotypes in other cell types that 
could make interpretations from this strain difficult.  These limitations have been resolved by the 
generation of the Irf8 +32–/– mice.  In these mice, Batf3 remains expressed normally in all 
immune lineages, but cDC1 development, both natural and compensatory, is ablated.  These 
mice should now allow for the analysis of cDC1 function in settings where it could not 
previously be studied. 
Our results also demonstrate how the cryptic activation of enhancers by transiently active 
transcriptional networks can control lineage diversification. Early models of hematopoiesis 
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proposed that the fate choices of progenitors are resolved by stochastic fluctuations in the 
expression of cross-antagonistic lineage-determining transcription factors. These fluctuations 
cause one factor to become dominant and impose fate commitment, which is reinforced by 
autoactivation of this factor and cross-inhibition of opposing factors.  One example is the 
PU.1/GATA1 circuit that regulates the choice between myeloid and megakaryocyte/erythrocyte 
fates.  PU.1 and GATA1 are able to inhibit one another 44,45 and also to activate their own 
transcription 46,47.  Further, these factors were thought to be co-expressed in progenitor cells that 
remained uncommitted until fluctuations in the levels of these two factors specified them to a 
single fate3. But this model was challenged by a recent study that used high-resolution analysis 
of single progenitor cells 4. Using reporters for PU.1 and GATA1 expression, that study 
demonstrated that no progenitor cells actually co-express these factors.  Rather, PU.1 levels 
decay before GATA1 is even expressed in progenitors destined for megakaryocyte/erythrocyte 
fate. This suggested that some unknown mechanism actually drives this particular cell fate by 
inducing GATA1, rather than stochastic fluctuations randomly generating this outcome. Our data 
also supports such a deterministic rather than stochastic model of fate divergence, in which 
transiently active transcriptional networks initiate the higher expression of lineage-determining 
transcription factors.  Specifically, we found that activation of the +41 kb Irf8 enhancer in CDPs, 
potentially by E proteins, induced Irf8 expression and subsequent cDC1 fate specification.  
Similarly, other transiently acting networks may act to induce factors such as PU.1 or GATA1 in 
progenitors of other lineages.  These networks may not be apparent in mature progeny, but might 
be revealed by the analysis of chromatin states of progenitors during development.  
Our study also highlights how different enhancers of the same gene can be required at 
different stages of development of a single lineage.  cDC1 development requires both the +41 kb 
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and the +32 kb Irf8 enhancers, but the requirements are manifested at different developmental 
stages. The +41 kb Irf8 enhancer is required for the specification of pre-cDC1s from CDPs, but 
its activity is subsequently extinguished and is not apparent in the fully developed cDC1.  On the 
other hand, the +32 kb Irf8 enhancer is active only after cDC1 specification, and remains active 
in the fully developed cDC1. The switch between these two enhancers reveals that different 
transcriptional networks are responsible for Irf8 expression during distinct periods of cDC1 
development.  Such switches in enhancer activity could occur throughout hematopoiesis, and 
analyzing them could help elucidate the mechanisms controlling other fate divergences that are 
still not fully understood.  
Finally, our finding that E proteins were potentially responsible for cDC1 specification 
was wholly unexpected.  However, since pDC development also relies on E proteins, it is unclear 
how cDC1 and pDC fates are separately specified.  Other factors important in cDC1 
development, such as Id2, could act to exclude pDC potential by blocking E protein activity, but 
why this would not also block cDC1 specification is unclear.  Future work will need to determine 
the precise sequence of transcriptional events that govern cDC1 development, including our 
newfound role for E proteins. 
 
3.5 Materials and Methods 
Mice. 
Batf3–/–, Irf8–/–, and Zbtb46GFP/+ mice have been described previously. Irf8 +32–/–, Irf8 -
50–/–, and Irf8 +41–/– mice were newly generated as described below. The following mice were 
purchased from Jackson Laboratories: R26Cas9/+ mice (B6N.129(Cg)-Gt(ROSA)26Sortm1.1(CAG-
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cas9*,-EGFP)Fezh/J), CD45.1+ mice (B6.SJL-Ptprca Pepcb/BoyJ), Tcf3gfp/+ mice (B6.129-
Tcf3tm1Mbu/J), and VavCretg mice (B6.Cg-Commd10Tg(Vav1-iCre)A2Kio/J). Tcf3–/– mice were a gift 
from B. Kee. All mice were on the C57BL6/J background except for Tcf3–/– mice, which were on 
the FVB/NJ background. All mice were generated, bred, and maintained in the Washington 
University in St. Louis School of Medicine specific pathogen-free animal facility. Animals were 
housed in individually ventilated cages covered with autoclaved bedding and provided with 
nesting material for environmental enrichment. Up to five mice were housed per cage. Cages 
were changed once a week, and irradiated food and water in autoclaved bottles were provided ad 
libitum. Animal manipulation was performed using standard protective procedures, including 
filtered air exchange systems, chlorine-based disinfection, and personnel protective equipment 
including gloves, gowns, shoe covers, face masks, and head caps. All animal studies followed 
institutional guidelines with protocols approved by the Animal Studies Committee at 
Washington University in St. Louis. 
Unless otherwise specified, experiments were performed with mice between 6 and 10 
weeks of age. No differences were observed between male and female mice in any assays 
performed and so mice of both genders were used interchangeably throughout this study. Within 
individual experiments, mice used were age- and sex-matched whenever possible. When mice 
were tracked for tumor growth or survival after Salmonella enterica Typhimurium infection, the 
monitoring scientist was blinded as to the genotypes of the mice in the experiment. 
 
Generation of Irf8 enhancer deletion mice 
sgRNAs that flanked the enhancers of interest were identified using GT-Scan (http://gt-
scan.braembl.org.au/gt-scan/). For deletion of the Irf8 +32 kb enhancer the following sgRNA 
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sequences were used: Irf8 +32 5’: gttgtgatctttgaggtaga, Irf8 +32 Mid: gtctccttctgaaatttcagtt, and 
Irf8 +32 3’: gaactggcctggggcaggtc. For the Irf8 -50 kb enhancer the following sgRNA sequences 
were used: Irf8 -50 5’: ggtgacatctgtctacggag and Irf8 -50 3’: atgcacccaaggcctggctc. For the Irf8 
+41 kb enhancer the following sgRNA sequences were used: Irf8 +41 5’: ggcccttgtagtttagctta 
and Irf8 +41 3’: aaagaagatctggggtatgt. Oligonucleotides that included these desired sgRNA 
sequences preceded by a T7 polymerase initiation site (ttaatacgactcactataggg) and followed by a 
portion of the tracrRNA sequence that annealed to the pX330 vector (gttttagagctagaaatagcaag) 
were then purchased (Sigma Aldrich). For example, the full Irf8 +32 5’ oligonucleotide 
purchased was 
TTAATACGACTCACTATAGGGgttgtgatctttgaggtagaGTTTTAGAGCTAGAAATAGCAAG. 
Each oligonucleotide was used in a PCR reaction with the PX330 Common Reverse Primer, 
aaaagcaccgactcggtgcc, and with the PX330 vector as a template to generate a complete DNA 
product containing the T7 polymerase initiation site, the sgRNA sequence, and the full tracrRNA 
sequence in order. RNA was then synthesized from these products using the MEGAscript T7 
Transcription Kit (Thermo Fisher Scientific). RNA was purified using the MEGAclear 
Transcription Clean-Up Kit (Thermo Fisher Scientific) and eluted into nuclease-free injection 
buffer. RNA was diluted and stored at -80°C until it was used for microinjection. Purified Cas9 
mRNA was a gift from W. Yokoyama. 
Day 0.5 single cell embryos from C57Bl/6 mice were isolated and underwent pronuclear 
micro-injection at the Department of Pathology Micro-Injection Core. Each embryo was injected 
with 50 ng of each sgRNA and 100 ng of Cas9 mRNA. Injected embryos were then transferred 
into the oviducts of pseudopregnant recipient mice. 
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The resulting pups were screened by PCR to identify those that had successful deletion of 
the enhancers of interest. Mice with the desired deletion were then outcrossed to wildtype 
C57Bl/6 mice, and the resulting heterozygous mice were intercrossed to generate homozygous 
enhancer deletion mice. 
 
Dendritic cell preparation. 
Lymphoid and nonlymphoid organ DCs were harvested and prepared as described 
previously48. Briefly, spleens and inguinal skin-draining LNs were minced and digested in 5 mL 
of Iscove’s modified Dulbecco’s media (IMDM) + 10% FCS (cIMDM) with 250 µg/mL 
collagenase B (Roche) and 30 U/mL DNaseI (Sigma-Aldrich) for 45 min at 37⁰C with stirring. 
Lungs were minced and digested in 5 mL of cIMDM with 4 mg/mL collagenase D (Roche) and 
30 U/mL DNaseI (Sigma-Aldrich) for 1.5 hours at 37⁰C with stirring. After digestion was 
complete, single cell suspensions from all organs were passed through 70-µm strainers and red 
blood cells were lysed with ammonium chloride-potassium bicarbonate (ACK) lysis buffer. Cells 
were subsequently counted with a Vi-CELL analyzer (Beckman Coulter) and 3-5x106 cells were 
used per antibody staining reaction. 
For peritoneal cell analysis, 5 mL of MACS buffer (DPBS + 0.5% BSA + 2mM EDTA) 
was injected into the peritoneum of mice using a 27 g needle. After injection the mice were 
shaken gently to dislodge peritoneal cells. A 25 g needle was then used to collect the peritoneal 
fluid. Cells were ACK lysed and counted as described above. 
 
Antibodies and flow cytometry 
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Cells were stained at 4ºC in MACS buffer in the presence of Fc block (2.4G2; BD 
Biosciences). 
The following antibodies were from BD Biosciences: CD11b PE (M1/70), CD19 Biotin 
(1D3), CD45R AlexaFluor488 (RA3-6B2), CD45.2 PerCP-Cy5.5 (104), CD64 AlexaFluor647 
(X54-5/7.1), CD103 BV421 (M290), CD117 BUV395 (2B8), CD127 BV421 (SB/199), CD135 
PE-CF594 (A2F10.1), I-A/I-E V500 (M5/114.15.2), Ly6C AlexaFluor 700 (AL-21). The 
following antibodies were from eBioscience: CD11b eFluor 450 (M1/70), CD11c PE (N418), 
CD24 PE-Cy7 (M1/69), CD172a PerCP–eFluor 710 (P84), CD317 APC (eBio927), F4/80 APC-
eFluor 780 (BM8), IRF4 PE (3E4), IRF8 PerCP-eFluor 710 (V3GYWCH), Siglec H PerCP-
Cy5.5 (eBio-440c). The following antibodies were from BioLegend: CD45R Biotin (RA3-6B2), 
CD45.2 PE (104), CD105 Biotin (MJ/718), CD115 BV711 (AFS98), CD127 biotin (A7R34), 
CD226 PE (10E5), F4/80 APC-Cy7 (BM8), F4/80 AlexaFluor700 (BM8), Ly6G Biotin (1A8), 
Ter119 Biotin (TER-119), XCR1 BV421 (ZET). The following antibodies were from Tonbo 
Bioscience: CD45.1 FITC (A20), CD3e Biotin (145-2c11). The following antibodies were from 
Invitrogen: CD11c APC-eFluor780 (N418). Cells were analyzed on a FACSCanto II or 
FACSAria Fusion flow cytometer (BD), and data were analyzed with FlowJo v10 software 
(TreeStar). 
For intracellular IRF8/IRF4 staining, cells were stained for surface markers and then 
fixed/permeabilized with the intracellular fixation and permeabilization buffer kit (eBioscience) 
for 1 hour-overnight at 4⁰C. Cells were then stained for 1 hr at room temperature with 
intracellular antibodies. The cells were then washed and analyzed by flow cytometry. 
 
Bone marrow isolation. 
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Bone marrow (BM) was harvested from the femur, tibia, and pelvis of mice. Bones were 
collected and fragmented by mortar and pestle in MACS buffer, and debris was removed by 
passing cells through a 70-µm strainer. Red blood cells were lysed with ACK lysis buffer and 
cells were subsequently counted on a Vi-CELL analyzer (Beckman Coulter). 3-5x106 were used 
per antibody staining reaction. For BM culture experiments, bulk BM cells were cultured at 37⁰C 
in 4 mL total volume of cIMDM supplemented with 100 ng/mL Flt3L (Peprotech) for nine days 
before further analysis. 
 
Progenitor sorting and culture. 
For sorting experiments, BM was isolated as described above and depleted of CD3-, 
CD19-, CD105-, Ter119-, and Ly6G-expressing cells by staining with the corresponding 
biotinylated antibodies followed by depletion with MagniSort Streptavidin Negative Selection 
Beads (Thermo Fisher). All remaining BM cells were then stained with fluorescent antibodies 
prior to sorting. Gates used to define MDPs, CDPs and pre-cDC1s were a combination of 
previously established markers21 and those identified in this study. MDPs were identified as Lin–
CD117hiCD135+CD115+CD11c–MHCII–. CDPs were identified as Lin–
CD117intCD135+CD115+CD11c–MHCII–. Pre-cDC1s were identified as either Lin–
CD117intCD135+Zbtb46-GFP+ or as Lin–CD117intCD135+CD226+. Pre-cDC2s were identified as 
Lin—CD117loCD135+CD115+. Lineage markers included CD3, CD19, CD105, CD127, NK1.1, 
Ter119, and Ly6G. For retroviral reporter assays and in vitro CRISPR/Cas9 deletion CD117hi 
cells were sorted. A FACSAria Fusion was used for sorting and cells were sorted into cIMDM. 
Sort purity of >95% was confirmed by post-sort analysis before cells were used for further 
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experiments. For culture experiments, DC progenitors were cultured at 37⁰C in 200 µL total 
volume of cIMDM supplemented with 100 ng/mL Flt3L (Peprotech) for five days before further 
analysis. 
 
Retroviral infection and culture 
Retroviruses were produced by transfecting retroviral vectors into Plat-E cells essentially 
as described 26 and collecting viral supernatants 2 days later. For reporter assays, Lin—CD117hi 
BM cells were sorted as described above and transduced with viral supernatants by 'spin 
infection' at 1800 RPM for 1 hour in the presence of 2 ug/mL polybrene. Infected cells were then 
cultured in Flt3L for 8 days before DCs were analyzed by flow cytometry. For in vitro 
CRISPR/Cas9 deletion, Lin— CD117hi BM cells from R26Cas9/+ mice were sorted and the same 
transduction protocol was used. 
The retroviral reporter vector (Thy1.1 pA GFP CMVp_min PmeI MCS RV) was 
generated by replacing the XhoI-EcoRI fragment containing the IRES-GFP from the MSCV 
IRES GFP vector49 with a XhoI-EcoRI fragment containing IRES Thy1.1 from the MSCV-
IRES-Thy1.1 vector50 to produce the Thy1.1 only RV. The SalI-BamHI fragment from hCD4 pA 
GFP RV51 containing GFP-Kb pA was then blunted using Pfu polymerase and inserted into the 
blunted EcoRI site of Thy1.1 only RV to produce a Thy1.1 pA GFP RV vector. Annealed oligos 
containing PmeI sites and NcoI and HindIII overhangs 
(CATGGTGGCATCCACTAGTTCTAGGATCCGTTTAAACA and 
AGCTTGTTTAAACGGATCCTAGAACTAGTGGATGCCAC) were then ligated into the 
NcoI-HindIII digested Thy1.1 pA GFP RV vector to produce the Thy1.1 pA GFP PmeI-MCS 
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RV vector. A PCR product containing the minimal CMV promoter and BamHI/BglII sites was 
then amplified from the GFP min CMVp vector 43 and ligated into the BamHI site of the Thy1.1 
pA GFP PmeI-MCS RV vector to produce the final Thy1.1 pA GFP CMVp_min PmeI MCS RV 
vector. Enhancer regions were cloned into this vector using HindIII and BamHI digests. 
The +32 kb enhancer regions were amplified from genomic DNA using Pfu polymerase. Purified 
PCR products were digested with HindIII and BglII and cloned into the HindIII and BamH1 
digested retroviral reporter vector (Thy1.1 pA GFP CMVp RV). The following primers were 
used for amplification. For the +32 kb WT region: GCAAGCTTTGAGGTAGAGGGCCCA and 
ACGAGATCTGAGGAACACCAGGTCCCA. For the +32 kb 5' region: 
GCAAGCTTTGAGGTAGAGGGCCCA and 
GAGCTAAGATCTCCTCAATGTCCAAGTTCACC. For the +32 kb 3' region: 
TATCGATAAGCTTACGCCAGCAACTTCCTGAATC and 
ACGAGATCTGAGGAACACCAGGTCCCA. 
A fragment of the Irf8 +32 kb enhancer containing the first three AICEs, either WT or 
mutated versions, were cloned into this same vector using annealed oligos with HindIII and BglII 
overhangs. The following primers were used. For the 3X AICE1 WT: 
AGCTTtctcttcttgtttctatttcaggttctccttctgaatttcagtttggctcaagttcctgcA and 
GATCTgcaggaacttgagccaaactgaaattcagaaggagaacctgaaatagaaacaagaagagaA. For 3X AICE1 
Mut: AGCTTtctcttcttgtttctatcaaaggttcaacttctgaatcaaagtttggctcaagttcctgcA and 
GATCTgcaggaacttgagccaaactttgattcagaagttgaacctttgatagaaacaagaagagaA. 
For in vitro CRISR/Cas9 deletion a Thy1.1-hU6-gRNA-BbsI stuffer RV vector was used 
(Thiesen et al, 2018). The following primers containing the sgRNA sequence and BbsI 
overhangs were annealed and cloned into the BbsI digested vector. For the αIrf8 sgRNA: 
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CACCGagtttaccgaattgtccccg and AAACcggggacaattcggtaaactC. For the αIrf8 +32 kb sgRNA: 
CACCGgagccaaactgaaattcaga and AAACtctgaatttcagtttggctcC. For the scramble sgRNA: 
CACCggcactaccagagctaactca and AAACtgagttagctctggtagtgcC. 
 
Tumor implantation 
The 1969 regressor fibrosarcoma has been previously described31. Tumor cells were 
thawed and propagated in R10 medium (RPMI + 10% FBS + 0.1% 2-ME). On the day of 
injection, cells were harvested by incubation in 0.05% trypsin-EDTA, washed three times with 
endotoxin-free PBS, and then 1x106 cells were injected subcutaneously in a total volume of 0.15 
mL of PBS into the shaved flanks of mice. Tumor size was measured every three days beginning 
on day 4 and is presented as the surface area of the tumor (length X width). 
 
IL-12 administration. 
Mice were injected intraperitoneally with either saline (vehicle) or 500 µg of recombinant 
IL-12 (Pfizer) on two consecutive days and then analyzed three days after the second injection. 
 
Bone marrow chimeras. 
Bone marrow cells from donor mice were collected as described above. Recipient 
CD45.1+ mice received a single dose of 950 rads of whole-body irradiation and then received a 
transplant of 10x106 total BM cells the next day. For mixed BM chimeras, donor marrow from 
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mice of each genotype was mixed at a ratio of 1:1 before transplantation. Mice were analyzed 
three to four weeks after transplantation for dendritic cell reconstitution. 
 
Salmonella typhimurium infection. 
Salmonella enterica Typhimurium wildtype strain SB300A1 52 was used for infection. 
Bacteria were grown with shaking overnight at 37°C in Luria-Bertain (LB) broth, subcultured for 
4 hours, and washed with with cold PBS prior to use. Intra-peritoneal infection was performed 
with an inoculum of 5x102 CFU bacteria. 
 
Expression microarray analysis 
Progenitor cells or their progeny from in vitro culture were sorted as described above. 
RNA from sorted populations was extracted with a NucleoSpin RNA XS Kit (Machery-Nagel), 
then was amplified with WT Pico System (Affymetrix) and hybridized to GeneChip Mouse Gene 
1.0 ST microarrays (Affymetrix) for 18 h at 45 °C in a GeneChip Hybridization Oven 640. The 
data was analyzed with the Affymetrix GeneChip Command Console. Microarray expression 
data was processed using Command Console (Affymetrix, Inc) and the raw (.CEL) files 
generated were analyzed using Expression Console software with Affymetrix default RMA Gene 
analysis settings.(Affymetrix, Inc).  Probe summarization (Robust Multichip Analysis, RMA), 
quality control analysis, and probe annotation were performed according to recommended 
guidelines (Expression Console Software, Affymetrix, Inc.). Data were normalized by robust 
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ChIP-seq of mature DCs was described previously21.  ChIP-seq of DC progenitors was 
performed similarly, with minor modifications. MDPs, CDPs, and pre-cDC1s were isolated from 
the BM of WT mice as described above and crosslinked prior to sorting. For crosslinking, cells 
were incubated for 8 min at room temperature with 1% formaldehyde. Reactions were then 
quenched with 1.25 M glycine, cells were washed twice with PBS, and pellets were “flash 
frozen” for storage at -80°C. Chromatin was sonicated at 4°C in sonication buffer (10 mM Tris-
HCl, pH 8.0; 100 nM NaCl; 1 mM EDTA, 0.5 mM EGTA; 0.1% sodium deoxycholate; and 
0.5% N-lauroylsarcosine) for 24 cycles of 20 s on and 50 s off per cycle with a Vivra-Cell 
VCX130PB and CV188 (Sonics & Material) to obtain DNA fragments from 140 bp to 500 bp. 
Chromatin was then immunoprecipitated overnight at 4°C with Dynabeads Protein A that had 
been pre-incubated with 2.5 µg of the appropriate antibody: anti-H3K27ac (Ab 4729; Abcam) or 
H3K4me1 (Ab 8895; Abcam). Beads containing protein-DNA complexes were washed seven 
times with RIPA buffer (50 mM HEPES, pH 7.5; 500 mM LiCl; 1 mM EDTA; 1% NP-40; and 
0.7% sodium deoxycholage). DNA fragments were eluted, and crosslinking was reversed by 
incubation in a solution containing 50 mM Tris-HCl, pH 8.0; 10 mM EDTA; 1% SDS; and 1 
mg/mL of proteinase K (New England Biolabs) for 5 hours at 65°C. DNA was purified by 
phenol-chloroform extraction followed by ethanol precipitation. Libraries for ChIP-Seq were 
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prepared with a ThruPLEX-FD kit (Rubicon Genomics) and were sequenced with an Illumina 
HiSeq 2500. 
ChIP-seq of B cells was described previously42. Briefly, in vitro LPS stimulated B cells 
were subjected to crosslinking at room temperature for either 10 min with 1% formaldehyde 
(single crosslinking) or for 45 min with 2 mM disuccinimidyl glutarate (Sigma) followed by 10 
min with 1% formaldehyde (double crosslinking). The chromatin was prepared as previously 
described53. The pelleted genomic DNA, crosslinked with proteins, were sheared with a 
Bioruptor® sonicator (Diagenode) followed by immunoprecipitation using an anti-E2A 
antibody. The precipitated DNA (1-2 ng) was used for library preparation and sequencing. 
 
ATAC-Seq 
ATAC-seq of DC progenitors was performed using the Omni-ATAC protocol as 
previously described with minor modifications 34. 10,000 MDPs, CDPs, and pre-cDC1s were 
sorted from bone marrow as described above and lysed in ice-cold ATAC-RSB buffer containing 
0.1% NP40, 0.1% Tween-20, and 0.01% digitonin. Cells were incubated at 4° C for 3 min, then 
washed with ATAC-RSB buffer containing only 0.1% Tween-20. Nuclei were spun down by 
centrifugation and then incubated in 50 µL of transposition buffer (25 µL 2X TD buffer, 22.5 µL 
dH2O, 2.5 µL Tn5 transposase (Nextera DNA Library Prep Kit, Illumina)) and incubated at 37° 
C for 30 min. If 10,000 cells could not be obtained for a certain population then the quantity of 
Tn5 transposase was titrated down proportionately to the number of cells obtained but cells were 
still incubated in 50 µL total. Transposed DNA was purified with a DNA Clean & Concentrator 
kit (Zymo Research), eluted in 21 µL of elution buffer, and stored at -20° C until amplification. 
Three biological replicates for each cell population were obtained and sequenced. ATAC-seq 
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libraries were prepared as previously described, barcoded and sequenced on an Illumina Nextseq 
500. 
ATAC-seq of cDC1s, pDCs, monocytes, peritoneal macrophages, neutrophils, and 
follicular B cells was obtained from the Immunological Genome Project Open Chromatin 
Regions54. 
ATAC-seq of LPS activated B cells was described previously 42. 
 
Computational analysis 
For computational analysis of ATAC-seq of DC progenitors, adapter sequences were 
trimmed using SeqPurge and aligned to mm10 genome using bowtie2. These reads were then 
filtered for mitochondrial reads, low mapping quality (samtools flag “-F 1804 -f 2 -q 20”), and 
PCR duplicates using Picard tools MarkDuplicates. The bam was then converted to a bed and the 
Tn5 corrected insertion sites were obtained (“+” stranded + 4 bp, “-” stranded -5 bp)33. To 
identify peaks, we called peaks for each sample using MACS2 “--shift -75 --extsize 150 --
nomodel --call-summits --nolambda --keep-dup all -q 0.01” using the insertion beds. To get a 
union peak set, the peak summits were then extended by 250 bp on either side to a final width of 
501 bp, filtered by the ENCODE mm10 blacklist 
(https://www.encodeproject.org/annotations/ENCSR636HFF/), and filtered to remove peaks that 
extend beyond the ends of chromosomes. Overlapping peaks were handled using an iterative 
removal procedure as previously described55. First, the most significant peak (defined by 
MACS2 score) is kept and any peak that directly overlaps with that significant peak is removed. 
Then, this process iterates to the next most significant peak and so on until all peaks have either 
been kept or removed due to direct overlap with a more significant peak. This resulted in a union 
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peak set of 188,509 equal width peaks. These peaks were then annotated using ChIPseeker and 
computed the occurrence of a TF motif using motifmatchr in R with chromVARMotifs 
mouse_pwms_v1 set 56. All insertions that fell within each peak were then counted using 
“countOverlaps” in R to get a counts matrix (peak x samples). To determined differential peaks, 
the raw counts matrix was used as input into DESeq2 using the modelMatrixType = "expanded" 
and were tested for whether or not a peak was greater than a Log2FoldChange of 0.5 
(lfcThreshold = 0.5, altHypothesis="greaterAbs") 57. A cutoff of an FDR < 0.1 was used to 
denote a differential peak. For clustering analyses, the counts matrix was then normalized by 
using edgeR’s “cpm(matrix , log = TRUE, prior.count = 5)” followed by a quantile 
normalization using preprocessCore’s “normalize.quantiles” in R. TF motif enrichment were 
calculated using a hypergeometric test in R testing the representation of a motif (from 
motifmatchr above) in a subset of peaks vs all peaks. To compute TF motif deviations, 
chromVAR was used in R with raw counts in distal peaks (defined as greater than 1kb from a 
TSS in TxDb.Mmusculus.UCSC.mm10.knownGene) and then the top 100 variable TF motifs 
were determined using variability scores 56.  To create sequencing tracks, the Tn5 corrected 
insertion sites were read into R and a coverage pileup was created that was binned every 100bp 
using rtracklayer and normalized by reads in peak such that they were all scaled to 30M total 
reads in peaks (from counts matrix). 
Computational analysis of ATAC-seq of LPS activated B cells was described 
previously42. ChIP-seq data sets were aligned to the mouse genome (GRCm38/mm10 assembly) 
by Bowtie software (version 1.1.1) with the following parameters: --sam -p 4 -t --verbose --trim5 
3 -m 1 mm10 --chunkmbs 1000. Data were visualized with the ‘makeUCSCfile’ program of the 
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Homer software package with default parameters. Peaks were identified with MACS software, 
version 1.4.2 (‘model based analysis for ChIP-Seq’) with a P value of 1x10-9. 
Motifs in the Irf8 +32 kb and +41 kb peaks were identified using the FIMO motif-
identification program at a P-value threshold of 1x10-3.  
 
Statistical analysis. 
Statistical analyses were performed with Prism (GraphPad Software). Results from 
independent experiments were pooled as indicated in figure legends. When comparing only two 
groups, unpaired two-tailed Student's t-test was used. When comparing more than two groups, 




The sequencing and microarray data generated during the course of this study have been 
deposited and are available on the GEO database. The ChIP-seq data of DC progenitors utilized 
in Fig. 3.7 can be accessed with the following accession number: GSE132239. The ATAC-seq 
data of DC progenitors utilized in Figs. 3.10 and 3.11 can be accessed with the following 
accession number: GSE132240. The microarrays utilized in Fig. 3.6 can be accessed with the 
following accession numbers: GSE123747, GSE132767, and GSE132768. 
All other primary data and materials that support the findings of this study are available 
from the corresponding author upon request. 
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Figure 3.1. The +32 kb Irf8 enhancer is required for cDC1 development. 
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(A) Normalized sequencing tracks of ChIP-seq with anti-p300, anti-BATF3, or anti-IRF8 
antibodies or of ATAC-seq in the indicated populations. Boxed is the +32 kb Irf8 enhancer. 
Shown below is the +32 kb Irf8 enhancer with the AICE motifs and sgRNA target sequences 
depicted. Data are pooled from two independent experiments and the Immunological Genome 
Project Open Chromatin Regions (n = 1 biological replicate per population). 
(B) Flow cytometry of live splenocytes from mice of the indicated genotypes was used to 
identify dendritic cell (DC) subsets. Numbers indicate the percent of cells in the indicated gates. 
Data are representative of four independent experiments with similar results (n = 5 mice for WT, 
n = 5 mice for Irf8 +32–/–, n = 3 mice for Batf3–/–, and n = 3 mice for Irf8–/–). 
(C) Intracellular staining for IRF8 in splenic pDCs of mice of the indicated genotypes. Numbers 
indicate the mean fluorescence intensity (MFI) of IRF8 protein levels in pDCs.  Data are 
representative of four independent experiments with similar results (n = 5 mice for WT, n = 5 
mice for Irf8 +32–/–, n = 3 mice for Batf3–/–, and n = 3 mice for Irf8–/–). 
(D) Statistical analysis of the frequency of splenic cDC1s and pDCs in mice of the indicated 
genotypes. Small horizontal lines indicate the mean. Data are pooled from four independent 
experiments (n = 5 mice for WT, n = 5 mice for Irf8 +32–/–, n = 3 mice for Batf3–/–, and n = 3 
mice for Irf8–/–). 
(E) Growth of 1969 regressor fibrosarcomas in WT and Irf8 +32 kb–/– mice. Data are pooled 
from two independent experiments (n = 8 mice for WT, n = 8 mice for Irf8 +32–/–). 




Figure 3.2. AICEs in the +32 kb Irf8 enhancer drive cDC1 development. 
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(A) Shown are the sequences, either wild type (3x AICE1 WT) or mutated (3x AICE1 Mut), of 
the first 3 AICEs from the +32 kb Irf8 enhancer used in retroviral reporter assays in (B). 
(B) The regions from (A) were placed in a reverse strand retroviral reporter and GFP activity was 
measured in either cDC1s or cDC2s as previously described21.  Gray histograms represent the 
activity of the empty reporter. Data are representative of three independent experiments with 
similar results (n = 3 biological replicates per group). 
(C) The full 574 bp +32 kb Irf8 enhancer (+32kb WT), or the 5’ half containing 4 AICE sites 
(+32 kb 5’) or the 3’ half containing no AICEs (+32 kb 3’), were assayed for activity in cDC1s 
using retroviral reporters as in (B). Numbers indicate the mean fluorescence intensity (MFI) of 
GFP in cDC1s. Data are representative of three independent experiments with similar results (n = 
3 biological replicates per group). 
(D) CD117hi BM cells from R26Cas9/+ mice were infected with a retroviral vector expressing a 
control scramble sgRNA (scramble), an sgRNA targeting the Irf8 coding sequence (aIrf8), or an 
sgRNA targeting the AICE site 4 shown in (A) (aIrf8 +32kb), and then cultured in Flt3L for 8 
days. Flow cytometry was then used to assess cDC1 development.  Cells are pre-gated as 
Thy1.1+, to identify infected cells, and as B220—MHC-II+CD11c+, to identify DCs. Numbers 
indicate the percent of cells in the indicated gates. Data are representative of three independent 
experiments (n = 3 biological replicates per group). 
(E) Shown is the nucleotide sequence of the +32 kb Irf8 enhancer region. The extent of deletion 
in the two mouse strains are indicated by colored fonts.  Pink nucleotides were deleted only in 
Irf8 +32 5’—/— mice, blue nucleotides were deleted in both Irf8 +32 5’—/— mice and Irf8 +32—/— 
mice, and red nucleotides were deleted only in Irf8 +32—/— mice. Red lines indicate the 
sequences of the sgRNAs used for CRISPR/Cas9 induced deletion in mice.  Green boxes 
indicate the AICE motifs. 
(F) PCR of the +32 kb locus in wildtype (WT), Irf8 +32 5’—/—, and Irf8 +32—/— mice 
demonstrating the deletions produced by CRISPR/Cas9 genome editing. Numbers indicate the 
size of the PCR product from each strain. Data are representative of two independent 
experiments with similar results (n = 2 biological replicates per population). 
(G,H) Flow cytometry of live splenocytes from mice of the indicated genotypes was used to 
identify dendritic cell (DC) subsets. Numbers indicate the percent of cells in the indicated gates 
(G). Statistical analysis of the frequency and absolute number of splenic cDC1s in mice of the 
indicated genotypes (H). Small horizontal lines indicate the mean. Data are pooled from three 
independent experiments (n = 6 mice for WT, n = 5 mice for Irf8 +32 5'–/–, and n = 5 mice for 
Irf8 +32–/–). 




Figure 3.3.  Loss of the +32 kb Irf8 enhancer does not impact non-cDC1 immune lineages. 
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(A,B) Flow cytometry of live splenocytes from mice of the indicated genotypes was used to 
examine myeloid and lymphoid cells. Numbers indicate the percent of cells in the indicated gates 
(A). Statistical analysis of the frequency of the indicated populations within spleens of mice of 
the indicated genotypes (B). Small horizontal lines indicate the mean. Data are pooled from four 
independent experiments (n = 5 mice for WT, n = 5 mice for Irf8 +32–/–, and n = 3 mice for Irf8–
/–). 
(C) Intracellular staining for IRF8 in the indicated populations in mice of the indicated 
genotypes. Data are representative of four independent experiments with similar results (n = 5 
mice for WT, n = 5 mice for Irf8 +32–/–, and n = 3 mice for Irf8–/–). 






Figure 3.4. The +32 kb Irf8 enhancer is required for compensatory cDC1 development but 
not for cDC1 specification. 
(A,B) Flow cytometry of SLNs from mice of the indicated genotypes was used to identify DC 
subsets. Numbers indicate the percent of cells in the indicated gates (A). Statistical analysis of 
the frequency of cDC1s in SLNs (B). Small horizontal lines indicate the mean. Data are pooled 
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from four independent experiments (n = 5 mice for WT, n = 5 mice for Irf8 +32–/–, n = 3 mice for 
Batf3–/–, and n = 3 mice for Irf8–/–). 
(C,D) Flow cytometry of live splenocytes from mice of the indicated genotypes after 
administration of vehicle or IL-12 was used to identify DC subsets. Numbers indicate the percent 
of cells in the indicated gates (C). Statistical analysis of the absolute number of cDC1s and 
cDC2s in mice of the indicated genotypes treated with either vehicle or IL-12 (D). Small 
horizontal lines indicate the mean. Data are pooled from two independent experiments (n = 4 
mice per group for WT, n = 4 mice per group for Irf8 +32–/–, n = 4 mice per group for Batf3–/–). 
(E) Flow cytometry of Lin—CD135+ bone marrow cells from mice of the indicated genotypes 
was used to identify pre-cDC1s. Numbers indicate the percent of cells in the indicated gates. 
Data are representative of three independent experiments with similar results (n = 3 mice for 
WT, n = 3 mice for Irf8 +32–/–, and n = 3 mice for Irf8–/–). 
(F) Intracellular staining for IRF8 within pre-cDC1s from mice of the indicated genotypes. 
Numbers indicate the MFI of IRF8 protein levels in the pre-cDC1. Black shaded histograms 
depict IRF8 protein levels from Irf8—/— mice. Data are representative of three independent 
experiments with similar results (n = 3 mice for WT, n = 3 mice for Irf8 +32–/–, and n = 3 mice 
for Irf8–/–). 
(G) CDPs (Lin—CD117intCD135+CD115+), pre-cDC1s (Lin—CD117intCD135+CD226+), or pre-
cDC2s (Lin—CD117loCD135+CD115+) from mice of the indicated genotypes were sorted and 
cultured for 5 days with Flt3L. Cells were then stained to identify DC subsets. Cells are pregated 
as CD11c+MHCII+ cells to identify DCs. Data are representative of three independent 
experiments with similar results (n = 3 mice for WT and n = 3 mice for Irf8 +32–/–). 
ns, not significant (P>0.05); *P<0.05, **P<0.01 and ****P<0.0001 (Ordinary one-way ANOVA 






Figure 3.5. The +32 kb Irf8 enhancer is required for all compensatory cDC1 development. 
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(A,B) Flow cytometry of lung cells from mice of the indicated genotypes was used to identify 
DC subsets. Numbers indicate the percent of cells in the indicated gates (A). Statistical analysis 
of the frequency of cDC1s among CD45+ cells from the lungs of mice of the indicated genotypes 
(B). Small horizontal lines indicate the mean. Data are pooled from four independent 
experiments (n = 5 mice for WT, n = 5 mice for Irf8 +32–/–, n = 3 mice for Batf3–/–, and n = 3 
mice for Irf8–/–). 
(C,D) BM cells from the mice of the indicated genotypes was transferred into irradiated WT 
mice and allowed to reconstitute for three weeks. Flow cytometry of live splenocytes from these 
chimeras was then used to identify DC subsets. Numbers indicate the percent of cells in the 
indicated gates (C). Statistical analysis of the frequency of splenic cDC1s in the indicated 
chimeras (D). Small horizontal lines indicate the mean. Data are pooled from two independent 
experiments (n = 3 for WT into WT chimeras, n = 5 for Irf8 +32–/– into WT chimeras, n = 5 for 
Batf3–/– into WT chimeras). 
(E) Statistical analysis of the frequency of pre-cDC1s in mice of the indicated genotypes. Small 
horizontal lines indicate the mean. Data are pooled from three independent experiments (n = 3 
mice for WT and n = 3 mice for Irf8 +32–/–). 
ns, not significant (P>0.05); **P<0.01 (Ordinary one-way ANOVA (B,D)) or unpaired two-




Figure 3.6. CD226 uniquely identifies pre-cDC1s in the bone marrow. 
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(A) Cd226 gene expression levels in CDPs and pre-cDC1s quantified by gene expression 
microarrays. Small horizontal lines indicate the mean. Data are pooled from three independent 
experiments (n = 3 biological replicates per population). 
(B) Flow cytometry of Lin— BM cells from WT mice was used to examine marker expression in 
pre-cDC1s. Data are representative of four independent experiments with similar results (n = 4 
mice). 
(C,D) CDPs (Lin—CD117intCD135+CD115+) and Zbtb46-GFP+ pre-cDC1s (Lin—
CD117intCD135+Zbtb46-GFP+) (C), or CDPs and CD226+ pre-cDC1s (Lin—
CD117intCD135+CD226+) (D) were sorted from mice and cultured for 5 days in Flt3L. Cells 
were then analyzed by flow cytometry to identify dendritic cell subsets. Data are representative 
of three independent experiments with similar results (n = 3 biological replicates per population). 
(E) Microarray analysis of cDC2s derived from in vitro culture of pre-cDC1s from Irf8 +32–/– 
mice compared to cDC1s derived from in vitro culture of WT pre-cDC1s (left) or compared to 
cDC2s derived from in vitro culture of WT pre-cDC2s (right), presented as M-plots. Green lines 
indicate the threshold for a two-fold difference in expression between samples. Data was pooled 
from two independent experiments (n = 2 biological replicates per population). 
(F) Microarray analysis of WT CD24+CD172a+ cDC2s compared to WT CD24–CD172+ cDC2s 
(left) or compared to WT CD24+CD172a– cDC1s (right), presented as M-plots. Green lines 
indicate the threshold for a two-fold difference in expression between samples. Data was pooled 
from two independent experiments (n = 2 biological replicates per population). 
(G) Irf4 expression levels in the indicated populations quantified by gene expression 
microarrays. Small horizontal lines indicate the mean. Data was pooled from two independent 
experiments (n = 2 biological replicates per population). 
(H) Microarray analysis of cDC2s derived from in vitro culture of Batf3–/– pre-cDC1s compared 
to cDC1s derived from in vitro culture of WT pre-cDC1s (left) or compared to cDC2s derived 
from in vitro culture of WT pre-cDC2s (right), presented as M-plots. Green lines indicate the 
threshold for a two-fold difference in expression between samples. Data was pooled from two 




Figure 3.7. The -50 kb Irf8 enhancer is not required for dendritic cell development. 
(A) Normalized sequencing tracks of ChIP-seq with anti-p300 or anti-H3K27Ac antibodies or of 
ATAC-seq in the indicated populations. Boxed is the -50 kb Irf8 enhancer. Shown below is the -
50 kb Irf8 enhancer with the PU.1 motifs and sgRNA target sequences indicated. Data are pooled 
from three independent experiments and the Immunological Genome Project Open Chromatin 
Regions (n = 1 biological replicate per population). 
(B) Flow cytometry of live splenocytes from mice of the indicated genotypes was used to 
identify DC subsets. Numbers indicate the percent of cells in the indicated gates. Data are 
representative of four independent experiments with similar results (n = 5 mice for WT, n = 5 
mice for Irf8 -50–/–, and n = 4 mice for Irf8–/–). 
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(C) Intracellular staining for IRF8 in splenic cDC1s and pDCs from mice of the indicated 
genotypes. Numbers indicate the MFI of IRF8 protein levels in cDC1s or pDCs as indicated. 
Data are representative of four independent experiments with similar results (n = 5 mice for WT, 
n = 5 mice for Irf8 -50–/–, and n = 4 mice for Irf8–/–). 
(D) Flow cytometry of Lin—CD135+ bone marrow cells from mice of the indicated genotypes 
was used to identify DC progenitors. Numbers indicate the percent of cells in the indicated gates. 
Data are representative of three independent experiments with similar results (n = 3 mice for 
WT, n = 3 mice for Irf8 -50–/–, and n = 3 mice for Irf8–/–). 
(E) Intracellular staining for IRF8 within MDPs, CDPs, and pre-cDC1s from mice of the 
indicated genotypes. Numbers indicate the MFI of IRF8 protein levels in the indicated 
populations. Black shaded histograms depict IRF8 levels from Irf8—/— mice. Data are 
representative of three independent experiments with similar results (n = 3 mice for WT, n = 3 










(A) PCR of the -50 kb locus in WT and Irf8 -50—/— mice demonstrating the deletion produced by 
CRISPR/Cas9 genome editing. Numbers indicate the size of the PCR product from each strain. 
Data are representative of two independent experiments with similar results (n = 2 biological 
replicates per population). 
(B) Shown is the nucleotide sequence of the -50 kb Irf8 enhancer region. The extent of deletion 
in Irf8 -50—/— mice is indicated by colored font. Red nucleotides were deleted in Irf8 -50—/— 
mice. Red lines indicate the sequences of the sgRNAs used for CRISPR/Cas9 induced deletion in 
mice.  Purple boxes indicate the PU.1 motifs. 
(C) Statistical analysis of the frequency of the indicated populations gated as in Fig. 3.3A in 
spleens of mice of the indicated genotypes. Small horizontal lines indicate the mean. Data are 
pooled from four independent experiments. (n = 5 mice for WT, n = 5 mice for Irf8 -50–/–, and n 
= 4 mice for Irf8–/–). 
(D) Intracellular staining for IRF8 in the indicated populations in mice of the indicated 
genotypes. Data are representative of four independent experiments with similar results (n = 5 
mice for WT, n = 5 mice for Irf8 -50–/–, and n = 4 mice for Irf8–/–). 







Figure 3.9. The -50 kb Irf8 enhancer controls IRF8 expression in monocytes and 
macrophages. 
(A) Normalized sequencing tracks of ATAC-seq in the indicated populations. Boxed is the -50 
kb Irf8 enhancer. Data are from the Immunological Genome Project Open Chromatin Regions (n 
= 1 biological replicate per population). 
(B) Flow cytometry of live splenocytes from mice of the indicated genotypes was used to 
identify monocytes. Numbers indicate the percent of cells in the indicated gates. Data are 
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representative of four independent experiments with similar results (n = 5 mice for WT, n = 5 
mice for Irf8 -50–/–, and n = 4 mice for Irf8–/–). 
(C) Intracellular staining for IRF8 in splenic monocytes of mice of the indicated genotypes. 
Numbers indicate the MFI of IRF8 protein levels in monocytes. Data are representative of four 
independent experiments with similar results (n = 5 mice for WT, n = 5 mice for Irf8 -50–/–, and 
n = 4 mice for Irf8–/–). 
(D) Statistical analysis of the percent of splenic monocytes in mice of the indicated genotypes. 
Data are pooled from four independent experiments (n = 5 mice for WT, n = 5 mice for Irf8 -50–
/–, and n = 4 mice for Irf8–/–). 
(E) Flow cytometry of peritoneal lavage cells from mice of the indicated genotypes was used to 
identify peritoneal macrophages. Numbers indicate the percent of cells in the indicated gates. 
Data are representative of four independent experiments with similar results (n = 5 mice for WT, 
n = 5 mice for Irf8 -50–/–, and n = 3 mice for Irf8–/–). 
(F) Intracellular staining for IRF8 in F4/80+ peritoneal macrophages of mice of the indicated 
genotypes. Numbers indicate the MFI of IRF8 protein levels in peritoneal macrophages. Data are 
representative of four independent experiments with similar results (n = 5 mice for WT, n = 5 
mice for Irf8 -50–/–, and n = 3 mice for Irf8–/–). 
(G) WT and Irf8 -50—/— mice were infected with Salmonella typhi and survival was monitored.  
Data are pooled from two independent experiments (n = 10 mice for WT and n = 10 mice for Irf8 
-50–/–). 
ns, not significant (P>0.05); ****P<0.0001 (Ordinary one-way ANOVA (D) or Log-rank 










(A) Pearson correlation of all distal ATAC-seq peaks for the indicated populations. Data are 
pooled from three independent experiments (n = 3 biological replicates per population).  
(B) Differential ATAC-seq peaks in the indicated populations. Colors indicate orders of 
significance derived from DESeq2 analysis, with grey (fdr>0.1), yellow (0.1>fdr>0.01) , orange 
(0.01>fdr>0.001), and red (fdr<0.001) . Data are pooled from three independent experiments (n 
= 3 biological replicates per population). 
(C) Heat map of k-means clusters for the top 25,000 varying distal ATAC-seq peaks. Colors 
indicate z-scores of reads in each peak compared with mean reads across all populations. Genes 
nearest to the clustered peaks and transcription factor motifs (TFs) enriched within peaks are 
indicated. Data are pooled from three independent experiments (n = 3 biological replicates per 
population). 
(D) Heat map of k-means clusters of TF deviation z-scores for ATAC-seq profiles of the 
indicated populations. Data are pooled from three independent experiments (n = 3 biological 
replicates per population).   
(E) Normalized sequencing tracks of ATAC-seq in the indicated populations are shown for genes 
in each k-means cluster. Mpo was present in k-cluster 1, Runx1 was present in k-cluster 3, Wdfy4 
was present in k-cluster 4, and Irf8 was present in k-clusters 4 and 5. Data are representative of 





Figure 3.11. The +41 kb Irf8 enhancer is required for cDC1 specification and development.  
(A) Normalized sequencing tracks of ChIP-seq with anti-p300 antibody or of ATAC-seq in the 
indicated populations.  Boxed is the +41 kb Irf8 enhancer. Shown below is the +41 kb Irf8 
169 
 
enhancer with the E box motifs and sgRNA target sequences indicated. ATAC-seq data are 
representative of three independent experiments with similar results (n = 3 biological replicates 
for MDP ATAC, CDP ATAC, and pre-cDC1 ATAC) and ChIP-seq data are pooled from two 
independent experiments and the Immunological Genome Project Open Chromatin Regions (n = 
1 biological replicate for cDC1 p300 IP, pDC p300 IP, cDC1 ATAC, and pDC ATAC).  
(B) Flow cytometry of live splenocytes from mice of the indicated genotypes was used to 
identify DC subsets. Numbers indicate the percent of cells in the indicated gates. Data are 
representative of five independent experiments with similar results (n = 6 mice for WT, n = 7 
mice for Irf8 +41–/–, and n = 4 mice for Irf8–/–). 
(C) Intracellular staining for IRF8 and IRF4 in splenic pDCs of mice of the indicated genotypes. 
Numbers indicate the MFI of IRF8 or IRF4 protein levels in pDCs.  Data are representative of 
four independent experiments with similar results (n = 5 mice for WT, n = 5 mice for Irf8 +41–/–, 
and n = 3 mice for Irf8–/–). 
(D) Statistical analysis of the frequency of cDC1s and pDCs in spleens of mice of the indicated 
genotypes. Small horizontal lines indicate the mean. Data are pooled from five independent 
experiments (n = 6 mice for WT, n = 7 mice for Irf8 +41–/–, and n = 4 mice for Irf8–/–). 
(E) Flow cytometry of Lin—CD135+ BM from mice of the indicated genotypes was used to 
identify MDPs and CDPs. Numbers indicate the percent of cells in the indicated gates. Data are 
representative of three independent experiments with similar results (n = 3 mice for WT, n = 3 
mice for Irf8 +41–/–, and n = 3 mice for Irf8–/–). 
(F) Intracellular staining for IRF8 within MDPs and CDPs from mice of the indicated genotypes. 
Red lines indicate the IRF8 protein level in MDPs and blue lines indicate the IRF8 protein level 
in CDPs. Numbers in red indicate the MFI of IRF8 protein levels in the MDP and numbers in 
blue indicate the MFI of IRF8 protein levels in the CDP. Data are representative of three 
independent experiments with similar results (n = 3 mice for WT, n = 3 mice for Irf8 +41–/–, and 
n = 3 mice for Irf8–/–). 
(G) Flow cytometry of Lin—CD135+ BM from mice of the indicated genotypes was used to 
identify pre-cDC1s. Numbers indicate the percent of cells in the indicated gates. Data are 
representative of three independent experiments with similar results (n = 3 mice for WT, n = 3 
mice for Irf8 +41–/–, and n = 3 mice for Irf8–/–). 






Figure 3.12. Loss of the +41 kb Irf8 enhancer does not impact non-DC immune lineages. 
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(A) PCR of the +41 kb locus in WT and Irf8 +41—/— mice demonstrating the deletion produced 
by CRISPR/Cas9 genome editing. Numbers indicate the size of the PCR product from each 
strain. Data are representative of two independent experiments with similar results (n = 2 
biological replicates per population). 
(B) Shown is the nucleotide sequence of the +41 kb Irf8 enhancer region. The extent of deletion 
in Irf8 +41—/— mice is indicated by colored font. Red nucleotides were deleted in Irf8 +41—/— 
mice. Red lines indicate the sequences of the sgRNAs used for CRISPR/Cas9 induced deletion in 
mice. Blue boxes indicate the E box motifs. 
(C) Statistical analysis of the frequency of the indicated populations gated as in Fig. 3.3A in 
spleens of mice of the indicated genotypes. Small horizontal lines indicate the mean. Data are 
pooled from five independent experiments (n = 7 mice for WT, n = 7 mice for Irf8 +41–/–, and n 
= 4 mice for Irf8–/–). 
(D) Intracellular staining for IRF8 in the indicated populations in mice of the indicated 
genotypes. Data are representative of four independent experiments with similar results (n = 5 
mice for WT, n = 5 mice for Irf8 +41–/–, and n = 3 mice for Irf8–/–). 






Figure 3.13. E proteins are required for cDC1 development  
(A) Normalized sequencing tracks of ChIP-seq with anti-E2A antibody or of ATAC-seq in 
lymph node B cells activated by LPS for the indicated number of days. Boxed are the +32 kb and 
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+41 kb Irf8 enhancers. Populations analyzed were activated B cells (CD22+CD138—; Act B), 
pre-plasmablasts (CD22—CD138—; pre-PB), and plasmablasts (CD22—CD138+; PB) from either 
WT or Tcf3—/—Tcf4—/— (E2A E2-2 DKO) mice.  B cells were either single (s)- or double (d)- 
crosslinked followed by ChIP with an E2A antibody as indicated. Data are pooled from two 
independent experiments (n = 1 biological replicate per population and per condition). 
(B) Flow cytometry of Lin—CD135+ BM cells or live splenocytes from mice of the indicated 
genotypes was used to determine intracellular E2A-GFP levels in the indicated populations. 
Numbers indicate the MFI of E2A-GFP levels. Data are representative of four independent 
experiments with similar results (n = 3 mice for Tcf3fl/+ and n = 6 mice for Tcf3fl/+VavCretg). 
(C,D) BM cells from WT or Tcf3—/— mice were cultured for 9 days in Flt3L. Cells were then 
analyzed by flow cytometry to identify DC subsets. Numbers indicate the percent of cells in the 
indicated gates (C). Statistical analysis of the frequency of cDC1s and pDCs from cultures is 
shown (D). Small horizontal lines indicate the mean. Data are pooled from three independent 
experiments (n = 3 mice for WT and n = 3 mice for Tcf3–/–). 






Figure 3.14. Tcf3–/– BM progenitors have reduced cDC1 and pDC potential  
(A) Flow cytometry of BM cells from mice of the indicated genotypes was used to determine 
intracellular E2A-GFP levels in the indicated populations. CMPs were gated as Lin–CD117hiSca-
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1–CD16/32+CD34+, CLPs were gated as Lin–CD127+CD135+CD117loB220–CD11c–, and pre-B 
cells were gated as Lin–CD19+CD25+. Numbers indicate the MFI of E2A-GFP levels. Data are 
representative of two independent experiments with similar results (n = 3 mice for Tcf3fl/+ and n 
= 3 mice for Tcf3fl/+VavCretg). 
(B,C) Flow cytometry of live splenocytes from mice of the indicated genotypes was used to 
identify dendritic cell subsets. Numbers indicate the percent of cells in the indicated gates (B). 
Statistical analysis of the frequency of splenic cDC1s and pDCs in mice of the indicated 
genotypes (C). Small horizontal lines indicate the mean. Data are pooled from three independent 
experiments. (n = 4 mice for WT and n = 3 mice for Tcf3–/–). 
(D,E) WT CD45.1 mice were lethally irradiated and reconstituted with Tcf3+/+ CD45.2: Tcf3+/+ 
CD45.1 BM at a 1:1 ratio or Tcf3+/+ CD45.2: Tcf3–/– CD45.1 BM at a 1:1 ratio. Mice were 
analyzed after four weeks of reconstitution. Flow cytometry of live splenocytes from the 
indicated chimeras was then used to identify DC subsets gated as the following: cDC2s, 
CD11c+MHCII+CD172a+; cDC1s, CD11c+MHCII+CD24+CD172a–; pDCs, B220+CD317+. 
Numbers indicate the percent of cells in the indicated gates (d). Summary data of the chimerism 
ratio of splenic cDC1s (left) or pDCs (right) presented as the ratio of CD45.1+ to CD45.2+ cells 
of each type normalized to the ratio of CD45.1+ to CD45.2+ cDC2s within the same mouse (e). 
Small horizontal lines indicate the mean. Data are pooled from two independent experiments (n 
= 6 mice for Tcf3+/+ chimeras and n = 4 mice for Tcf3–/– chimeras). 
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 In this dissertation, we addressed several mechanisms controlling the development and 
function of dendritic cells. First, we found that promiscuous cytokines and their receptors can 
support dendritic cell development and differential sensitivity to these cytokines provides the 
basis for the discrepancy between Flt3–/– and Flt3l–/– mice. Flt3L, long thought to be a cytokine 
that instructs DC development, is in fact not necessary for the DC lineage and instead supports 
the maturation of already committed DC progenitors. This supportive action can be replicated by 
other cytokines whose receptors are expressed by these progenitors, including M-CSF and SCF. 
The less severe DC deficiency in Flt3–/– mice is due to the increased sensitivity of progenitors in 
these mice to these compensatory cytokines. We next examined the mechanisms by which 
enhancers in the lineage-determining transcription factor for cDC1s, Irf8, control its induction 
within the multipotent CDP. We found that two separate enhancers are utilized during the 
maturation of cDC1s. First, a +41 kb Irf8 enhancer is activated during the CDP stage to induce 
Irf8 and commit these cells towards cDC1 fate. Next, a +32 kb Irf8 enhancer is activated in 
cDC1-specified cells to autoactivate Irf8 and drive maturation of these cells. The differential 
utilization of enhancers allowed us to determine that E proteins are critical regulators of Irf8 
induction and are necessary for cDC1 lineage commitment. Collectively our studies have 







4.2 The role of supportive cytokines in hematopoiesis 
We found that M-CSF and SCF can support DC development and that there was 
continued development of committed DC progenitors in Flt3–/– mice, which together suggest that 
DC lineage commitment does not require the Flt3 pathway and that multiple cytokines can 
provide the supportive signals necessary for the maturation of these progenitors. Further, the 
DCs that develop in Flt3–/– mice were functional and had transcriptional profiles 
indistinguishable from WT DCs, suggesting that the actions of Flt3L in DC development can be 
compensated entirely by other cytokines. Though we had originally hypothesized that WT DCs 
would possess a gene signature indicative of their maturation in response to Flt3 signaling, that 
we did not see such a signature or a corresponding gene signature suggestive of M-CSF signaling 
in the Flt3–/– DCs suggests that these cytokines may not impose any long-lasting genetic 
instruction upon mature DCs, but instead simply support their development. DCs are therefore 
another example of a lineage that continues to develop and function in the absence of its 
principal growth factor, similar to granulocytes 1, erythrocytes 2 and lymphocytes 3,4. Findings 
such as these help elucidate the precise role of cytokines in hematopoietic lineage commitment 
and suggest at least some level of promiscuity between cytokine pathways and cell types. 
If cytokines are not instructive but rather support the maturation of already committed 
progenitors, then determining the instrinsic signals that lead to this commitment is paramount to 
understanding hematopoiesis. Cascades of transcription factors together lead to the exclusion of 
certain fates in multipotent progenitors and the specification of others. But isolating the exact 
circuitry in control of these lineage choices has been a challenge, as knocking out factors one by 
one and determining the effect on development or tracking the expression of single factors using 
reporter mice is labor intensive and costly. With the rapid acceleration in our ability to globally 
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survey the chromatin landscapes and mRNA expression in cell populations, we may soon have 
more robust tools for dissecting these problems. With future advances we may soon be able to 
understand the full complexity of hematopoietic lineage diversification. 
 
4.3 Evolving enhancer landscapes in hematopoiesis 
Our findings of differential Irf8 enhancer usage highlight how activation of enhancers by 
transiently active transcriptional networks can control lineage diversification. Early models of 
hematopoiesis proposed that progenitor fate choice is resolved through stochastic fluctuations in 
the expression of lineage-determining transcription factors, such as the PU.1/GATA1 circuit 
detailed previously that regulates the choice between myeloid and megakaryocyte/erythrocyte 
fates.  PU.1 and GATA1 can inhibit one another 5,6 and can also activate their own transcription 
7,8.  Further, these factors were thought to be co-expressed in progenitor cells that remained 
uncommitted until fluctuations in the levels of these two factors specified them to a single fate 9. 
But recent studies using high-resolution analysis of single progenitor cells demonstrated that no 
progenitor cells actually co-express these factors 10. Rather, PU.1 levels decay before GATA1 is 
even expressed in progenitors destined for megakaryocyte/erythrocyte fate. This suggested that 
an unknown mechanism “chooses” this particular cell fate by inducing GATA1, rather than 
stochastic fluctuations randomly generating the outcome. Our findings support such a 
deterministic rather than stochastic model of fate divergence, in which transiently active 
transcriptional networks initiate the higher expression of lineage-determining transcription 
factors.  Specifically, we found a novel requirement for an enhancer regulated by E proteins in 
the induction of Irf8 at the CDP stage that is a wholly unexpected but obligate requirement for 
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cDC1 specification.  Other transiently acting networks may regulate the induction of factors such 
as PU.1 or GATA1 in progenitors of other lineages. 
Whether enhancers are redundant in critical developmental genes appears to vary on a 
gene-by-gene basis 11-14. Our results demonstrate that non-redundant enhancers entirely control 
Irf8 expression in different lineages, including cDC1s (+32 kb Irf8 enhancer), pDCs (+41 kb Irf8 
enhancer), and monocytes/macrophages (-50 kb Irf8 enhancer).  Possibly, these different 
enhancers allow Irf8 to be expressed in various lineages despite the distinct set of transcription 
factors regulating each cell type. For example, E proteins expressed by B cells and pDCs can 
drive Irf8 expression from the +41 kb enhancer, while BATF3/IRF8 can drive its expression in 
cDC1s via the +32 kb enhancer.  Differential enhancer activity thereby allows various lineages to 
express shared genes while still retaining the unique transcriptional circuitry that defines their 
cellular identity. 
 
4.4 Future Directions 
  Our finding that multiple cytokines support development of dendritic cells opens up an 
avenue to explore how receptor expression on DC progenitors is transcriptionally regulated. 
Since multiple receptors are expressed on MDPs and CDPs but only Flt3 is expressed on mature 
DCs, identifying the transcription factors that control receptor expression in progenitors and in 
mature cells could identify additional mechanisms that contribute to lineage specification. For 
example, as alternative fate potentials are lost during the transition from the MDP to the CDP, 
the factors that control expression of c-Kit or CSF1R could be silenced while the factors that 
control Flt3 expression are maintained. Isolating these factors could help to explain how DC fate 
is separately specified from monocyte or granulocyte fate. 
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  The supportive actions of cytokines further raise questions regarding hematopoietic 
niches in the bone marrow. It is possible that different cyotkines are expressed in different 
locations within the bone marrow and that this contributes to the development of different 
lineages only in certain locations. Alternatively, cytokines in different locations could contribute 
at different stages of progenitor maturation depending upon the movement of progenitors 
through the stroma during the course of their development. These questions could be addressed 
using fluorescent reporters for cyotkines that map their precise location within the bone marrow. 
  Our analysis of Irf8 enhancer usages reveals the mehanisms by which this transcription 
factor is induced during the transition from the MDP to the CDP, how it is initially expressed 
remains unclear. Early work had suggested it was initially expressed through activity of the -50 
kb Irf8 enhancer, but we had demonstrated that deletion of this enhancer did not affect Irf8 
expression in DC progenitors. ATAC-seq analysis of hematopoietic stem cells and CMPs may 
identify additional enhancers not found by our analysis that could regulate early Irf8 expression. 
  We identified a switch in enhancer usage from the +41 kb Irf8 enhancer to the +32 kb 
Irf8 enhancer during the progression from the pre-cDC1 to the cDC1. The mechanisms by which 
these enhancers switch could be in trans, as the factors that act at each are induced separately, or 
they could be in cis, as the activity of one enhancer activates the other intrachromosomally. 
Generating mice heterozygous in each enhancer could resolve this question, and could more 
generally identify the mehchanisms utilized by enhancers to act in succession during the 
development of a cell type. 
  




 1.  Lieschke,G.J. et al. Mice lacking granulocyte colony-stimulating factor have chronic 
neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired 
neutrophil mobilization. Blood 84, 1737-1746 (1994). 
 2.  Wu,H., Liu,X., Jaenisch,R. & Lodish,H.F. Generation of committed erythroid BFU-E and 
CFU-E progenitors does not require erythropoietin or the erythropoietin receptor. Cell 83, 
59-67 (1995). 
 3.  Freeden-Jeffry,U. et al. Lymphopenia in interleukin (IL)-7 gene-deleted mice identifies IL-
7 as a nonredundant cytokine. J Exp. Med 181, 1519-1526 (1995). 
 4.  Peschon,J.J. et al. Early lymphocyte expansion is severely impaired in interleukin 7 
receptor-deficient mice. J Exp. Med 180, 1955-1960 (1994). 
 5.  Zhang,P. et al. PU.1 inhibits GATA-1 function and erythroid differentiation by blocking 
GATA-1 DNA binding. Blood 96, 2641-2648 (2000). 
 6.  Nerlov,C., Querfurth,E., Kulessa,H. & Graf,T. GATA-1 interacts with the myeloid PU.1 
transcription factor and represses PU.1-dependent transcription. Blood 95, 2543-2551 
(2000). 
 7.  Tsai,S.F., Strauss,E. & Orkin,S.H. Functional analysis and in vivo footprinting implicate 
the erythroid transcription factor GATA-1 as a positive regulator of its own promoter. 
Genes Dev. 5, 919-931 (1991). 
 8.  Chen,H. et al. PU.1 (Spi-1) autoregulates its expression in myeloid cells. Oncogene 11, 
1549-1560 (1995). 
 9.  Miyamoto,T. et al. Myeloid or lymphoid promiscuity as a critical step in hematopoietic 
lineage commitment. Dev. Cell 3, 137-147 (2002). 
 10.  Hoppe,P.S. et al. Early myeloid lineage choice is not initiated by random PU.1 to GATA1 
protein ratios. Nature 535, 299-302 (2016). 
 11.  Sagai,T., Hosoya,M., Mizushina,Y., Tamura,M. & Shiroishi,T. Elimination of a long-range 
cis-regulatory module causes complete loss of limb-specific Shh expression and truncation 
of the mouse limb. Development 132, 797-803 (2005). 
 12.  Shim,S., Kwan,K.Y., Li,M., Lefebvre,V. & Sestan,N. Cis-regulatory control of 
corticospinal system development and evolution. Nature 486, 74-79 (2012). 
 13.  Frankel,N. et al. Phenotypic robustness conferred by apparently redundant transcriptional 
enhancers. Nature 466, 490-493 (2010). 
 14.  Osterwalder,M. et al. Enhancer redundancy provides phenotypic robustness in mammalian 
development. Nature 554, 239-243 (2018). 
 
 
